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ABSTRACT
Protein-protein interactions are central to all biological processes. Designer
reagents that selectively bind to proteins and inhibit their interactions can be used to
probe protein interaction networks, discover druggable targets, and generate potential
therapeutic leads. Current technology makes it possible to engineer proteins and
peptides with desirable interaction profiles using carefully selected sets of experiments
that are customized for each design objective. There is great interest in improving the
protein design pipeline to create protein binders more efficiently and against a wider
array of targets.
In this thesis, I describe the design and development of selective peptide
inhibitors of anti-apoptotic BcI-2 family proteins, with an emphasis on targeting Bfl-1.
Anti-apoptotic Bcl-2 family proteins bind to short, pro-apoptotic BH3 motifs to support
cellular survival. Overexpression of BfI-1 has been shown to promote cancer cell
survival and the development of chemoresistance. Prior work suggests that selective
inhibition of Bfl-1 can induce cell death in Bfl-1 overexpressing cancer cells without
compromising healthy cells that also rely on anti-apoptotic BcI-2 proteins for survival.
Thus, Bfl-1-selective BH3 mimetic peptides are potentially valuable for diagnosing Bfl-1
dependence and can serve as leads for therapeutic development.
In this thesis, I describe three distinct approaches to designing potent and
selective Bfl-1 inhibitors. First, I describe the design and screening of libraries of
variants of BH3 peptides. I show that peptides from this screen bind in a previously
unobserved BH3 binding mode and have large margins of specificity for Bfl-1 when
tested in vitro and in cultured cells. Second, I describe a computational model of the
specificity landscape of three anti-apoptotic Bcl-2 proteins including Bfl-1. This model
was derived from high-throughput affinity measurement of thousands of peptides from
BH3 libraries. I show that this model is useful for designing peptides with desirable
interaction profiles within a family of related proteins. Third, I describe the use of a
scoring potential built on the amino acid frequencies from well-defined structural motifs
complied from the Protein Data Bank to design novel BH3 peptides targeting Bfl-1.
Thesis Supervisor: Amy E. Keating
Title: Professor of Biology and Bioengineering
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Protein-protein interactions (PPIs) are central to nearly every biological process
including signaling, molecular recognition, immunity, transcription, translation, the cell
cycle, cell division, and myriad other essential processes. The human genome encodes
for -30,000 unique proteins, and current estimates suggest that the human interactome
consists of at least 400,000 PPIs1 . Given the massive potential for interaction of a
protein with many different partners, PPI selectivity is essential to protein function.
Whether through the loss of interaction or formation of new complexes, abnormal PPIs
can promote and drive diseases including neurodegenerative diseases and cancer.
In nature, PPIs are continually created, lost, and modulated through a
combination of genomic plasticity and evolutionary selection. Gene duplications, base-
pair substitutions, indels, and genomic recombinations create new proteins and diversify
their amino acid sequences all while evolutionary forces shape protein interactomes.
Similar processes of genetic diversification and evolutionary selection are occurring at
different timescales throughout all domains of life, enabling nature to create a large
number of protein sequence variants and simultaneously test them for function. It has
been estimated that as many as 105 protein sequences have been tested for function
during the earth's 4 billion year history2.
Given the biologically important roles of PPIs, there is tremendous practical and
scientific value in interaction engineering and design. Targeting PPIs can be useful for
the development of diagnostics, biosensors, research reagents, and therapeutics.
Additionally, the quantitative descriptions of molecular interactions developed for protein
design can be applied to studies of evolution, protein function, and molecular
mechanisms of disease. However, whereas nature uses evolution to create and test
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large numbers of sequences over a vast amount of time, to design proteins in the lab,
affinity and specificity must be explicitly accounted for either experimentally,
computationally, or by using both approaches.
Protein design is technically challenging for a number of reasons. First, sequence
space is massive (2 0 ' where n represents protein length in number of amino acids).
Although there may be many possible sequences that can achieve a desired design
profile, there is no guarantee that any such sequence is only a few mutations away from
a known sequence, which is the space most frequently searched in design projects.
Second, PPIs are structurally diverse and complex. PPIs can be formed by folded
domains that fit together like pieces from a puzzle, by proteins that lack significant
structure before binding, or by proteins that form 'fuzzy' complexes with high degrees of
structural heterogeneity 4 . Further, many PPIs exhibit structural plasticity, which
complicates design even when an experimentally determined structure is available.
Finally, mutations can exhibit epistasis or, in other words, the effect of a mutation can
differ depending on the sequence context in which that mutation occurs 5'6 . Mutational
epistasis complicates protein design by creating rugged fitness landscapes.
This thesis addresses the topic of peptide design for tight and selective binding to
a target protein, as well as methods and approaches for systematically navigating
mutational space. To provide context for this work, it is important to recognize that there
are many strategies that can be used to make a protein with desired properties. I will
summarize the most common approaches to protein design, which are directed





A common approach to design proteins with desirable PPI profiles is to use DE
wherein the search through mutational space is guided by experiment 7. Similarly to
natural selection, DE relies on nucleotide sequence randomization in combination with
screens or selections of protein function. By iterating through this process, mutations
accumulate until a protein sequence that meets the design objectives is discovered, as
illustrated in Figure 1.1 A, B.
A B
DNA ftIVA translation
diversification I4iDU# into protein
.. screen or
DNA selection 0 library starting point - accepted step
amplification for function 0 local minimum - rejected step
0 global minimum
Figure 1.1. An overview of the key steps and limitations of directed evolution. A) Genetic diversity is
generated and the effect of mutations is determined empirically with screens or selections. Mutations
accumulate through repetition of the cycle. B) Through several rounds of directed evolution, sequence
space (as illustrated here as a three-dimensional fitness landscape) can be navigated. In this illustration,
identifying the maximum fitness requires crossing a "fitness valley". The ruggedness of the fitness
landscape results from epistatic interactions between sets of mutations.
As in natural selection, genetic diversity is central to DE. Random mutagenesis is
used to introduce mutations into a protein-coding gene whose phenotype can later be
experimentally evaluated with genetic screens or selections. One of the advantages of
this approach is that proteins can be designed without any detailed knowledge of their
structure. This is a valuable feature, considering that the structures of many PPIs are
unknown. Although mutations to a target gene can be generated in vivo8, in vitro
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methods allow more control over mutational sampling. For example, low-fidelity
polymerases can be used in error-prone PCR to generate point mutations9 . Mutational
biases of nucleotide substitutions can be countered experimentally, for example by
altering dNTP concentrations". However, there isn't a direct correspondence between
nucleotide mutations and protein mutations, so amino acid substitutions introduced in
this way are biased by the genetic code. Point mutations can also be introduced at the
codon level through assembly with synthetic DNA primers that contain mixed bases by
assembly PCR1  or DNA ligation'. Sequence diversity can also be created through
mimicking homologous recombination in vitro with approaches like DNA shuffling1 5'1 6 or
assembly PCR17 .
Mutational space is too large to comprehensively search with existing
experimental approaches for all but the shortest peptide sequences. The limit of how
much mutational space can be explored in DE depends on experimental throughput and
library transformation efficiency. A powerful and flexible platform for screening PPIs is
yeast cell-surface display18' 19. In this approach, protein libraries are expressed on the
yeast cell surface through genetic fusion with the yeast mating adhesion receptor Aga2.
Binding to fluorescently labeled target protein can be measured and screened with
fluorescence-activated cell sorting (FACS). Assays that measure binding to cell surface-
expressed molecules have the advantage of providing researchers with control over the
stringency of the screen, which can be tuned by altering target protein concentration.
This experimental design also facilitates negative screening or counterscreening against
off-target binding. Yeast libraries can be as large as -10 9 transformants, but FACS
sorting speed limits the number of cells that can be screened to ~10 7. Cell-surface
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display platforms have been developed for other organisms including bacteria20 and
mammalian cells21 . Other screening approaches include modest-throughput plate-based
screens and screens in artificial cell-like compartments such as water-oil emulsions for
FACS-based22 or microfluidic screening23. Because genetic selections don't require
each library member to be inspected for phenotype, they can be used to search larger
library spaces. Affinity-based selections can be used to query larger libraries using
phage display (~10" variants) 24, ribosome display (~1012 - 1013 variants) 25 , and mRNA
display (~1012 - 1013 variants) 26.
DE is routinely used to engineer proteins with enhanced binding and specificity
profiles. DE approaches have proven particularly valuable in designing antibodies with
enhanced affinities for their targets. For example, Boder et al. used DE to design a
fluorescein-binding antibody that bound with a 48 fM KD, more than 1,000-fold tighter
than its parent antibody 27. Similar approaches have been used to develop affinity
matured antibodies against cholera toxin (1,300-fold improvement) 28, Her2/Neu (10-fold
improvement)29, TNF-a (30-fold improvement) 30, and many other targets as summarized
in reviews by Boder et al. 3 1 and Cherf et al.32 Antibody engineering using DE techniques
has contributed to the development of many of engineered antibodies that have been
approved for clinical use or entered clinical trials 33. DE is also commonly used to
engineer affinity agents on non-antibody scaffolds, including DARPins 34 35 , knottins 36,
fibronectin type Ill domains 37, T-cell receptors38, interleukin-I variants 39, and myriad
other proteins.
DE can be a powerful approach to protein design, but it has some limitations. For
example, it can be challenging to discover sequences far from the starting template with
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DE because deleterious mutations are much more frequent than beneficial mutations40.
For example, Bershtein et al. demonstrated that only ~1/10 3 random mutations were
beneficial for TEM-1 P-lactamase function, but 1/3 mutations were deleterious 41. Thus,
researchers typically keep the mutational load in each round of DE low to avoid masking
beneficial mutations with deleterious mutations. Epistasis presents another challenge to
discovering diverse functional sequence spaces, because some mutations are only
beneficial after non-beneficial or deleterious mutations have accumulated, as illustrated
by the fitness valley in Figure 1.1 B.
Structure-based design
PPIs can be designed computationally with the use of structure-based scoring
potentials. There are three general categories of scoring potentials commonly used in
computational design: physics-based potentials, knowledge-based potentials, and
hybrid potentials that include both elements.
In theory, given a structure, it should be possible to explore vast amounts of
mutational space by calculating the energetic effects of mutations in silico. Physics-
based scoring potentials, including AMBER 42 and CHARMM 43, have been developed to
score the potential energy of proteins using principles of molecular mechanics. Physics-
based scoring potentials are mathematical models of molecular forces (van der Waals
attraction and repulsion, Columbic interactions, bond energies, etc.) whose energetic
contributions have been weighted based on chemical and physical theory or
experimental measurement44 . These scoring functions are optimized to predict the
lowest-energy protein conformations by calculating the potential energy of different
conformations for a single sequence, as is commonly done in molecular dynamics
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simulations. Scoring with physics-based potentials is computationally expensive, which
puts practical constraints on how much mutational space can be explored. These
methods aren't used alone for design, at least not without introducing many
approximations.
Alternatively, the effect of a mutation can be inferred from statistical (sometimes
called knowledge-based) potentials derived from structures in the Protein Data Bank
(PDB). These potentials are derived from frequencies of structural features like rotamer
positions and the geometries of interacting residue pairs. Statistical potentials assume
that structural features are Boltzmann distributed, such that the lowest energy structural
features will be the most frequently observed. Since their inception in the 1970's4 5,
statistical potentials have been used with some success in structure prediction6 '47 ,
structural quality assessment48,49, PPI prediction 0, and affinity prediction 1,52. In
comparison with physics-based potentials, knowledge-based potentials are fast to
evaluate and do not require structural minimization for scoring. But the accuracy of
these scoring functions limits their application in design. For example, Su et al. reported
a modest correlation (R= 0.76) between a knowledge-based scoring potential and the
previously published affinities of 86 protein-protein complexes, but the standard
deviation between the predictions and measured affinities was reported to be 2.24
kcal/mol ( 16x KD) 5 1 , limiting its potential use as a design tool . In attempts to improve
the accuracy of these methods for design, there has been considerable work done to
find new ways to define and score structural features. One promising way of describing
proteins was recently developed by Mackenzie et aP3 , who demonstrated that protein
structures can be decomposed into a defined set of tertiary motifs (TERMs) that have
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similar secondary, tertiary, and quaternary structure5 3. Further, TERMs have associated
sequence preferences, and Zheng et al. showed that a statistical potential derived from
the sequence statistics of TERMs predicts changes in protein stability upon mutation at
least as well as state-of-the-art physics-based potentials 54. A function that relates a
sequence to its fitness on a structure can be used for design, and design using TERM
energies (dTERMen) has been implemented in the Grigoryan lab and tested on a small
number of problems. The dTERMen scoring procedure is outlined in Figure 1.2.
Chapter 4 of this thesis demonstrates the potential of dTERMen to accurately design
PPIs with highly diversified sequences.
sequence model 2 . Sl enewrgy parameter













Figure 1.2. An overview of dTERMen scoring function. Mutational energies are calculated by describing
the local structural environment and matching the geometry of the design template with a database of
tertiary motifs (TERMs) or sub-TERMs compiled from the PDB. Positional and pair amino-acid




Many of the most commonly used scoring functions for protein design combine
physics-based and knowledge-based scoring functions to speed scoring of large
mutational spaces. For example, the Rosetta scoring function was initially developed as
a statistical potential55 , but many additional physics-based energy terms have been
added to account for hydrogen bonding, van der Waals interactions, solvation, etc.56-58 .
Another commonly used platform for protein design is FoldX, which is a scoring function
based primarily on physical terms parameterized by empirical data, but includes some
statistical terms from the PDB to account for backbone and side chain entropies59 . The
accuracy of the hybrid scoring functions depends on which energetic terms are used
and how each term is weighted relative to each other. Scoring functions can be highly
customizable, leading to significant variability between research groups and particular
design tasks44. Hybrid potentials can be used to search large mutational spaces 60,61,
though the modest accuracy of these models typically necessitates experimental
screening to identify successful designs, as discussed below.
Combining experimental screening with computational design
DE and SBD are highly complementary methods that when combined can
produce superior results6 2,6 3 . For example, SBD can be used to design novel proteins
that can then be further optimized with DE. This approach has been widely used in
enzyme design and to design protein binders. Fleishman et al. used Rosetta to design
proteins to bind a conserved epitope of hemagglutinin (influenza) from the 1918 H1N1
pandemic virus starting from a structure of hemagglutinin bound to an antibody
fragment. They then affinity maturated the designs using DE to engineer proteins that
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bind to hemagglutinin with low nanomolar affinity61 . Similar approaches are routinely
used by the Baker lab and others to design novel protein binders.
SBD can be used to guide mutational selection for focused DE libraries. As
discussed in the preceding sections, experimental screens and selections are limited in
the number of unique sequences that can be explored and the mutational load that can
be encoded in those sequences. SBD can be used to identify which residue positions
are directly involved in PPIs and predict which mutations at those positions have the
most potential to improve function. Further, SBD can be used to identify and exclude
potentially disruptive mutations that have the potential to "poison" any fraction of the
library that encodes them. This makes it possible to construct libraries that encode
40larger sets of mutations that explore farther away from the design template sequence .
In this way, SDB can be used to design focused, combinatorial libraries that can be
assembled using well-established randomization strategies 64. This approach has been
shown to be more efficient than DE by random mutagenesis. For example, focused
libraries of GFP mutants designed with SBD were found to encode a broader range of
fluorescent activities than mutagenic PCR-generated libraries 65. Structure-based library
design has become a routine approach to improving protein affinity, specificity66- 8 , and
regulation 9 . One advantage of focused, combinatorial libraries is their potential to
explore epistatic landscapes, as sets of mutations have increased potential to escape
local minima. An example of a focused combinatorial library that led to the discovery of
a peptide with a set of episatic mutations that would be difficult to discover with DE is
presented in chapter 2 of this thesis.
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Data-driven design
Techniques for measuring binding affinities in high-throughput have begun to
provide new opportunities for alternative and complementary approaches to protein
design. Here I discuss a few of the technologies that enable high-throughput PPI affinity
measurement, before discussing how these data can be used for protein design.
Peptide SPOT arrays and microarrays provide qualitative binding measurements
for peptides immobilized on a solid surface either by spotting, as done for ELISAs, or by
in situ synthesis7 0' 71 . In this way, hundreds or thousands of peptides to be assayed for
binding in parallel. These approaches are best suited for probing mutations in short
peptides. Although it is possible to synthesize peptides 50 amino acids or longer on
peptide arrays 72, 6-18 amino acids is optimal70. Synthesis quality and yield varies from
sequence to sequence, contributing to measurement uncertainty in these datasets.
A semi-quantitative measurement of affinity can be extracted from DE
experiments by deep-sequencing mutant libraries before and after one or several
rounds of screening or selection73-75. For example McLaughlin et al. used enrichment of
a bacterial two-hybrid library containing all possible single point mutants of a PDZ
domain to measure the affect of mutation over a broad range of affinities (-0.1-200 pM)
as evidenced by a linear relationship between enrichment values and independently
measured KDS (correlation coefficient not reported) 73. In more recent work, Younger et
al. used a Saccharomyces cerevisiae mating efficiency screen to measure KDS from
<500 pM to >300 pM 74. They reported a linear relationship between KD and mating
efficiency (R 2 =0.878). Approaches like these that capture trends in binding affinities are
increasingly being used as a general means to understand how function relates to
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sequence, but are not currently widely adopted for protein design. Resolution of these
methods might be limited in part by their reliance on separation into binary groups of
either binders or non-binders. Further, biases from growth in preparation for deep-
sequencing might further reduce resolution.
Screening methods that separate samples into multiple phenotypic classes have
been developed to increase measurement resolution 7~79. Reich et al. developed a
method called SORTCERY to sort individual yeast cells from a library by their apparent
degree of binding76 ,80. In this method, yeast cells are sorted and deep-sequenced to
rank-order thousands of mutant peptides by affinity. SORTCERY has the advantage of
not requiring a growth step between sorting and deep sequencing. Chapter 3 of this
thesis presents a strategy to extract absolute affinities from SORTCERY data. Adams et
al. used multi-state sampling in combination with titration to create binding curves from
which the affinities of thousands of yeast-displayed proteins can be measured in
parallel 78. One significant advantage of this approach is that it provides researchers
control over the range of affinities that are measured. A minor drawback is that this
protocol requires growth steps in preparation for deep sequencing, which can contribute
to measurement noise.
Another potentially rich source of experimental data that could be exploited for
design is databases of measurements compiled from the literature, such as Ab-Bind81
and SKEMP18 2 . However, measurements made for the same protein interaction can
vary significantly between labs, methods, and experimental conditions, making it
infeasible to make reliable comparisons across studies. Databases assembled from the
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literature can also suffer from lack of mutational diversity. In particular, a
disproportionately large fraction of alanine mutants are observed in these datasets.
Large mutational datasets are valuable for benchmarking the performance of
computational models and improving protein design83 84 . For example, Rocklin et al.
used a high-throughput screen of protease sensitivity for a yeast-displayed library of
mini-proteins to measure protein stability in high-throughput. By comparing the
experimental measurements of stability with predictions made by Rosetta, the authors
85were able to reweight Rosetta energy terms and improve their design success rate
Similar data-driven reweighting of Rosetta terms was shown to improve PPI design 6
Mutational datasets can be used to build models of PPI for protein design. For
example, Wiedemann et al. measured hundreds of single point mutants for binding to
PDZ domains using SPOT arrays87. They then modeled the effect of mutation and
designed three novel peptide ligands, all of which bound modestly tighter (< 5-fold) than
the sequences from which they were designed. The model used for design assumed
that each residue contributes independently to binding, which isn't always the case for
PDZ domains88 .
Models that capture relationships between sequence and binding can be used to
guide the design of focused libraries. This approach is particularly valuable for
designing focused libraries in the absence of experimental structures. For example,
Dutta et al. used mutational data from SPOT arrays to develop position specific scoring
matrices (PSSMs) that were used to guide the selection of mutations to include in a
peptide library to achieve specificity against the anti-apoptotic protein Bcl-w, for which
there was no experimental structure available at the time8 9. Experimental data has also
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been used for library design in enzyme engineering in the form of "scouting"
experiments in which experimental data is used to provide clues as to which residues
are most important for function, to guide the design of focused libraries. For example,
this approach was used to change the substrate specificity of glutaryl acylase (for which
no structure was available at the time) toward adipyl compounds using random
mutagenesis to create a small (10,000 colony) pilot library90 . Screening revealed three
mutations that affected substrate specificity. Those three positions were randomized in
subsequent libraries with saturation mutagenesis to further improve catalytic efficiency
three-fold. Data-driven library design is being used to create focused libraries with
reduced size that decrease the amount of screening required to engineer proteins with
improved properties9 .
Machine learning on mutational datasets has been used to capture the
relationship between protein sequence and complex protein properties including
solubiity92 ,93 , cellular localization9 4' 95, crystallization propensity9 6 , and protein function97.
Additionally, there is evidence that given enough data, machine learning can be used to
model epistatic effects for use in PPI design. For example, Potapov et al. used a large
quantitative set of >4,500 coiled-coiled interactions to develop a model whose predictive
performance approached experimental error when intramolecular terms were
inicuded98 . One barrier to using machine learning in protein design is that these models
tend to generalize poorly and are best suited for predicting sequences that are close to
those used to train the model. Chapter 3 of this thesis provides evidence that machine
learning can, at least in some cases, be used to design sequences distant from those
used for model training.
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Summary of protein design approaches
In this Introduction, I discussed experimental and computational approaches that
have been used to design PPIs. Perhaps the most widely adopted PPI design strategy
is DE, which is limited in the amount of sequence space it can explore. When a protein
structure is available, SBD is a common approach to explore vast amounts of sequence
space, but is rarely used on its own to design novels proteins due to accuracy
limitations. SBD and DE are highly synergistic approaches that can be and increasingly
are used in combination to great effect. In the absence of structure, however, it is
difficult to model and explore vast amounts of sequence space. Although data-driven
design is still in its infancy, the ever-growing amount of experimental data is beginning
to transform PPI design. It is likely that data-driven design will greatly enhance our
design capabilities, especially in combination with well established DE and SBD
approaches.
Anti-apoptotic Bcl-2 protein family as a model system for protein design
The Bcl-2 protein family regulates the intrinsic pathway of apoptosis through
PPIs. Anti-apoptotic Bcl-2 proteins including Bcl-2, BcI-xL, Mcl-1, Bcl-w, and Bfl-1
promote cellular survival by binding to BH3 motifs. BH3 motif peptides are unfolded in
isolation but adopt a helical conformation upon binding, as shown in Figure 1.3. Anti-
apoptotic protein interactions with BH3 motifs prevent the pro-apoptotic proteins BAX
and BAK from homo-oligomerizing into pores in the mitochondrial outer membrane, a
"point of no return" in apoptotic signaling9 9'100 .
Anti-apoptotic Bcl-2 proteins are valuable therapeutic and diagnostic targets.
Overexpression of anti-apoptotic Bcl-2 proteins is known to contribute to oncogenesis
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and confer resistance to chemotherapeutic agents99 . Diagnostic determination of anti-
apoptotic protein dependencies from patient samples can be used to guide clinical
treatment options,1 01 and therapeutic inhibition of over-expressed anti-apoptotic proteins
can sensitize malignant cells to treatment102
Figure 1.3. The anti-apoptotic protein Bfl-1 (blue) bound to the natural BH3 motif of Puma (red, 5UUL113)
is shown.
There has been significant progress in targeting Bcl-2 family proteins
therapeutically with BH3-mimetic small molecules. For example, the small molecule
ABT-263 was found to promote apoptosis in lymphocytic leukemia cells overexpressing
Bcl-2104. Unfortunately, cross-reactivity of ABT-263 with Bcl-xL caused dose-limiting
thrombocytopenia, ultimately leading to failure in clinical trials 05106. By including
selectivity as a design criteria in subsequent work, a small molecule (ABT-199) that
bound to Bcl-2 but not Bcl-xL was developed and approved by the FDA for clinical
usel04,107. These results highlight the importance of sub-family selectivity when targeting
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members of this protein family therapeutically. Small molecules selectively targeting
Mcl-1 have since been developed 08.
As an alternative strategy, BH3 mimetic peptides are being developed to target
anti-apoptotic Bcl-2 family proteins. Peptides that selectively inhibit members of this
protein family are valued as therapeutic leads and as diagnostic reagents that can
probe anti-apoptotic protein dependencies to guide clinical treatments 01 . Protein design
has enabled the development of many selective reagents that are being used to study
Bcl-2 biology and develop diagnostic assays. For example, computationally designed,
focused yeast-display libraries have been used to design Bcl-xL 89 and Mcl- 1 109 selective
peptides.
Selective peptides or small molecules have proven difficult to develop for BfI-1.
Dutta et al. used a data-driven approach to design a combinatorial library and
discovered a peptide with >30 fold selectivity for Bfl-1. However, this peptide failed to
inhibit Bfl-1 in cellular studies" 0. Berger et aL. designed helical proteins with BH3
domains using Rosetta that selectively inhibit Bfl-1111, but these proteins are
comparatively large (>13 kDa), making cellular delivery a challenge. There have also
been attempts at designing small molecules targeting Bf-11 12- 115, though these small
molecules have only modest specificity for Bfl-1 relative to other Bcl-2 family members
and bind with low affinity (high nanomolar to low micromolar).
Research approach
In my thesis work, I designed potent and selective peptide inhibitors for the anti-
apoptotic protein Bfl-1. My thesis project began by designing a set of libraries to
selectively target anti-apoptotic Bcl-2 proteins. In chapter 2, I describe how these yeast-
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displayed libraries were designed and screened for Bfl-1 selectivity. The designed
peptides were characterized biochemically using solution binding assays, mutagenesis,
and X-ray crystallography. Our collaborators tested the designed peptides in cells and
confirmed selective Bfl-1 inhibition of apoptotic signaling. In chapter 3, l describe my
work with Vincent Xue to measure the apparent affinities of thousands of peptides from
these libraries for binding to Bfl-1, Mcl-1, and Bcl-xL in high-throughput. This work
required the development of a method to extract binding affinities from datasets of
binding profiles. These data were used to build a data-driven model of the specificity
landscape for these proteins. Further, we used this model to successfully design highly
selective peptides many mutations away from any sequence used to train the model.
Finally, in chapter 4, I describe collaborative work using dTERMen to design novel
sequences using structures of Mcl-1 and Bfl-1 complexes as input.
33
References-
1. Chen TS, Petrey D, Garzon JI, Honig B. Predicting peptide-mediated interactions on a genome-
wide scale. PLoS Comput Biol. 2015;11(5):e1004248. doi: 10.1371/journal.pcbi. 1004248.
2. Mandecki W. The game of chess and searches in protein sequence space. Trends Biotechnol.
1998;16(5):200-202. doi:10.1016/SO167-7799(98)01188-3.
3. Borgia A, Borgia MB, Bugge K, et al. Extreme disorder in an ultrahigh-affinity protein complex.
Nature. 2018;555(7694):61-66. doi:10.1038/nature25762.
4. Tompa P, Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein
interactions. Trends Biochem Sci. 2008;33(1):2-8. doi:10.1016/j.tibs.2007.10.003.
5. Miton CM, Tokuriki N. How mutational epistasis impairs predictability in protein evolution and
design. Protein Sci. 2016;25(7):1260-1272. doi: 10.1 002/pro.2876.
6. Podgornaia Al, Laub MT. Protein evolution. Pervasive degeneracy and epistasis in a protein-
protein interface. Science. 2015;347(6222):673-677. doi: 10.1126/science. 1257360.
7. Packer MS, Liu DR. Methods for the directed evolution of proteins. Nat Rev Genet.
2015;16(7):379-394. doi:10.1038/nrg3927.
8. Ravikumar A, Arrieta A, Liu CC. An orthogonal DNA replication system in yeast. Nat Chem Biol.
2014;10(3):175-177. doi:10.1038/nchembio.1439.
9. Cadwell RC, Joyce GF. Randomization of genes by PCR mutagenesis. PCR Methods Appl.
1992;2(1):28-33. http://www.ncbi.nlm.nih.gov/pubmed/1490172. Accessed April 5, 2018.
10. Vanhercke T, Ampe C, Tirry L, Denolf P. Reducing mutational bias in random protein libraries.
Anal Biochem. 2005;339(1):9-14. doi:10.1016/j.ab.2004.11.032.
11. Gibson DG. Enzymatic Assembly of Overlapping DNA Fragments. In: Methods in Enzymology. Vol
498. ; 2011:349-361. doi:10.1016/B978-0-12-385120-8.00015-2.
12. Quan J, Tian J. Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways.
Ho PL, ed. PLoS One. 2009;4(7):e6441. doi:10.1371/journal.pone.0006441.
13. Ashraf M, Frigotto L, Smith ME, et al. ProxiMAX randomization: a new technology for non-
degenerate saturation mutagenesis of contiguous codons. Biochem Soc Trans. 2013;41(5):1189-
1194. doi: 10.1042/BST20130123.
14. Wells JA, Vasser M, Powers DB. Cassette mutagenesis: an efficient method for generation of
multiple mutations at defined sites. Gene. 1985;34(2-3):315-323.
http://www.ncbi.nlm.nih.gov/pubmed/3891521. Accessed April 5, 2018.
15. Stemmer WPC. Rapid evolution of a protein in vitro by DNA shuffling. Nature.
1994;370(6488):389-391. doi:10.1038/370389a0.
16. Ness JE, Kim S, Gottman A, et al. Synthetic shuffling expands functional protein diversity by
allowing amino acids to recombine independently. Nat Biotechnol. 2002;20(12):1251-1255.
doi: 10.1 038/nbt754.
17. Zha D, Eipper A, Reetz MT. Assembly of designed oligonucleotides as an efficient method for
gene recombination: a new tool in directed evolution. Chembiochem. 2003;4(1):34-39.
doi: 10.1 002/cbic.20039001 1.
18. Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity,
and stability. Methods Enzymol. 2000;328:430-444.
http://www.ncbi.nlm.nih.gov/pubmed/11075358. Accessed April 5, 2018.
19. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat
Biotechnol. 1997;15(6):553-557. doi: 10.1 038/nbt0697-553.
20. Daugherty PS, Chen G, Olsen MJ, Iverson BL, Georgiou G. Antibody affinity maturation using
bacterial surface display. Protein Eng. 1998;11(9):825-832.
http://www.ncbi.nlm.nih.gov/pubmed/9796833. Accessed April 5, 2018.
34
21. Wolkowicz R, Jager GC, Nolan GP. A random peptide library fused to CCR5 for selection of
mimetopes expressed on the mammalian cell surface via retroviral vectors. J Biol Chem.
2005;280(15):15195-15201. doi:10.1074/jbc.M500254200.
22. Bernath K, Hai M, Mastrobattista E, Griffiths AD, Magdassi S, Tawfik DS. In vitro
compartmentalization by double emulsions: sorting and gene enrichment by fluorescence
activated cell sorting. Anal Biochem. 2004;325(1):151-157.
http://www.ncbi.nlm.nih.gov/pubmed/14715296. Accessed April 5, 2018.
23. Agresti JJ, Antipov E, Abate AR, et al. Ultrahigh-throughput screening in drop-based microfluidics
for directed evolution. Proc Nat Acad Sci U S A. 2010;107(9):4004-4009.
doi:10.1073/pnas.0910781107.
24. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying
antibody variable domains. Nature. 1990;348(6301):552-554. doi:10.1038/348552a0.
25. Hanes J, PlOckthun A. In vitro selection and evolution of functional proteins by using ribosome
display. Proc Nat! Acad Sci U S A. 1997;94(10):4937-4942.
http://www.ncbi.nlm.nih.gov/pubmed/9144168. Accessed April 5, 2018.
26. Wilson DS, Keefe AD, Szostak JW. The use of mRNA display to select high-affinity protein-binding
peptides. Proc Nat Acad Sci. 2001;98(7):3750-3755. doi:10.1 073/pnas.061028198.
27. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent
femtomolar antigen-binding affinity. Proc Nat Acad Sci. 2000;97(20):10701-10705.
doi: 10.1 073/pnas. 170297297.
28. Tasumi S, Velikovsky CA, Xu G, et al. High-affinity lamprey VLRA and VLRB monoclonal
antibodies. Proc Natl Acad Sci U S A. 2009; 106(31):12891-12896. doi: 10.1 073/pnas.0904443106.
29. Wozniak-Knopp G, Bartl S, Bauer A, et al. Introducing antigen-binding sites in structural loops of
immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and
antibody properties. Protein Eng Des Sel. 2010;23(4):289-297. doi:10.1093/protein/gzqOO5.
30. Rajpal A, Beyaz N, Haber L, et al. A general method for greatly improving the affinity of antibodies
by using combinatorial libraries. Proc Nat Acad Sci. 2005;102(24):8466-8471.
doi: 10.1 073/pnas.0503543102.
31. Boder ET, Raeeszadeh-Sarmazdeh M, Price JV. Engineering antibodies by yeast display. Arch
Biochem Biophys. 2012;526(2):99-106. doi:10.1016/j.abb.2012.03.009.
32. Cherf GM, Cochran JR. Applications of Yeast Surface Display for Protein Engineering. Methods
Mo! Biol. 2015;1319:155-175. doi:10.1007/978-1-4939-2748-7_8.
33. Saeed AFUH, Wang R, Ling S, Wang S. Antibody Engineering for Pursuing a Healthier Future.
Front Microbiol. 2017;8:495. doi: 1 0.3389/fmicb.2017.00495.
34. Steiner D, Forrer P, Pluckthun* A. Efficient Selection of DARPins with Sub-nanomolar Affinities
using SRP Phage Display. 2008. doi:10.1016/j.jmb.2008.07.085.
35. Seeger MA, Zbinden R, Flutsch A, et al. Design, construction, and characterization of a second-
generation DARP in library with reduced hydrophobicity. Protein Sci. 2013;22(9):1239-1257.
doi: 10.1002/pro.2312.
36. Silverman AP, Levin AM, Lahti JL, Cochran JR. Engineered cystine-knot peptides that bind
alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol. 2009;385(4):1064-1075.
doi:10.1016/j.jmb.2008.11.004.
37. Koide A, Bailey CW, Huang X, Koide S. The fibronectin type Ill domain as a scaffold for novel
binding proteins. J Mol Biol. 1998;284(4):1141-1151. doi:10.1006/JMBI.1998.2238.
38. Holler PD, Holman PO, Shusta E V, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T
cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A. 2000;97(10):5387-5392.
doi: 10.1 073/pnas.080078297.
39. Balaji M. Rao t, Ian Driver t, Douglas A. Lauffenburger and, K. Dane Wittrup* . High-Affinity
35
CD25-Binding IL-2 Mutants Potently Stimulate Persistent T Cell Growtht. 2005.
doi:10.1021/B1050436X.
40. Goldsmith M, Tawfik DS. Enzyme engineering by targeted libraries. Methods Enzymol.
2013;523:257-283. doi:10.1016/B978-0-12-394292-0.00012-6.
41. Bershtein S, Tawfik DS. Ohno's model revisited: measuring the frequency of potentially adaptive
mutations under various mutational drifts. Mol Biol Evol. 2008;25(11):2311-2318.
doi: 10.1 093/molbev/msn 174.
42. Case DA, Cheatham TE, Darden T, et al. The Amber biomolecular simulation programs. J Comput
Chem. 2005;26(16):1668-1688. doi: 10.1 002/jcc.20290.
43. Brooks BR, Brooks CL, Mackerell AD, et al. CHARMM: the biomolecular simulation program. J
Comput Chem. 2009;30(10):1545-1614. doi:10.1002/jcc.21287.
44. Boas FE, Harbury PB. Potential energy functions for protein design. Curr Opin Struct Biol.
2007;17(2):199-204. doi:10.1016/J.SBI.2007.03.006.
45. Tanaka S, Scheraga HA. Medium- and long-range interaction parameters between amino acids for
predicting three-dimensional structures of proteins. Macromolecules. 1976;9(6):945-950.
http://www.ncbi.nlm.nih.gov/pubmed/1004017. Accessed April 6, 2018.
46. Park J, Saitou K. ROTAS: a rotamer-dependent, atomic statistical potential for assessment and
prediction of protein structures. BMC Bioinformatics. 2014;15(1):307. doi:10.1186/1471-2105-15-
307.
47. Shen M, Sali A. Statistical potential for assessment and prediction of protein structures. Protein
Sci. 2006;15(11):2507-2524. doi:10.1110/ps.062416606.
48. Sippl MJ. Recognition of errors in three-dimensional structures of proteins. Proteins Struct Funct
Genet. 1993;17(4):355-362. doi:10.1002/prot.340170404.
49. Eramian D, Shen M, Devos D, Melo F, Sali A, Marti-Renom MA. A composite score for predicting
errors in protein structure models. Protein Sci. 2006;15(7):1653-1666. doi:10.1110/ps.062095806.
50. Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand
interactions. J Mol Biol. 2000;295(2):337-356. doi: 10.1 006/jmbi. 1999.3371.
51. Su Y, Zhou A, Xia X, Li W, Sun Z. Quantitative prediction of protein-protein binding affinity with a
potential of mean force considering volume correction. Protein Sci. 2009;18(12):2550-2558.
doi:10.1002/pro.257.
52. DeBartolo J, Dutta S, Reich L, Keating AE. Predictive Bcl-2 Family Binding Models Rooted in
Experiment or Structure. J Mol Biol. 2012;422(1):124-144. doi:10.101 6/j.jmb.2012.05.022.
53. Mackenzie CO, Zhou J, Grigoryan G. Tertiary alphabet for the observable protein structural
universe. Proc Natl Acad Sci U S A. 2016;113(47):E7438-E7447. doi:10.1073/pnas.1607178113.
54. Zheng F, Grigoryan G. Sequence statistics of tertiary structural motifs reflect protein stability.
Srinivasan N, ed. PLoS One. 2017;12(5):e0178272. doi:10.1371/journal.pone.01 78272.
55. Simons KT, Kooperberg C, Huang E, Baker D. Assembly of protein tertiary structures from
fragments with similar local sequences using simulated annealing and Bayesian scoring functions.
J Mol Biol. 1997;268(1):209-225. doi: 10.1 006/jmbi.1997.0959.
56. Simons KT, Ruczinski 1, Kooperberg C, Fox BA, Bystroff C, Baker D. Improved recognition of
native-like protein structures using a combination of sequence-dependent and sequence-
independent features of proteins. Proteins. 1999;34(1):82-95.
http://www.ncbi.nlm.nih.gov/pubmed/10336385. Accessed April 6, 2018.
57. Kuhlman B, Baker D. Native protein sequences are close to optimal for their structures. Proc Natl
Acad Sci U S A. 2000;97(19):10383-10388. http://www.ncbi.nlm.nih.gov/pubmed/10984534.
Accessed April 6, 2018.
58. Alford RF, Leaver-Fay A, Jeliazkov JR, et al. The Rosetta All-Atom Energy Function for
Macromolecular Modeling and Design. J Chem Theory Comput. 2017;13(6):3031-3048.
36
doi: 10.1021/acs.jctc.7b00125.
59. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an
online force field. Nucleic Acids Res. 2005;33(Web Server):W382-W388. doi:10.1093/nar/gki387.
60. Chevalier A, Silva D-A, Rocklin GJ, et al. Massively parallel de novo protein design for targeted
therapeutics. Nature. 2017;550(7674):74-79. doi:10.1038/nature23912.
61. Fleishman SJ, Whitehead TA, Ekiert DC, et al. Computational Design of Proteins Targeting the
Conserved Stem Region of Influenza Hemagglutinin. Science (80- ). 2011;332(6031):816-821.
doi:10.1 126/science.1202617.
62. Rosenfeld L, Heyne M, Shifman JM, Papo N. Protein Engineering by Combined Computational
and In Vitro Evolution Approaches. Trends Biochem Sci. 2016;41(5):421-433.
doi: 10.101 6/j.tibs.2016.03.002.
63. Chen TS, Keating AE. Designing specific protein-protein interactions using computation,
experimental library screening, or integrated methods. Protein Sci. 2012;21(7):949-963.
doi: 10.1 002/pro.2096.
64. Wang W, Saven JG. Designing gene libraries from protein profiles for combinatorial protein
experiments. Nucleic Acids Res. 2002;30(21):e120.
http://www.ncbi.nlm.nih.gov/pubmed/12409479. Accessed April 5, 2018.
65. Treynor TP, Vizcarra CL, Nedelcu D, Mayo SL. Computationally designed libraries of fluorescent
proteins evaluated by preservation and diversity of function. Proc Natl Acad Sci U S A.
2007;104(1):48-53. doi:10.1073/pnas.0609647103.
66. Smith SN, Wang Y, Baylon JL, et al. Changing the peptide specificity of a human T-cell receptor
by directed evolution. Nat Commun. 2014;5:5223. doi: 10.1 038/ncomms6223.
67. Foight GW, Keating AE. Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of
Anti-Apoptotic BcI-2 Proteins. J Mol Biol. 2015;427(15):2468-2490. doi: 10.101 6/j.jmb.2015.05.015.
68. Chen TS, Palacios H, Keating AE. Structure-Based Redesign of the Binding Specificity of Anti-
Apoptotic Bcl-xL. J Mol Biol. 2013;425(1):171-185. doi:10.1016/j.jmb.2012.11.009.
69. Guntas G, Hallett RA, Zimmerman SP, et al. Engineering an improved light-induced dimer (iLID)
for controlling the localization and activity of signaling proteins. Proc Nat Acad Sci U S A.
2015;112(1):112-117. doi:10.1073/pnas.1417910112.
70. Hilpert K, Winkler DFH, Hancock REW. Peptide arrays on cellulose support: SPOT synthesis, a
time and cost efficient method for synthesis of large numbers of peptides in a parallel and
addressable fashion. Nat Protoc. 2007;2(6):1333-1349. doi: 10.1 038/nprot.2007.160.
71. Beyer M, Nesterov A, Block I, et al. Combinatorial Synthesis of Peptide Arrays onto a Microchip.
Science (80-). 2007;318(5858):1888-1888. doi:10.1 126/science. 1149751.
72. Toepert F, Knaute T, Guffler S, et al. Combining SPOT Synthesis and Native Peptide Ligation to
Create Large Arrays of WW Protein Domains. Angew Chemie !nt Ed. 2003;42(10):1136-1140.
doi: 10.1 002/anie.200390298.
73. McLaughlin RN, Poelwijk FJ, Raman A, Gosal WS, Ranganathan R. The spatial architecture of
protein function and adaptation. Nature. 2012;491(7422):138-142. doi: 10.1038/nature11500.
74. Younger D, Berger S, Baker D, Klavins E. High-throughput characterization of protein-protein
interactions by reprogramming yeast mating. Proc Natl Acad Sci U S A. 2017;114(46):12166-
12171. doi:10.1073/pnas.1705867114.
75. Fowler DM, Araya CL, Fleishman SJ, et al. High-resolution mapping of protein sequence-function
relationships. Nat Methods. 2010;7(9):741-746. doi: 10.1 038/nmeth. 1492.
76. Reich LL, Dutta S, Keating AE. SORTCERY-A High-Throughput Method to Affinity Rank Peptide
Ligands. J Mol Biol. 2015;427(11):2135-2150. doi:10.1016/j.jmb.2014.09.025.
77. Kinney JB, Murugan A, Callan CG, Cox EC. Using deep sequencing to characterize the
biophysical mechanism of a transcriptional regulatory sequence. Proc Nat Acad Sci.
37
2010;107(20):9158-9163. doi:10. 1 073/pnas.1004290107.
78. Adams RM, Mora T, Walczak AM, Kinney JB. Measuring the sequence-affinity landscape of
antibodies with massively parallel titration curves. Elife. 2016;5. doi: 1 0.7554/eLife.23156.
79. Sharon E, Kalma Y, Sharp A, et al. Inferring gene regulatory logic from high-throughput
measurements of thousands of systematically designed promoters. Nat Biotechnol.
2012;30(6):521-530. doi:10.1038/nbt.2205.
80. Reich L "Luther," Dutta S, Keating AE. Generating High-Accuracy Peptide-Binding Data in High
Throughput with Yeast Surface Display and SORTCERY. In: ; 2016:233-247. doi:10.1007/978-1-
4939-3569-7_14.
81. Sirin S, Apgar JR, Bennett EM, Keating AE. AB-Bind: Antibody binding mutational database for
computational affinity predictions. Protein Sci. 2016;25(2):393-409. doi: 10.1 002/pro.2829.
82. Moal IH, Fernendez-Recio J. SKEMPl: a Structural Kinetic and Energetic database of Mutant
Protein Interactions and its use in empirical models. Bioinformatics. 2012;28(20):2600-2607.
doi: 10.1 093/bioinformatics/bts489.
83. Kortemme T, Baker D. A simple physical model for binding energy hot spots in protein-protein
complexes. Proc Nat/ Acad Sci U S A. 2002;99(22):14116-14121. doi:10.1073/pnas.202485799.
84. Moretti R, Fleishman SJ, Agius R, et al. Community-wide evaluation of methods for predicting the
effect of mutations on protein-protein interactions. Proteins. 2013;81(11):1980-1987.
doi: 10.1 002/prot.24356.
85. Rocklin GJ, Chidyausiku TM, Goreshnik I, et al. Global analysis of protein folding using massively
parallel design, synthesis, and testing. Science. 2017;357(6347):168-175.
doi:10.1 126/science.aan0693.
86. Chevalier A, Silva D-A, Rocklin GJ, et al. Massively parallel de novo protein design for targeted
therapeutics. Nature. 2017;550(7674):74-79. doi:10.1038/nature23912.
87. Wiedemann U, Boisguerin P, Leben R, et al. Quantification of PDZ domain specificity, prediction of
ligand affinity and rational design of super-binding peptides. J Mol Biol. 2004;343(3):703-718.
doi:10.1016/j.jmb.2004.08.064.
88. Gfeller D, Butty F, Wierzbicka M, et al. The multiple-specificity landscape of modular peptide
recognition domains. Mol Syst Biol. 2011;7(1):484. doi:10.1038/msb.2011.18.
89. Dutta S, Ryan J, Chen TS, Kougentakis C, Letai A, Keating AE. Potent and specific peptide
inhibitors of human pro-survival protein Bcl-xL. J Mol Biol. 2015;427(6 Pt B):1241-1253.
doi:10.1016/j.jmb.2014.09.030.
90. Sio CF, Riemens AM, van der Laan J-M, Verhaert RMD, Quax WJ. Directed evolution of a glutaryl
acylase into an adipyl acylase. Eur J Biochem. 2002;269(18):4495-4504.
http://www.ncbi.nlm.nih.gov/pubmed/12230561. Accessed April 16, 2018.
91. Chaparro-Riggers JF, Polizzi KM, Bommarius AS. Better library design: data-driven protein
engineering. Biotechnol J. 2007;2(2):180-191. doi: 10.1 002/biot.200600170.
92. Habibi N, Mohd Hashim SZ, Norouzi A, Samian M. A review of machine learning methods to
predict the solubility of overexpressed recombinant proteins in Escherichia coli. BMC
Bioinformatics. 2014;1 5(1):134. doi:10.1186/1471-2105-15-134.
93. Wilkinson DL, Harrison RG. Predicting the solubility of recombinant proteins in Escherichia coli.
Biotechnology (N Y). 1991;9(5):443-448. http://www.ncbi.nlm.nih.gov/pubmed/1367308. Accessed
April 3, 2018.
94. Bedbrook CN, Yang KK, Rice AJ, Gradinaru V, Arnold FH. Machine learning to design integral
membrane channelrhodopsins for efficient eukaryotic expression and plasma membrane
localization. Maranas CD, ed. PLOS Comput Biol. 2017;13(10):e1005786.
doi: 10.1371/journal.pcbi. 1005786.
95. Chang CCH, Li C, Webb GI, Tey B, Song J, Ramanan RN. Periscope: quantitative prediction of
38
soluble protein expression in the periplasm of Escherichia coli. Sci Rep. 2016;6(1):21844.
doi: 10.1 038/srep21844.
96. Wang H, Feng L, Zhang Z, Webb GI, Lin D, Song J. Crysalis: an integrated server for
computational analysis and design of protein crystallization. Sci Rep. 2016;6(1):21383.
doi: 10.1038/srep2l383.
97. Radivojac P, Clark WT, Oron TR, et al. A large-scale evaluation of computational protein function
prediction. Nat Methods. 2013;10(3):221-227. doi:10.1038/nmeth.2340.
98. Potapov V, Kaplan JB, Keating AE. Data-driven prediction and design of bZIP coiled-coil
interactions. PLoS Comput Biol. 2015;1 1(2):el 004046. doi: 10.1371/journal.pcbi. 1004046.
99. Opferman JT. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family
members. FEBS J. August 2015. doi:10.1111/febs.13472.
100. Moldoveanu T, Follis AV, Kriwacki RW, Green DR. Many players in BCL-2 family affairs. Trends
Biochem Sci. 2014;39(3):101-111. doi:10.1016/j.tibs.2013.12.006.
101. Montero J, Sarosiek KA, DeAngelo JD, et al. Drug-Induced Death Signaling Strategy Rapidly
Predicts Cancer Response to Chemotherapy. Cell. 2015;160(5):977-989.
doi: 10.1016/j.cell.2015.01.042.
102. Ni Chonghaile T, Sarosiek KA, Vo T-T, et al. Pretreatment mitochondrial priming correlates with
clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129-1133.
doi:10.1 126/science.1206727.
103. Jenson JM, Ryan JA, Grant RA, Letai A, Keating AE. Epistatic mutations in PUMA BH3 drive an
alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. Elife. 2017;6:e25541.
doi:10.7554/eLife.25541.
104. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic
leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or
refractory disease. J Clin Oncol. 2012;30(5):488-496. doi: 10.1 200/JCO.2011.34.7898.
105. Rudin CM, Hann CL, Garon EB, et al. Phase I Study of Single-Agent Navitoclax (ABT-263) and
Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. Clin Cancer Res.
2012;18(11).
106. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a
transient thrombocytopathy that undermines the hemostatic function of platelets. Blood.
2011;118(6).
107. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor,
achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
doi:10.1038/nm.3048.
108. Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in
diverse cancer models. Nature. 2016;538(7626):477-482. doi: 10.1 038/naturel 9830.
109. Foight GW, Ryan JA, Gulle S V, Letai A, Keating AE. Designed BH3 Peptides with High Affinity
and Specificity for Targeting Mcl-1 in Cells. ACS Chem Biol. 2014;9(9):1962-1968.
doi: 10.1021 /cb500340w.
110. Dutta S, Chen TS, Keating AE. Peptide ligands for pro-survival protein Bfl-1 from computationally
guided library screening. ACS Chem Biol. 2013;8(4):778-788. doi:10.1021/cb300679a.
111. Berger S, Procko E, Margineantu D, et al. Computationally designed high specificity inhibitors
delineate the roles of BCL2 family proteins in cancer. Elife. 2016;5:1422-1432.
doi: 10.7554/eLife.20352.
112. Mathieu A-L, Sperandio 0, Pottiez V, et al. Identification of Small Inhibitory Molecules Targeting
the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737. J Biomol Screen.
2014;19(7):1035-1046. doi:10.1177/1087057114534070.
113. Cashman JR, MacDonald M, Ghirmai S, et al. Inhibition of Bfl-1 with N-aryl maleimides. Bioorg
39
Med Chem Lett. 2010;20(22):6560-6564. doi:10.1016/j.bmcl.2010.09.046.
114. Zhai D, Jin C, Shiau C-W, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of
antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008;7(6):1639-1646. doi:10.1158/1535-
7163.MCT-07-2373.
115. Zhai D, Godoi P, Sergienko E, et al. High-throughput fluorescence polarization assay for chemical




Epistatic mutations in PUMA BH3 drive an alternate binding mode to
potently and selectively inhibit anti-apoptotic Bfl-1
Jenson JM, Ryan JA, Grant RA, Letai A, Keating AE. Epistatic mutations in PUMA BH3
drive an alternate binding mode to potently and selectively inhibit anti-apoptotic BfI-1.
Elife. 2017;6:e25541. doi:10.7554/eLife.25541.
This work is licensed under a Creative Commons Attribution 4.0 International License.
J.M.J. and A.E.K. designed and wrote the study. J.A.R. performed the BH3 profiling




Overexpression of anti-apoptotic Bcl-2 family proteins contributes to cancer
progression and confers resistance to chemotherapy. Small molecules that target Bcl-2
are used in the clinic to treat leukemia, but tight and selective inhibitors are not available
for Bcl-2 paralog Bfl-1. Guided by computational analysis, we designed variants of the
native BH3 motif PUMA that are > 150-fold selective for Bfl-1 binding. The designed
peptides potently trigger disruption of the mitochondrial outer membrane in cells
dependent on Bfl-1, but not in cells dependent on other anti-apoptotic homologs. High-
resolution crystal structures show that designed peptide FS2 binds Bfl-1 in a shifted
geometry, relative to PUMA and other binding partners, due to a set of epistatic
mutations. FS2 modified with an electrophile reacts with a cysteine near the peptide-
binding groove to augment specificity. Designed Bfl-1 binders provide reagents for




Anti-apoptotic members of the Bcl-2 family are broadly recognized as promising
cancer therapeutic targets. Human anti-apoptotic proteins BcI-2, Bcl-xL, Bcl-w, Mcl-1,
and Bfl-1 have a globular, helical fold and function by binding to short, a-helical Bcl-2
homology 3 (BH3) motifs in pro-apoptotic proteins, as shown in Figure 2.1A.
Competition for binding among BH3-containing proteins regulates mitochondrial outer
membrane permeabilization (MOMP), which is an irreversible step towards caspase
activation and cell death. The appropriate balance of interactions between pro-survival
and pro-death Bcl-2 family members in healthy cells is often disrupted in cancer cells,
where overexpression of anti-apoptotic Bcl-2 proteins can promote oncogenesis and
confer resistance to chemotherapeutic agents'.
There has been considerable progress developing BH3 mimetic peptides and
small molecules to inhibit the function of anti-apoptotic Bcl-2 proteins by blocking their
interactions. One outstanding example is the small molecule venetoclax, which targets
BcI-2 and was recently approved by the FDA for treatment of chronic lymphocytic
leukemia2 3 . A major challenge in developing venetoclax was achieving specificity,
which is important because Bcl-2 family members support survival of healthy cells. For
example, the small molecule ABT-263 inhibits both BcI-2 and Bcl-xL, but Bcl-xL cross-
reactivity leads to dose-limiting thrombocytopenia- 6 . In the laboratory, highly selective
inhibitors of anti-apoptotic proteins are used for profiling experiments that can establish
which anti-apoptotic proteins are essential for cancer cell survival in individual patients
and predict chemotherapeutic response in vivo7-9. There has been progress towards
creating a panel of reagents specific for each mammalian anti-apoptotic protein that can
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advance such diagnostic assays. Useful reagents for this purpose include peptides and
small molecules that are selective for McI- 11 0 or Bcl-xL1
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Figure 2.1. Computational design of a library of PUMA BH3 variants selective for B~fl-1. (A) PUMA BH3 is
pan-selective; the design objective was a peptide that binds tightly only to B~fl-1. (B) Sequence of PUMA
BH3 showing the heptad numbering convention used in this paper. (C) Overview of the computational
library design procedure. (D-E) Scores for members of three libraries designed to target B~fl-1 (blue), Mcl-
1 (green), or Bcl-xL (red). (D) PSSMsPOT scores (E) STATIUM z-scores. (F-1) The affinities of library
peptides for different Bcl-2 proteins were predicted to be strongly correlated. (F) PSSMsPOT scores for
binding to Bcl-xL versus B~fl-1, (G) PSSMSPOT Scores for binding to Mcl-1 versus B~fl-1, (H) STATIUM z-
scores for binding to Bcl-xL versus B~fl-1, (1) STATIUM z-scores for binding to Mcl-1 versus Bfl-1. For (D-1),
each point represents one peptide sequence and higher scores correspond to higher predicted affinities
for the indicated target. Points on the dashed line have the same low specificity as PUMA BH3 (which is
shown with a black open circle).
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The role of anti-apoptotic protein BfI-1 in cancer is less characterized than that of
Mcl-1 or Bcl-xL, but many lines of evidence suggest that BfI-1 is also a critical target. In
melanoma, Bfl-1 overexpression confers resistance to BRAF inhibitors, and siRNA
mediated knockdown of Bfl-1 induces cell death in melanoma cell lines but not non-
malignant cels13-15 . Mis-regulation of Bfl-1 is also implicated in hematological
malignancies, where elevated levels of Bfl-1 confer resistance to common
chemotherapeutic agents. Bfl-1 knockdown suppresses resistance and sensitizes
malignant B-cells to chemotherapy 1 6. Bfl-1 expression can also counteract the effects of
inhibitors of other anti-apoptotic family members (e.g. Mcl-1, Bcl-2) in leukemia and
lymphoma 17. Bfl-1 mRNA is over-expressed in myriad malignancies including solid
tumor samples from breast, colon, ovary, and prostate tissues18 . Thus, Bfl-1 is an
intriguing therapeutic target and biomarker for resistance to cytotoxic anticancer drugs.
Identifying Bfl-1-selective interaction inhibitors has proven difficult. Small
molecules must compete with an extended protein-peptide interface, and development
of small-molecule inhibitors of Bcl-xL, Bcl-2, and Mcl-1 required years of work, guided by
intensive NMR studies of fragment binding 2 ,19,20. Screening has identified small-
molecule inhibitors of Bfl-1, but these compounds have IC50 values in the high
nanomolar to low micromolar range and exhibit only modest specificity for Bfl-1 relative
to other Bcl-2 family members 21 24 . Recently, helical bundle proteins that incorporate a
BH3 motif have been designed to inhibit Bfl-1 and other anti-apoptotic proteins. These
proteins are tight and selective binders, but their function relies on them being folded,
and delivering proteins of molecular weight > 13 kDa into cells is problematic given
current technologies 25.
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An attractive strategy for inhibiting Bcl-2 family proteins is to develop short
peptides that mimic the interaction geometry of native Bcl-2 protein complexes (Figure
2.1A). Screening BH3-like peptide libraries previously led to identification of a molecule
with -50 nM affinity for Bfl-1 and 30-fold specificity for Bfl-1 over Mc-I1,26 but this
peptide was not shown to induce mitochondrial depolarization in cell-based assays.
Identifying Bfl-1 selective peptides is complicated by the extremely large sequence
space of short BH3-like helical binders. There are more than 1029 possible peptides of
length 23 residues. This sequence space is too large to exhaustively search
experimentally. Furthermore, the BH3 motif is a weak motif (only three positions are
strongly conserved) that does little to restrict possible binders. Another confounding
factor is that Bfl-1 interacts with fewer BH3-like peptides than other anti-apoptotic Bcl-2
family paralogs do 2 7,28 , and no native interaction partners are known to be selective for
Bfl-1, suggesting that there may be limited opportunities for achieving specificity.
The results described here showcase our computational/experimental roadmap
for designing selective peptide inhibitors. We used computational models to design a
focused library of ~107 candidate binders and screened it to identify three peptides,
FS1, FS2, and FS3, that bind tightly and specifically to Bfl-1. Mutational studies and
high-resolution structures revealed that the high specificity comes from a BH3 binding
mode that is markedly different from what has been seen in prior structures of Bfl-1:BH3
complexes 29,30. Importantly, FS1, FS2, and FS3 are specific in BH3 profiling, an assay
that tests for MOMP in cells. Subsequent rational introduction of an acrylamide moiety
to covalently react with Bfl-1 further enhanced Bfl-1 inhibitor specificity. FS1, FS2, FS3
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and their chemical derivatives provide new reagents with utility for studying Bfl-1 biology
and a launching point for developing Bfl-1 targeting therapeutics.
Results
Computational analysis prioritizes mutations for targeted library design
To reduce the enormous space of possible 23-mer sequences to < 107 candidates that
could be tested experimentally, we used computational modeling to design focused
combinatorial libraries. We first scored mutations throughout the BH3 motif using: (1) a
position-specific scoring matrix (PSSM) derived from SPOT peptide array data
(PSSMSPOT) and (2) STATIUM, a structure-based statistical potential that previously
showed good performance evaluating Bcl-2 protein binding to BH3-like peptides (2.
1BC)28 ,31 . Mutations were modeled in the BIM BH3 motif, with the intention of testing
the mutations in the context of both BIM and PUMA BH3 motifs. These two BH3-only
proteins, as well as tBID, interact tightly with Bfl-1. BIM and PUMA bind with low
nanomolar affinity to Bfl-1, but also to anti-apoptotic paralogs Bcl-2, Bcl-xL, Mcl-1, and
Bcl-w 26 ,2 7. Thus, our design challenge was to introduce mutations that eliminate off-
target binding without destabilizing Bfl-1 binding. Bfl-1 shares 38% binding-groove
sequence identity with Mci-1 and 30% binding-groove identity to Bcl-xL. Bcl-2 and Bcl-w
are closely related to Bcl-xL, with 60% sequence identity in the binding groove2 7. To
model cross-reactivity, we compared how mutations in BIM were predicted to affect
binding to Bfl-1 relative to Bcl-xL and Mcl-1, for which high quality structures of
complexes are available. The predicted binding scores of diverse sequences for the
three proteins were highly correlated, and most single mutations were predicted to
weaken Bfl-1 binding compared to the wild-type sequence (Figure 2.2).
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Figure 2.2. Affinities of BIM point mutants for different Bcl-2 proteins are predicted to be strongly
correlated. Larger scores predict tighter binding. Red points represent wt PUMA BH3. (A) PSSMSPOT
scores for binding to Bcl-xL versus Bfl-1, (B) PSSMSPOT scores for binding to Mcl-1 versus Bfl-1, (C)
STATIUM z-scores for binding to Bcl-xL versus Bfl-1, (D) STATIUM z-scores for binding to Mcl-1 versus
Bfl-1. Single point mutations to all residues other than cysteine and methionine were measured at
positions 2d, 2e, 2g-3b, and 3d-4a for PSSMSPOT (A, B). Single point mutations to all residues were
calculated for positions 1g, 2a, 2c-2e, 2g-3b, 3d-3f, 4a, 4b, 4e, and 4f for STATIUM (C, D). Pearson
correlation coefficients are indicated.
Mutational scoring identified promising positions for introducing sequence
variation (helix positions are defined in Figure 2.1B above the sequence of PUMA BH3).
Bfl-1, Bcl-xL, and Mci-1 -were predicted to have distinct residue preferences at
conserved hydrophobic positions 3d and 4a, consistent with previous observations32 .
Many mutations at position 4e were predicted to be strongly Bfl-1 selective, which is













weakened by mutations at this position33 . Mutations at positions 2a and 3g were also
predicted to confer Bfl-1 specificity. In native BH3 motifs, these sites are generally
occupied by small charged or polar residues that can form hydrogen bonds/salt-bridges
with Bcl-xL and Mci-1 groups that are absent in Bfl-1. Finally, the region around sites 2e
and 2g has local structural differences in Bfl-1, McI-1 and BcI-xL.
We used in-house software to select degenerate codons at variable sites that
optimized the predicted BfI-1 binding affinity and specificity and that provided chemical
diversity in the resulting library26 ,34 . The final library design included > 6.8*106 unique
sequences (Table 2.1), most of which were predicted to be Bfl-1 selective by PSSMSPOT
and STATIUM (2.1 F-1). As a control, we designed similarly sized libraries to be
selective for Bcl-xL and Mcl-1 (Table 2.1). PSSMSPOT predicted each library to be
enriched in peptides selective for the appropriate target, as shown in Figure 2.1D. In
contrast, STATIUM predicted significantly more cross-reactivity for library members
(Figure 2.1E, Figure 2.3).
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Table 2.1. Composition of the Bcl-xL, Mcl-1, and Bfl-1 targeted libraries
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Mci-1 STATIUM z-score
Figure 2.3. Scores for members of three libraries designed to target Bfl-1 (blue), Mcl-1 (green), or BcI-xL
(red). Scores show predicted affinities of peptides in each library for each target. Larger scores predict
tighter binding. (A) PSSMSPOT scores for binding to Bcl-xL versus Bfl-1, (B) PSSMSPOT scores for binding
to Mcl-1 versus Bfl-1, (C) STATIUM z-scores for binding to Bcl-xL versus Bfl-1, (D) STATIUM z-scores for
binding to Mcl-1 versus Bfl-1. Points on the dashed line have the same low specificity as PUMA BH3
(open black circle).
Experimental Library screening
Oligonucleotides encoding the peptide libraries designed to be specific for Bfl-1,
Bcl-xL, and McI-1 were synthesized in the context of BIM and PUMA BH3 sequences.
Pooled BIM-based libraries and pooled PUMA-based libraries were then screened
separately for tight and selective binding to Bfl-1. Screening the libraries designed for
McI-1 and Bcl-xL for binding to Bfl-1, in addition to the library designed to target Bfl-1,



















We used yeast-surface display to identify selective Bfl-1-binding peptides from
our mixed libraries (Figure 2.4A). FACS analysis revealed that the initial libraries had a
modest number of cells expressing peptides that bound to Bfl-1 at 100 nM (Figure
2.4B). This is consistent with predictions that less than 6.5% or 4% of the theoretical



























Figure 2.4. Experimental library screening for
Bfl-1 affinity and selectivity. (A) Yeast-surface
display configuration. BH3 peptides were
expressed as fusions to Aga2; HA tag
expression was detected with APC and Bfl-1
binding was detected with PE. (B) FACS
analysis showed that only -5 % of cells in the
unsorted PUMA libraries bound to Bfl-1 at 100
nM. (C) Library binding to 100 nM Bfl-1 after one
round of enrichment. (D-G) Library binding to
off-target proteins (100 nM) after one round of
enrichment: (D) Bcl-xL (E) Bcl-2 (F) Bcl-w (G)
McI-1. (H) Library binding to 100 nM Myc-tagged
Bfl-1 in the presence of excess unlabeled
competitor (McI-1, BcI-2, Bcl-w, and Bcl-xL; 1 pM
each) after six rounds of enrichment. (1)
Inhibition constants determined using
fluorescence anisotropy for 23-residue peptides
corresponding to PUMA BH3, FS1, FS2 and
FS3.
log APC fluorescence (expression)
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Most of the peptides that bound Bfl-1 were cross-reactive with one or more other
Bcl-2 family proteins (Figure 2.4C-G). This cross-reactivity was expected based on the
high correlation of predicted binding scores for Bfl-1, Mci-1, and BcI-xL and highlights
the challenge of identifying specific binders (Figure 2.1 D-E, Figure 2.2). Six rounds of
positive, negative, and/or competition FACS screening were used to isolate cells that
expressed the tightest and most Bfl-1 -selective peptides (Figure 2.5). McI-1, Bcl-xL, Bcl-
2, and Bcl-w were included in the screen as untagged competitors. Early screening
provided many Bfl-1 selective hits from the PUMA libraries, but few from the BIM
libraries, so the BIM libraries were not pursued (Figure 2.6). After several rounds of
competition screening, the PUMA library was enriched in cells displaying peptides that
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Figure 2.5. The PUMA BH3 library was screened to enrich for selective binders of Bfl-1. Several positive,
negative, and competition screens were used to identify tight and selective Bfl-1 binders. Competition
screens included unlabeled competitors at the indicated concentrations. In negative screens, cells that did
not bind to the indicated labeled proteins were collected. Nearly all clones sequenced from pools FL5 and
FL6 contained a cysteine in positions 1g-2e. Sorts FS5 and FS6 were repeated with the cysteine-to-









Figure 2.6. FACS analysis of the designed libraries after first two rounds of sorting (FL2, see Figure 2.5).
Plots show binding of library peptides to 100 nM Myc-tagged Bfl-1 in the presence of excess unlabeled
competitor (Mcl-1, Bcl-2, Bcl-w, and Bcl-xL; 1 pM each) when encoded in (A) a BIM background or (B) a
PUMA background. Cells displaying Bfl-1 selective peptides fall in the region outlined by dotted lines.
50 colonies isolated in the final round of screening were sequenced, providing 13
unique sequences. 9 sequences were from the Bfl-1 specific library, 2 were from the
Bcl-xL library, and 2 were from the Mcl-1 library (Table 2.2). We tested three Bfl-1
selective peptides that were recovered two or more times (FS1, FS2, and FS3). FS1,
FS2, and FS3 were all derived from the Bfl-1 targeted library, although FS1 also
contained one mutation caused by a spurious single-base pair mutation. FS1, FS2, and
FS3 each had reduced affinity for Bfl-1 relative to PUMA, but significantly increased
specificity (Figure 2.41 and Table 2.3). FS1 bound Bfl-1 with Ki = 15 nM and at least
150-fold specificity for Bfl-1 relative to BcI-xL, Bcl-2, Bcl-w, and Mcl-1.
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Table 2.2. Conventionally sequenced clones from pool FL6'.
name sequence library count
FS1 QWVREIAAGLRLAADNVNAQLER Bfl-1 25
FS2 QWVREIAAGLRRAADDVNAQVER Bfl-1 10











Table 2.3. Peptide affinities for Bfl-1, BcI-xL, Mcl-1, Bcl-2, and BcI-w. Ki obtained from competition assays
with fluoresceinated BIM peptide. Data are mean SD of three replicates.
Sequence
Peptide ---- 2------3-----4--- K (nM)
fgabcdefgabcdefgabcdefg Bfi-I Mci-I BcI-XL BcI-w BcI-2
PUMA QWAREIGAQLRRMADDLNAQYER 4.8 .6 2.4 .8 2.3 1.9 3 2 6 4
FS1 QWVREIAAGLRLAADNVNAQLER 15 3 > 5000 2400 1 400 > 5000 > 5000
FS2 QWVREIAAGLRRAADDVNAQVER 21 6 3200 300 > 5000 > 5000 2400 500
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Figure 2.7. FS2 mutations made in a BIM background generate a weak binder of Bfl-1. Fluorescence
anisotropy competition experiments for unlabeled BIM (blue) vs. BIM including mutations from FS2 (BIM-
FS2; E2bV, A2eA, E2gG, 13dA, F4aV, Y4eV; red). BIM-FS2 (Ki = 720 110 nM) binds > 1000-fold more
weakly than native BIM (Ki < 0.1 nM). Data from are 3 independent measurements. Ki values are mean
SD at least three replicates.
To analyze enrichment trends and to assess the success of our library design,
we deep sequenced samples from the naive pool and from pools collected after 3, 4, 5,
and 6 rounds of sorting (sorting conditions are detailed in Figure 2.5). The naive pool
was diverse and not dominated by any particular subset of sequences. In contrast, FS1
(38% of sequences, the most prevalent library member), FS2 (25% of sequences), and
many other peptides from the Bfl-1 targeted library were prominent in the final screening
pool. Analysis of sequential pools showed that peptides from the Bfl-1 targeted library
were substantially enriched relative to peptides from the Bcl-xL and McI-1 targeted
libraries (Figure 2.8A). 73.9% of the unique sequences in the final pool were from the
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Figure 2.8. Evaluation of the library design. (A) Sequences from the Bfl-1 library were preferentially
enriched during sorting. Sequences with no more than 1 amino-acid mutation from the Bfl-1 (blue), Mcl-1
(green), or Bcl-xL (red) targeted libraries are plotted. Other sequences are shown in magenta. (B) The
large majority of unique sequences in the final pool originated from the Bfl-1 library (colors as in part a).
(C-F) Comparison of PSSMSPOT and STATIUM scores for the library before and after sorting. Peptides
from the final sorted pool (red dots) are superimposed on the distribution of scores for the theoretical
library (blue contour plots). Points to the left of the dotted lines correspond to peptides predicted to bind
more selectively to Bfl-1 than does PUMA, with respect to the indicated competitor protein (BcI-xL in C













We scored peptides from the Bfl-1 targeted library that passed all rounds of
screening with the STATIUM and PSSMSPOT models used in library design (Figure 2.8
C-F). Most sequences were predicted to have improved selectivity for Bfl-1 relative to
PUMA (98-99% with improved specificity over Bcl-xL or McI-1 by PSSMSPOT, and 95% or
62% with improved specificity over Bcl-xL or Mci-1, respectively, by STATIUM). The
selected sequences were not among those predicted by either model to be the tightest
or most Bfl-1 selective in the theoretical library.
The binding mode of BfI-1-selective peptides
FS1, FS2, and FS3 included mutations to larger residues than those in PUMA at
their N-termini (red in Figure 2.9B,C), and smaller residues at their C-termini (blue in
Figure 2.9B,C). Deep sequencing of additional selective sequences supported this
trend: Of 612 unique peptide sequences from the final round of sorting that originated
from the Bfl-1 targeted library sequences, 364 showed this type of residue size
patterning at the same sites (sequence logo in Figure 2.9A).
To assess whether the combination of large and small residues played a role in
establishing binding specificity, we tested PUMA/FS2 chimeric peptides for binding to all
five anti-apoptotic proteins. Mutating PUMA to introduce smaller residues at positions
2g, 3d, 4a, and 4e differentially impaired binding to all receptors and resulted in weak
yet specific binding to Bfl-1 (Table 2.4). Mutating residues at the N-terminus of PUMA to
larger residues at positions 2a and 2e gave a modest 2.3-fold increase in affinity for Bfl-
1. But the same mutations in the context of smaller residues at positions 2g, 3d, 4a, and
4e improved affinity for Bfl-1 by 28.6-fold (Figure 2.9D). The different effects of these
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mutations, when made in different contexts, indicates an energetic coupling consistent
with a structural repositioning of the designed peptides in the groove of Bfl-1.
A
B 
- - - - - - ---- 4 -- -I
f g a b c d e f g a b c d e f g a b c d e f g
PUMA Q W A R E I G A Q L R R M A D D L N A Q Y E R
FS1 QWVRE I AAGLRL AADNVNAQ LER
FS2 QWVRE I AAGLRRAADDVNAQVER
FS3 QW IRE I AAGLRRF AD I LNAQVER
increase size decrease size
Figure 2.9. Epistatic mutations in PUMA confer
Bfl-1 binding specificity. (A) Sequence logo of
unique peptide sequences in the final sorted
pool from the Bfl-1 targeted library. (B) Location
of mutated sites in FS1, FS2, and FS3.
Mutations at positions 2a and 2e are in red and
positions 2g, 3d, 4a, and 4e are in blue. (C)
Structure of Bfl-1 (gray surface) bound to PUMA
(green, this work) with residues at positions 2a
and 2e in red and those at 2g, 3d, 4a, and 4e in
blue. (D) Non-additive mutational energies for
PUMA/FS2 chimeric proteins indicate coupling
between N- and C-terminal mutations. Data are





4.8 0.6 nMv \tighter
AG GAVV VAQMLY
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Table 2.4. Affinities of FS2 chimeric proteins binding to Bfl-1, BcI-xL, Mcl-1, Bcl-2, and Bcl-w. Ki obtained
from competition assays with fluoresceinated BIM peptide. Data are mean SD of three replicates.
Sequence
Peptide ---- 2-------3-----4--- K, (nM)a
fgabcdefgabcdefgabcdefg Bfi-1 McI-1 BcI-XL Bcl-w BcI-2
Puma QWAREIGAQLRRMADDLNAQYER 4.8 .6 2.4 .8 2.3 1.9 3 2 6 4
FS2_N/PumaC QWVREIAAQLRRMADDLNAQYER 2.1 .1 .3 .3 2.4 1.2 1.2 .3 14 2
PumaN/FS2_C QWAREIGAGLRRAADDVNAQVER 600 100 > 5000 1100 300 > 5000 2000 160
FS2 QWVREIAAGLRRAADDVNAQVER 21 6 3200 300 > 5000 > 5000 2400 500
To better understand the structural basis for the epistasis, we solved X-ray
crystal structures of Bfl-1 bound to PUMA, at 1.33 A resolution, and of Bfl-1 bound to
FS2 at 1.2 A resolution (Table 2.5). In comparison with all available X-ray structures of
BH3 peptides bound to human or murine Bfl-1, PUMA and FS2 each adopt new, distinct
positions in the binding groove (Figure 2.1 OA and Figure 2.11). FS2 is shifted 1.2 A and
rotated 170 in the binding groove compared to its parent peptide PUMA. The peptide C-
terminus, which harbors the large-to-small mutations, is repositioned more dramatically
than the N-terminus (Figure 2.10B). Despite the shifts in peptide binding geometry, the
structures of Bfl-1 in these newly solved complexes are highly similar. The all-atom
RMSD for residues in the binding pocket (within 5 A of the BH3 peptide) of Bfl-1:FS2 vs.























1 0 z- 2(FS2-BID) STATIUM z-score
Figure 2.10. High-resolution structures of PUMA and FS2 bound to human Bfl-1. (A) Binding groove of
Bfl-1 (gray, surface) with PUMA (yellow) and FS2 (purple). (B) CM- Ca shifts between FS2 and PUMA.
Sites with larger/smaller residues in FS2 are indicated in red/blue. (C) The canonical Bfl-1:BH3 salt bridge
between D3f and R88 is observed in the Bfl-1:PUMA complex but not the Bfl-1:FS2 complex. (D)
Tryptophan at 1g is rotated into the Bfl-1 binding groove in the Bfl-1:FS2 complex and away from the
binding groove in the Bfl-1:PUMA complex. (E) In contrast with the solvent exposed arginine at position
3c of the Bfl-1:PUMA complex, R3c is oriented into the BH3 binding groove in the Bfl-1:FS2 complex,
forming a hydrogen bond with N51 of Bfl-1. (F) Bfl-1 targeted library sequences score better on the Bfl-
1:FS2 structure than on the Bfl-1:BID structure used for the initial library design; higher scores predict
tighter binding. STATIUM z-scores for the Bfl-1 targeted library are in blue. FS1, FS2, and FS3 are
indicated in red and PUMA in green. (G) Sorting enriched sequences that score better on the Bfl-1:FS2
template than on the Bfl-1:BID template. STATIUM z-scores for the input Bfl-1 library are in blue and
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helix position
Figure 2.11. Comparison of PUMA and FS2 binding poses with crystal structures of BH3:Bfl-1 deposited
in the PDB. All Bfl-1:peptide structures were aligned to Bfl-1 and the mean C-alpha positions were
calculated for each BH3 peptide position. Mean distances were calculated separately for all complexes in
the asymmetric unit. (A) The C-alpha distance deviation from the mean is plotted for all structures. (B)
Box plots illustrate the positional variability at each site. FS2 is significantly shifted at peptide positions 3f,
3g, and 4c. The following structures from the PDB were included in this comparison: 2VM629, 2VOF3 ,
2VOG 3, 2VOH 30, 2VO13, 3MQP3 , and 4ZEQ64.
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Table 2.5. Summary of X-ray data collection and refinement statistics.
Bfl-1:Puma Bfl-1:FS2 Bfi-1:FS2_1fX Mcl-1:FS2
Data Collection
Space Group P 1 21 1 P 1 21 1 P 1 21 1 C 12 1
Cell parameters
a, b, c 43.21,43.43, 47.38 43.25, 43.33, 45.74 43.40, 43.50, 47.07 132.62, 62.76, 48.79
a, P, y 90, 114.40, 90 90, 110.90, 90 90, 114.78, 90 90, 98.142, 90
Rmeas 0.066 (0.328) .075 (534) .083 (.357) .164 (1.007)
Rpim 0.026 (0.166) .022 (.196) .035 (.185) .067(.493)
Mean I/a(l) 35.0 (3.0) 58.6 (3.8) 21.0 (2.4) 19.8 (2.5)
Completeness (%) 97 (75) 95 (89) 94 (52) 99 (96)
Redundancy 5.8 (3) 10.2 (5.5) 5.0 (2.6) 5.8 (3.6)
Refinement
Resolution (A) 43-1.33 (1.36-1.33) 36.59-1.199 (1.24 -1.199) 39.4-1.726 (1.788-1.726) 27.33-2.35 (2.41-2.35)
No. Reflections 35893(2869) 47325(4377) 15892(974) 16697(1625)
Rwork/Rfree 0.1325/0.1555 0.1435/0.1629 0.1802/0.2060 0.2162/0.2508(0.1692/0.2385) (0.2054/0.2287) (0.3157/0.3360) (0.2840/0.3594)
Number of non- 1597 1608 1529 3011hydrogen atoms
Average B-factors 21.68 27.32 29.24 48.77
Rmsd
Bond lengths (A) 0.006 0.008 0.003 0.003
Bond angles (*) 0.778 0.9 0.49 0.5
Values in parentheses are for the highest-resolution shell.
Further structural analysis showed that the Bfl-1:FS2 complex supports several
key side-chain interactions that are absent in Bfl-1:PUMA and that may be important for
selective binding. Surprisingly, aspartate at position 3f (D3f) in FS2, which is strongly
conserved in known BH3 motifs, makes different interactions than what is observed in
numerous previously solved Bcl-2 complex structures. D3f typically forms a salt bridge
with arginine 88 (R88) in helix 4 in Bfl-1 or the corresponding arginine in Bcl-xL, McI-1,
Bcl-w, or BcI-2 (Figure 2.10C). In the Bfl-1:FS2 structure, the carboxylate of D3f is
shifted 5.6 A away from the guanidinium group of R88, and is highly solvent exposed
(Figure 2.10C). Because D3f does not form the canonical D3f:R88 interaction and is
solvent exposed, we reasoned that FS2 should tolerate mutations at this site. This was
confirmed by the tight binding of 6 peptides with alanine, serine, asparagine, glutamate,
histidine or tyrosine at this position (Figure 2.12). Disruption of the D3f:R88 salt bridge
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would be expected to reduce affinity for Bfl-1 and for all of the other anti-apoptotic
receptors. However, in the Bfl-1:FS2 complex this change may be partially
compensated by hydrogen bonding on the opposite side of the FS2 helix between
arginine at position 3c (R3c) of FS2 and asparagine 51 (N51) of Bfl-1 (Figure 2.10E). In
Bfl-1:FS2, position 3c is positioned closer to helix 2 of Bfl-1 than in Bfl-1:PUMA, allowing
R3c to fill the space left by an adjacent methionine-to-alanine mutation at 3d when it
adopts this hydrogen-bonded position. N51 at this position of helix 2 is unique to Bfl-1
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Figure 2.12. FACS analysis of cells displaying FS2 or FS2 with single point mutants at position 3f. FACS
profiles for mutants are nearly indistinguishable from that of FS2. Data were collected the same day with




Bfl-1 VLQNVAFSVQKEVE KSCLDNVNvVVs ARTLFNQV1EKEFEDGI iNWGRIVTIFAFEGILIK
Mci-1 TLRRVGDGVQRNHE OGMLRKLDIKN d-rDVKSLSRVMIHVFSDGVtNWGRIVTLISFGAFVAK
Bcl-xL ALREAGDEFELRY SDLTSQLHITP -rAYOSFEQVVNELFRDGV-NWGRIVAFFSFGGALCV
Bcl-2 TLRQAGDDFSRRY AEMSSQLHLTP P-IARGRFATVVEELFRDGV-NWGRIVAFFEFGGVMCV
sBc-w AMRAAGDEFETRF SDLAAQLHVTP 4 - AQQRF'ToVSDELFOGGP-NWGRLVKFFVfGAALCA
Figure 2.13. Multiple-sequence alignment of helices 2-4 of human anti-apoptotic Bfl-1 homologs. Bfl-1
has an amino-acid insertion that may contribute to the widened binding groove between helices 3 and 4
(dotted box). Additionally, there is an asparagine that is unique to Bfl-1 at the elbow between helix 2 and
3 that forms a hydrogen bond with FS2 (solid box). This interaction may contribute to the Bfl-1 specificity
of FS2. Sequence alignment made using Cobalt65.
Other structural differences between PUMA and FS2 binding are apparent near
the N-terminal end of the peptide. Modeling FS2 mutations in the Bfl-1:PUMA structure
suggested that the small-to-large mutation of alanine at position 2a in PUMA to the
valine in FS2 would result in steric clashes with helix 4 of Bfl-1 for all backbone-
dependent rotamers (Figure 2.14). This change is accommodated by the shift in the Bfl-
1:FS2 structure. Also, a rotation of FS2 in the Bfl-1 binding groove partially buries the
phenylalanine at position 1g that is solvent-exposed in the PUMA complex, which may
be energetically favorable (Figure 2.1OD).
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----------- a2 ------------ I|1--1- | ---------- a4 ------------ I I|---------- a5 ----------
BfI-1:PUMA BfI-1:FS2
Figure 2.14. Residues in FS2 are not readily accommodated in the PUMA binding geometry. Modeling on
a fixed backbone indicates that all valine rotamers would clash (red spheres) with Bfl-1 (green) when
modeled in to position 2a of PUMA (gray). Shown here is the most preferred rotamer. The shifted binding
mode of FS2 accommodates valine at position 2a. Model made using Pymol. Red lozenge indicates a
steric clash as detected by the program.
Because the altered binding mode of FS2 is expected to impact predictions made
using structure-based models, we re-scored the designed Bfl-1 library on the shifted Bfl-
1:FS2 structure using STATIUM. FS1 and FS2 scored much better (higher) on the
shifted model than on the original model, whereas PUMA scored better on the original
model (Figure 2.10F). Analysis of the entire pool of sequences that passed screening
showed that these peptides were enriched in sequences that scored better on the
shifted model, compared to the input library, consistent with our observation of size
patterning in the majority of these sequences (Figure 2.10G).
Structural analysis of off-target binding to Mcl-1
To better understand the structural basis of FS2 binding specificity, we solved the
X-ray crystal structure of FS2 bound to Mcl-1 at 2.35 A resolution. FS2 binding to Mcl-1
is > 100-fold weaker than binding to Bfl-1. Similar to the way FS2 binds to Bfl-1, FS2
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engages Mci-1 in a shifted orientation relative to BIM (Figure 2.15A, B). As is the case
for FS2 binding to Bfl-1, this shift re-positions the highly conserved aspartate at peptide
position 3f to a location 4.8 A away from McI-1, disrupting the canonical salt bridge with
arginine 92 (Figure 2.15C). This disruption would be expected to reduce affinity for Mcl-
1, but it doesn't account for the specificity of FS2 for Bfl-1, because the salt bridge is
lost in both complexes. There are other differences between the Bfl-1:FS2 and Mcl-
1:FS2 structures that may account for some of the affinity difference. For example, R3c
in FS2 forms a hydrogen bond with N51 of Bfl-1, but does not form an equivalent
interaction with Mcl-1 and is instead solvent exposed (Figure 2.15D). In McI-1, there is
an alanine (A55) at this site, and an adjacent histidine (H53) would be expected to clash
with R3c if it adopted this conformation. The N-terminus of FS2 is also buried further
into the binding groove of Bfl-1 than Mcl-1 (Figure 2.15E). The Bfl-1 binding groove is
wider in this region than the Mcl-1 binding groove, as illustrated by aligning many Bfl-1
and Mcl-1 structures (Figure 2.16). This region of the groove is formed by helices 3 and
4. There is an amino acid insertion in the loop between helices 3 and 4 that is unique to

















Figure 2.15. Crystal structure of FS2 bound to human Mcl-1. (A) Binding groove of Mci-1 (blue, surface)
with BIM (yellow, 2PQK 6) and FS2 (purple). (B) Ca- C0 shifts between FS2 and BIM when bound to Mcl-1.
(C) The canonical Bfl-1:BH3 salt bridge between D3f and R92, formed in McI-1:BIM, is not observed in
the McI-1:FS2 complex. (D) In contrast with the arginine at position 3c of the Bfl-1:FS2 complex, which
makes packing and hydrogen-bond interactions the interface, R3c is oriented away from the BH3 binding
groove in the McI-1:FS2 complex. (E) The McI-1 binding groove between helix 3 and helix 4 is narrower
than the Bfl-1 binding groove, and the N-terminus of FS2 is shifted in the McI-1:FS2 structure in




Figure 2.16. Alignment of all crystal structures in the PDB of Bfl-1/Mcl-1 bound to BH3 peptides. Helix 3
in Bfl-1 is shifted relative to Mcl-1, resulting in a widened binding groove.
Biological Activity of Designed Bfl-1 inhibitors
We tested our designed peptides for Bfl-1 selective targeting by carrying out BH3
profiling of cells with known dependencies on anti-apoptotic proteins. In this assay,
peptides are titrated into permeabilized cells, and mitochondrial depolarization is
measured using the voltage-sensitive dye JC-1 (Figure 2.17A)8 . We tested the apoptotic
sensitivity of BCR-ABL-expressing B-lineage acute lymphoblastic leukemia cell lines
engineered to depend on Bcl-2, Bcl-xL, Mcl-1, or Bfl-1 overexpression for survival 35 . The
percent depolarization from these assays is shown in Figure 2.17B. In comparison with
a shorter, truncated PUMA BH3 (PUMAle-4c, PUMASh), which promoted mitochondrial
depolarization in all of the cell lines tested, at 100 nM the Bfl-1 selective inhibitors FS1,
FS2, and FS3 promoted depolarization only in Bfl-1 dependent cells. An inactive
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PUMAsh mutant, PUMA L3aA;D3fA (PUMA 2A) was used as a negative control 36. EC50
values for inducing mitochondrial permeabilization in the engineered cell lines agreed
well with trends in Bfl-1 binding affinities, as expected based on the mechanism of
action (Figure 2.17C). As an additional test for on-pathway activity, we measured
cytochrome c release in the same engineered cell lines in response to peptide
treatment, using iBH3 profiling37. The specificity pattern observed when monitoring
cytochrome c release was consistent with that obtained by BH3 profiling read out using
JC-1 (Figure 2.17D, Figure 2.18). A Mci-1 selective peptide, MS1 was used as a
control10 . In both assays, FS3 promoted mitochondrial depolarization more potently than
FS1 or FS2, but was less selective, with significant cross reactivity at 30 pM peptide
concentration.
FS1, FS2, and FS3 were based on the sequence of PUMA BH3, which has been
proposed to directly activate apoptosis through interactions with BAK and BAX38 ,3 9. To
test the possibility that FS1, FS2, or FS3 may directly activate BAK and BAX, we
measured cytochrome c release in two "unprimed" cell lines (PC-3 and SF295).
Unprimed cells require BAK/BAX activators to release cytochrome c40. We observed
cytochrome c release in cells treated with BIM or PUMA BH3 but not in cells treated
with as much as 100 pM FS1 or FS2 (Figure 2.19). Treatment with FS3 or PUMAsh
peptide led to cytochrome c release at 32 and 100 pM (Figure 2.19). This may indicate
that FS3 and PUMAsh have very weak activator function. Taken together, our data show
that FS1 and FS2 are not themselves activators, but that they instead act as apoptotic
sensitizers by competing with activators or with BAX or BAK for binding to anti-apoptotic
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Figure 2.17. Designed Bfl-1 inhibitors selectively induce MOMP in Bfl-1 dependent cells. (A) The BH3
profiling assay detects MOMP by monitoring JC-1 fluorescence in permeabilized cells treated with
different peptides. (B-C) Depolarization of mitochondria induced by designed peptides in four cell lines
that depend on ectopic expression of Mcl-1, Bcl-2, Bcl-xL, or Bfl-1 for survival. (C) Correlation between Ki
in solution studies and EC50 values in BH3 profiling. Open circles indicate lower bound estimates of EC50










































Figure 2.18. At low concentrations, FS1, FS2, and FS3 selectively induced cytochrome c release only in
Bfl-1 dependent cell lines. iBH3 was performed on highly primed cells of known anti-apoptotic
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Figure 2.19. iBH3 was performed on unprimed cells to test for activation function. These cells require a
BAK/BAX activator to release cytochrome c. Cytochrome c release is stimulated by the known activator
peptides BIM and PUMA BH3. Truncated PUMA (le-4c), PUMAsh, and FS3 have reduced capacity to
promote cytochrome c release. FS1 and FS2 show no cytochrome c release up to 100 pM. Data are
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Covalent Inhibitors of Bfl-1 Enhance Specificity
Our initial sorts for Bfl-1 selective binders identified many sequences that
included cysteine at position 1g or 2b (Table 2.6). Interestingly, cysteines encoded at
several other positions along the BH3 motif were not enriched. Furthermore, cysteine
was not enriched in previous screens for Bfl-1 binding 26. This observation led us to
hypothesize that Bfl-1 binding selectivity could be improved in non-reducing conditions if
the peptide ligand formed a disulfide bond with cysteine 55 (C55) of Bfl-1, which is
adjacent to the binding cleft of Bfl-1 and unique to Bfl-1 among Bcl-2 family paralogs
(Figure 2.20). Testing yeast-displayed peptides for binding to a Bfl-1 cysteine-to-serine
(C55S) mutant confirmed that PUMA and BIM bound to Bfl-1 C55S, whereas the
majority of the peptides in the cysteine-enriched pool bound to wild type Bfl-1 but not to
Bfl-1 C55S (Figure 2.21). Rescreening our library using Bfl-1 C55S led to the
identification of FS1, FS2 and FS3, as described above. But, in addition, the discovery
that BH3 peptides in our library could access a unique, reactive cysteine in Bfl-1 led us
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Figure 2.20. An electrophilic variant of FS2 reacts covalently with Bfl-1. (A) C55 in Bfl-1 is close to the
BH3 binding groove in BIM:Bfl-1 structure 2VM629. (B-C) Modeling suggested two ways in which an N-
terminal acrylamide group could be incorporated into a BH3 peptide with good reaction geometry, leading
to peptides FS2_lgX (modification shown in B) or FS2_lfX (modification shown in C) (D) FS2_lfX (red)
reacted more rapidly with Bfl-1 than FS2_1gX (green). Bfl-1 crosslinking as a function of reaction time
was measured using gel-shift assays; data are mean SD of 2 or more independent measurements.
Crosslinking did not occur with the acetylated control peptide FS2_1fAc (blue). (E) FS2_lfX (red) was
more potent than FS2_1fAc (blue) in BH3 profiling assays of Bfl-1 dependent cells. Data are mean SD
of 3 or more independent measurements. (F) X-ray structure of Bfl-1 covalently cross-linked to FS2_lfX.
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Figure 2.21. Library members bind covalently to Bfl-1 cysteine 55. FACS analysis of yeast cells
displaying (A) PUMA in the presence of Bfl-1, (B) PUMA in the presence of the cysteine-to-serine point
mutant Bfl-1 C55S, (C) the FL6 library pool in the presence of Bfl-1, and (D) the FL6 library pool in the
presence of Bfl-1 C55S.
We used structure-based modeling to choose appropriate cysteine-reactive
electrophiles and optimize their placement in different BH3 positions in the 2VM6
structure of Bfl-1 bound to BIM BH329. Our two most promising designs featured N-
terminal Michael acceptors at position 1g (FS2_lgX; Figure 2.20B) or 1f (FS2_lfX;
Figure 2.20C) of peptide FS2. We tested our designs for covalent modification of Bfl-1
and Bfl-1 C55S using gel-shift assays. Both FS2_1gX and FS2_1fX modified Bfl-1 once








A2 other solvent-exposed cysteine residues) did not react with these electrophilic
peptides for at least 6 hours (Figure 2.22). Using densitometry, we measured the
fraction of Bfl-1 reacted as a function of time for both designs. FS2_1fX reacted with Bfl-
1 with a half-life of 6.5 min and FS2_1gX reacted more slowly with a half-life of 138 min
(Figure 2.20D). We tested FS2_1fX in BH3 profiling and found that it improved on-
pathway targeting of Bfl-1 compared to N-terminally acetylated control (Figure 2.20E)
and was selective for Bfl-1 (Figure 2.23). We solved a crystal structure of FS2_1fX
bound to Bfl-1 that showed clear electron density consistent with a covalent bond to
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Figure 2.22. Kinetics of the reaction of Bfl-1 with electrophilic peptides. (A) There is a time-dependent
shift in apparent molecular weight, as assessed by SDS-PAGE, when Bfl-1 is incubated with FS2_1fX but
not when Bfl-1 C55S 1 is incubated with FS2_lgX, consistent with covalent modification of Bfl-1 at
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Figure 2.23. Depolarization of mitochondria induced by designed peptides, including covalent inhibitor
FS2_gX, in four cell lines that depend on ectopic expression of McI-1, Bcl-2, Bcl-xL, or Bfl-1 for survival.
Data are mean SD of 3 or more independent measurements.
Discussion
Bfl-1 is implicated in cancer progression, and inhibiting its anti-apoptotic function
may be therapeutically beneficial. Because the role of Bfl-1 in disease is less
characterized than that of McI-1 or Bcl-2, selective targeting agents will likely be critical
for disentangling the roles of different anti-apoptotic proteins. Prior efforts to identify Bfl-
1 selective inhibitors provided molecules with only modest binding affinity and/or
selectivity2 -24 ,26. More recent work has shown, as we demonstrate here, that reaction of
an electrophilic group on a Bfl-1 inhibitor with a cysteine near the BH3 binding site
confers both infinitely tight and covalently selective interactions with Bfl-1 in preference
to other BcI-2 protein family members. This strategy has been used to target Bfl-1 with a
BIM peptide chemically modified to react with cysteine41 -43. But BIM is a promiscuous
binder of Bcl-2, Bcl-xL, Bcl-w and McI-I, as well as an activator of BAX and BAK44.
Thus, although Bfl-1 is the only covalent target of electrophilic BIM, this approach does
not provide an optimal strategy for dissecting the contributions of Bfl-1 to cell survival,
because BIM peptides are expected to have many effects on the apoptotic protein-
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interaction network. Here, we addressed this by successfully re-engineering PUMA, a
promiscuous binder of anti-apoptotic proteins, to make it highly selective for Bfl-1 both
as a non-covalent and as a covalent inhibitor.
In re-designing PUMA, we confronted the enormous space of possible mutational
variants. The challenge was to identify combinations of mutations that would reduce
binding to Bcl-2, Bcl-xL, Bcl-w, and Mcl-1, while not substantially weakening Bfl-1
interaction. We used computational modeling and existing experimental data to guide
our design of focused libraries of peptides predicted to provide the desired specificity.
We tested libraries of combinations of the best-ranked mutations both in the context of
BIM and in the context of PUMA.
Interestingly, our experimental results showed stark differences in binding
behavior between two libraries that introduced the same mutations into BIM vs. PUMA
BH3 peptides. Our carefully designed library was rich in Bfl-1 selective binders when
tested in a PUMA background, but poor in binders when encoded in a BIM BH3
sequence. This was not because PUMA is a tighter or more selective binder of Bfl-1
than is PUMA; published data indicate that BIM BH3 binds at least as tightly to Bfl-1 as
does PUMA BH326 . Also, deep sequencing of the two input libraries indicated that they
were of similar quality; each had only a small percentage of sequences that were not
designed (6.6% for the BIM library and 4.4% for the PUMA library). Given that dramatic
differences were observed between the libraries early in screening (pool FL2, Figure
2.6), and that the PUMA library still contained just 5.9% non-designed mutations in pool
FL3, it is unlikely that random mutations were the source of the observed differences.
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We think it likely that the difference between the PUMA vs. BIM libraries arose
because background sequence differently influenced the contributions of library
mutations, or combinations of mutations, to binding. For example, this could be the case
if PUMA variants but not BIM variants could undergo the conformational shifts we
observed in our structures. Consistent with this, we found that introducing the 6
mutations of FS2 into BIM BH3 rather than PUMA BH3, giving BIM-FS2, weakened BIM
BH3 binding to Bfl-1 by >1000-fold; Figure 2.7. Differential effects of mutations based on
BH3 context were also observed by DeBartolo et al., who reported modest correlation
between the influence of point mutations on Mcl-1 binding tested in the context of BIM
vs. NOXA BH3 (Pearson r -0.55), and between the effect on Bcl-xL binding of mutations
made in BIM vs. BAD (r ~ 0.78)31. Our results are also consistent with the experiments
of Dutta et al., who studied Bfl-1 binding selectivity in BIM-based libraries but identified
only modestly selective peptides in screening26 . Other groups have reported similarly
dramatic background effects of context in protein engineering, e.g. in antibody libraries,
and have obtained different success rates from screens and selections that started with
different framework sequences4.
Epistasis between mutations contributed to selective Bfl-1 binding (Figure 2.9D).
Crystal structures of Bfl-1 bound to PUMA vs. FS2 show that epistasis arises from a
substantial alteration of the Bfl-1-binding mode. FS2 binds in a shifted and rotated
orientation relative to PUMA (Figure 2.10A), and does not make a key salt bridge that is
conserved in nearly all structures of Bcl-2 protein complexes. Interestingly, sorting for
Bfl-1 selective binders enriched sequences that score better when modeled using the
FS2 binding conformation than with the BIM or PUMA binding geometry (Figure 2.10G),
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suggesting that this structural shift may be a common feature of many sequences that
we identified and a general strategy for achieving Bfl-1 specificity. The FS2 structures
now provide a springboard to permit the design of further improvements in Bfl-1
selectivity, affinity, cell permeability, and other physicochemical properties. For
example, the structures of FS2 bound to Bfl-1 can be used to design chemical
crosslinks to reinforce helicity and promote cellular uptake46-49, the structure of FS2
bound to Mcl-1can be used to further reduce Mcl-1 binding, and the structure of
FS2_1fX can be used as a platform for the design of therapeutic peptides and small
molecules that covalently target Bfl-1.
By combining the strengths of computational design and library screening, we
successfully identified rare peptides with desired binding specificities. It is unlikely that
computational approaches alone could have identified FS1, FS2, or FS3 in the absence
of structural templates for the FS2 binding mode. Also, library sequences that were
predicted to give the best Bfl-1 affinity and specificity over BcI-xL and Mcl-1 (the top/left
edge of the score distribution for sequences in Figure 2.1F-1) were not among the hits
recovered in screening. This could be because of deficiencies in the models, or
because the experiments included competitor homologs Bcl-w and Bcl-2, which were
not modeled in library design. A structure of Bcl-w bound to a BH3 peptide was not
available when we deigned our libraries, so designing specificity against Bcl-w would
have been subject to the inaccuracies of homology models. It is also possible that even
the highest affinity sequences that bind in the geometry that we modeled cannot match
the tight binding or specificity that can be achieved with a conformational shift.
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Conversely, unguided library approaches (including random mutagenesis) would
probably not generate FS1, FS2, or FS3. More than 6 x 1012 sequences are 6 mutations
away from 23-residue PUMA BH3, and most mutations are predicted to weaken
binding. Furthermore, our models predict that most mutations will have correlated
effects on binding to different Bcl-2 family members (Figure 2.2), which dramatically
reduces the random chance of finding mutations that confer specificity. Library
approaches that take advantage of iterative randomization would have difficulty finding
sequences that contain synergistic mutations like those in FS2.
Random mutagenesis is a powerful tool for exploring a local sequence space
(e.g. by error-prone PCR), and this could be a strategy for further improving peptides
identified in library screens such as this one. The low frequency of non-designed
mutations in our libraries introduced a random sampling element, but this did not appear
to be important for success in this study. FS2 and FS3 were included in the designed
library, and FS1 had only a single non-designed mutation, at a solvent-exposed site.
The peptides we designed in this work have immediate value as biochemical
reagents and tools for therapeutic development. FS1, FS2, and FS3 selectively trigger
apoptosis of Bfl-1 dependent cells in a BH3 profiling assay, and given that Bcl-2, Mcl-1,
and Bcl-xL dependencies are predictive of therapeutic response to cytotoxic anticancer
drugs7- 9, we speculate that diagnosing Bfl-1 dependence using these peptides will
provide additional predictive power to guide the use of existing treatments50.
Furthermore, recent studies with an electrophilic variant of BIM show that targeting Bfl-1
enhances cytotoxicity and caspase 3/7 activity in at least 3 Bfl-1 expressing melanoma
cell lines41. Finally, the high affinity and selectivity of these peptides, along with the
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available structural data, make them promising starting points for the development of
peptide- or small-molecule therapeutics directly targeting Bfl-1. Therapeutic applications
using peptides require a solution to the cell delivery problem. But chemical modification
by hydrocarbon stapling, carefully optimized, has proven effective for delivering other
helical BH3 peptides into cells46-4 9. We are optimistic that similar modifications will be
effective for FS1, FS2, and/or FS3, and we predict rapid development of a range of cell-
deliverable Bfl-1 targeting agents that draws on lessons learned from Bcl-xL and Mcl-1
inhibitor design as well as the new structural insights that we provide here.
Methods
Peptide synthesis and purification
Library peptides, the PUMA BH3 peptide, and PUMA BH3 peptide mutants had
N-terminal acetlyation and C-terminal amidation. Fluoresceinated BIM (fluorescein-
IWIAQELRRIGDEFNAYY) BH3 was synthesized with N-terminal 5/6-fluorescein amidite
and C-terminal amidation. Covalent peptide inhibitors had N-terminal acrylamide and C-
terminal amidation. Peptides were synthesized by the MIT Biopolymers Laboratory. The
crude synthesis product was purified by HPLC on a C18 column with a linear gradient of
acetonitrile in water. Peptides were verified by mass spectrometry.
Fluorescence polarization assay
Competition fluorescence polarization experiments were performed by titrating 0-
10 pM of unlabeled peptide into 50 nM receptor plus 25 nM fluoresceinated BIM
(fluorescein-IWIAQELRRIGDEFNAYY) in FP buffer (25 mM Tris pH 7.8, 50 mM NaCl, 1
mM EDTA, 5% DMSO, 0.001% v/v Triton-X). C-myc-tagged receptors were used for all
Bcl-2 homologs, as previously described'"'. Plates were mixed at 23 0C for 3 h. Plates
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were read again at 24 to check equilibration. Experiments were done in at least
triplicate. Data were fit, as described for competition fluorescence anisotropy
experiments in Foight et al.10 , to a complete competitive binding model (equation 17 in
Roehrl et al., 2004)51 using a Python script.
Library design
Position-specific scoring matrices based on SPOT array intensities (PSSMSPOT)
were described previously 31' 32 52 . PSSMSPOT scores were normalized to wild-type BIM
BH3, as described by Dutta et a1 32 . The structure-based statistical potential STATIUM
was used to predict and score the effect of mutations in BH3 peptides on binding to Bfl-
1, McI-1, Bcl-xL2 8 ,3 1. The crystal structures used to create the STATIUM models were
the same as those used in previous studies 28' 31: 3MQP (Bfl-1:Noxa)5 3, 3PK1 (Mcl-
1:BAX)54, and 3108 (Bcl-xL:BIM3aF) 55. STATIUM z-scores were normalized using the
score distribution for the human proteome, as described by DeBartolo et al2 8.
Libraries were constructed using degenerate codons chosen by a computational
optimization protocol56 . To guide codon selection, we divided residue substitutions into
three categories: preferred, required, and disruptive. Preferred substitutions were those
that scored higher than the median of all point mutants of BIM at positions 2a-4e on
either PSSMSPOTBfI-1 or STATIUMBfl-1. Additionally, some substitutions that did not meet
these criteria but that had large specificity scores from either PSSMSPOTBfl-1 or
STATIUMBM-1 were included. Required substitutions, designated manually, were a
subset of the most promising preferred residues, particularly those predicted to be
highly selective for Bfl-1 or BIM/PUMA wild-type residues. Specificity for Bfl-1 over Bcl-
XL or Mcl-1 was determined by the difference of PSSMSPOT scores or the difference in
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STATIUM z-scores. Disruptive residues included mutations with PSSMSPOT or STATIUM
scores for Bfl-1 that were more than 1 standard deviation worse than wild-type BIM.
Degenerate codons were considered as possibilities for design if they included all of the
required residues at a site and none of the disruptive residues. Codons that encoded 3
or fewer variants were eliminated, to decrease the likelihood that a large percentage of
the library would be "poisoned" by a disruptive substitution that wasn't identified by our
models. Combinations of degenerate codons were optimized with integer linear
programming, as previously described, to maximize the number of sequences
composed of preferred residues 56. The library was limited to at most 1 x 107 DNA
sequences. The final Bfl-1 targeted library contained a large number of protein
sequences (6.84 x 106), many of which were predicted to be tight and selective Bfl-1
binders by the PSSMSPOT and STATIUM models. The entire design process was
repeated to produce libraries selective for Bcl-xL and Mci-1.
Construction of the yeast-display vector and the combinatorial library
DNA encoding PUMA-BH3 (residues 132-172 from human PUMA, UniProt #
Q9BXH1-1) with a carboxy-terminal FLAG tag was subcloned into the plasmid
pCTCON2 57 between Nhel and Xhol restriction digest sites (5' Nhel-
GGTACCGGATCCGGTGGC-PUMA BH3-
GGCGGCCGCGATTATAAAGATGATGATGATAAATAA-Xhol-3'). The BH3 peptide
library was constructed with homologous recombination. The inserts were constructed
using the PUMA-BH3 yeast display vector as a template, a reverse primer (5'
CTAAAAGTACAGTGGGAACAAAGTCG 3'), and forward primers with degenerate
bases (PUMA Bfl-1 targeted library: 5' C GGA TCC GGT GGC CAA TGG VHA CGT
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GAA ATT KVT GCC NDC CTG CGT CGC NBC GCG GAT VWK NHT AAT GCC CAA
NYT GAA CGT CGT CGC CAG GAG GAA C 3'; BIM Bfl-1 targeted library: 5' GGA TCC
GGT GGC CGT CCG VHA ATT TGG ATT KVT CAG NDC CTG CGT CGT NBC GGC
GAT VWK NHT AAT GCG TAT NYT GCG CGT CGC GTG TTT CTG AAT 3'; PUMA
Bcl-xL targeted library: 5' C GGA TCC GGT GGC CAA TGG VWS CGT GAA NWT GGC
GCC CAA CTG RBA CGC NNC GSC GAT GAT CTG VHC RMA CAA NVC GAA CGT
CGT CGC CAG GAG GAA C 3'; BIM BcI-xL targeted library: 5' GGA TCC GGT GGC
CGT CCG VWS ATT TGG NWT GCG CAG GAA CTG RBA CGT NNC GSC GAT GAA
TTT VHC RMA TAT NVC GCG CGT CGC GTG TTT CTG AAT 3'; PUMA Mcl-1
targeted library: 5' GT ACC GGA TCC GGT GGC CAA NSG GCG BNC SAW RYC RBT
GCC CAA CTG RNA CGC ATG GCG GAT GAT NHT VAK GCC CAA TAT GAA CGT
CGT CGC C 3'; BIM Mcl-1 targeted library: 5' TACCGGATCCGGTGGCCGT NSG
GAA BNC SAW RYC RBT CAGGAACTG RNA CGTATTGGCGATGAA NHT VAK
GCGTATTATGCGCGTCGCGT 3'). To complete insert construction, the 5' ends of
these PCR products were further extended until there was at least 40 bp of homology to
the acceptor vector on both ends of the library inserts. The acceptor vector was
prepared by cleaving the yeast display vector with the endonucleases Xhol and Nhel
and purifying the cleavage product with a gel purification kit (Qiagen). The library inserts
and acceptor vector were mixed and transformed into yeast following the procedure of
Gietz et al.58 . 20 electroporations produced > 10 fold more transformants than the
theoretical size of each library with vector background estimated at < 0.01%. DNA from
transformed cells was PCR amplified to check for randomization.
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Flow cytometric analysis and sorting
The yeast-displayed Bfl-1 library was grown and sorted using fluorescence
activated cell sorting (FACS) according to a protocol adapted from Reich et a 59. The
libraries were grown from glycerol stocks that were inoculated to a final OD600 of 0.05 in
a volume sufficient to oversample the estimated library diversity by at least 10-fold in
selective media containing glucose (SD+CAA: 5 g/L casamino acids, 1.7 g/L yeast
nitrogen base, 5.3 g/L ammonium sulfate, 10.2 g/L Na2HPO4-7H 20 and 8.6 g/L
NaH2PO4-H 20, 2% glucose). Cultures were grown for 12 h at 30 0C and then cells were
diluted to OD600 of 0.005-0.01 in SD+CAA and grown to OD600 of 0.1-0.6 (-12h) at 30
0C. To induce expression, cultured were diluted (40 mL inoculate/L) into selective media
containing galactose (SG+CAA: 5 g/L casamino acids, 1.7 g/L yeast nitrogen base, 5.3
g/L ammonium sulfate, 10.2 g/L Na2HPO4-7H 20 and 8.6 g/L NaH 2PO4-H 20, 2%
glucose) and grown to OD600 of 0.2-0.5 (16-24h) at 30 C. Induced yeast cells were
filtered with 0.45 pm filter plates or bottle-top filters and washed twice with BSS (50 mM
Tris, 100 mM NaCl, pH 8, 1 mg/ml BSA). Sufficient cells to oversample the library
diversity at least 10-fold were resuspended in BSS with at least 10-fold molar excess
target protein and incubated for 2 h at room temperature with gentle shaking. Cells were
filtered, washed twice in chilled BSS, and incubated with a mixture of primary antibodies
(anti-HA mouse, Roche, RRID:AB_514505, and anti-c-myc rabbit, Sigma,
RRID:AB_439680) at 1:100 dilution in a volume of 20 pl per 106 cells for 15 min at 4 'C
in BSS. Cells were filtered, washed twice in chilled BSS, and incubated in a mixture of
secondary antibodies (1:40 APC rat anti-mouse, BD, RRID:AB_398465, and 1:100 PE
goat anti-rabbit, Sigma, RRID:AB_261257) in BSS at 4 0C in the dark for 15 min. The
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filtering and washing steps were repeated and the labeled cells were resuspended in
BSS and analyzed on a BD FACSCanto flow cytometer or sorted on a BD FACSAria
using FACSDiva software. The sorted cells were collected in selective media containing
glucose (SD+CAA) and grown to an OD600 of 6-10 for -48 hours in the presence of
streptomycin/penicillin to prevent bacterial growth, then pelleted, washed, and stored as
glycerol stocks in SD+CAA+20% glycerol. A series of positive, negative, and
competition sorts were used to enrich Bfl-1 selective binders. The detailed sorting
scheme is given in Figure 2.5.
Illumina sequencing and data processing
Glycerol stocks from each pool isolated during sorting were grown overnight in
SD+CAA, using sufficient stock to oversample the estimated library diversity by at least
10-fold. 1 x 108 cells from each pool were pelleted in a microcentrifuge tube at 300 x g
for 1 min and washed twice with PBS. The plasmid DNA from yeast was extracted using
the Zymoprep Yeast Plasmid Miniprep II (Zymo Research) reagents and Qiagen
miniprep columns. The DNA was eluted in water. The BH3 library was amplified with
PCR using primers that encoded an Mmel restriction enzyme binding site at 5' end and
a universal Illumina sequencing region on the 3' end. After purification with the Qiagen
PCR purification kit, the PCR products were digested with Mmel (3.45 pmol DNA:2 pL
Mmel, NEB) for 1 h at 37 *C before being heat inactivated at 80 'C for 20 min. Each
digestion product was then ligated by treatment with T4 DNA ligase (NEB) for 30 min at
20 'C to double-stranded DNA fragments containing Illumina adapters, with the adapter
containing a unique barcode, and heat inactivated for 10 min at 65 0C. Barcodes were
varied by at least two bases and were used to assign Illumina reads to the appropriate
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pool. A final PCR amplified the ligation product and extended the 5' and 3' regions to
include adaptor sequences for Illumina sequencing. Samples were then multiplexed and
run in one lane on an Illumina Nextseq with paired-end reads of 75 bp using the
universal Illumina forward sequencing primer and a PUMA construct-specific Illumina
read primer reverse (5' CGCCTTGTTCCTCCTGGCGACGACGTTCATATTGGGC 3').
Illumina deep sequencing data was processed in python. The data was filtered for
sequences with barcodes that had high Phred Scores (> 20). Sequences were
reconstructed by aligning pair end reads. Sequences observed fewer than 20 times
were removed from the data set.
Crystallography
Crystals of Bfl-1 in complex with PUMA, FS2 or FS2_1fX peptides were grown in
hanging drops over a reservoir containing 1.8 M ammonium sulfate, 0.1 M MES pH 7.0
at room temperature. Crystals were seeded with drops containing parent crystals grown
in higher ammonium sulfate (2.2-2.4 M) using a cat whisker. The protein was mixed with
peptide at a 1:1 molar ratio and concentrated to 4 mg/ml in 20 mM Tris, 150 mM NaCl,
1% glycerol, 1 mM DTT, pH 8.0. The hanging drops contained 1.5 pL of complex mixed
with 1.5 pL of reservoir solution. Crystals were cryo-protected by transferring into 2.0 M
lithium sulfate with 10% glycerol prior to flash freezing. Diffraction data were collected at
the Advanced Photon Source at the Argonne National Laboratory, NE-CAT beamline
24-ID-C. The Bfl-1:FS2 data were integrated and scaled to 1.2 A using HKL2000 and
phased using PHENIX ridged body refinement of chain A of structure 4ZEQ using
PHENIX 60'61 . The peptide was built into the difference density from the rigid body
90
refinement and the structure was refined with iterative rounds of refinement and model
building using PHENIX and COOT6 1,2 . The PUMA and FS2_1fX complex data sets
extended to 1.33 A and 1.73 A respectively and were phased with the Bfl-1 chain of the
FS2 complex model63.
Crystals of the Mcl-1/FS2 peptide complex were grown at room temperature in
hanging drops over a reservoir containing 0.2 M zinc sulfate, 0.1 M imidazole (pH 6.5),
and 3% 6-aminohexanoic acid. The protein was mixed with peptide at a 1:1 molar ratio
and diluted to 2 mg/ml in 20 mM Tris, 150 mM NaCl, 1% glycerol, 1 mM DTT, pH 8.0.
The hanging drops contained 1.5 pL of complex mixed with 1.5 pL of reservoir solution.
Crystals were cryoprotected by transferring into 15% glycerol, 0.2 M zinc sulfate, 0.1 M
imidazole (pH 6.5), and 3% 6-aminohexanoic acid prior to flash freezing. Diffraction data
were collected at the Advanced Photon Source at the Argonne National Laboratory, NE-
CAT beamline 24-ID-E. The data to were processed to 2.35 A and phased using
molecular replacement with chain A of structure 3PK1 54 using PHASER and refined
using PHENIX and COOT6-
Gel shift assays
Myc-tagged Bfl-1 (5 pM) was incubated with BH3 peptide (25 pM) in 200 pL of
FP in 200 pL FP buffer (see above). 20 pL subsamples were taken at 0, 1, 2, 4, 8, 16,
32, 64, and 128 minutes and quenched in 7 pL loading buffer. Samples were
immediately flash frozen in liquid nitrogen, and stored at -80 C. Samples were run on a
14% acrylamide SDS-PAGE gel and visualized with Coomassie Brilliant Blue. Bands
were quantified with ImageJ. Data were fit in python to the equation y=C*(1-e-kt) where
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y is the fraction of cross-linked Bfl-1, C is the upper limit, t is time, and k is the decay
constant.
Cell lines
The creation and characterization of the BCR-ABL-expressing B-lineage acute
lymphoblastic leukemia suspension cell lines with engineered dependencies on human
versions of anti-apoptotic genes is detailed in Koss et aP5 and was grown in RPMI (Life
Technologies, CA) with 10% fetal bovine serum, 2 mM L-glutamine, 100 l.U./mL
penicillin, 100 pg/mL streptomycin, 25 mM HEPES, and 1 mM non-essential amino
acids. The adherent cell lines PC-3 and SF295 are from the NC160 panel and were
grown in RPMI (Life Technologies, CA) with 10% fetal bovine serum, 2 mM L-glutamine,
penicillin, and streptomycin.
BH3 profiling assays
Peptides were titrated by serial dilution in MEB buffer (150 mM Mannitol, 10 mM
HEPES-KOH pH 7.5, 50 mM KCI, 0.02 mM EGTA, 0.02 mM EDTA, 0.1% BSA, and 5
mM Succinate) containing 20 pg/mL oligomycin, 50 pg/mL digitonin, 2 pM JC-1, and 10
mM 2-mercaptoethanol in 384-well plates. Controls for no depolarization (1% DMSO)
and complete depolarization with the mitochondrial oxidative phosphorylation uncoupler
FCCP (20 pM) were included for data normalization. Cells were suspended at 1.67 x
106 cells/mL in MEB. 15 pL of cell suspension was added to each well containing 15 pL
of treatment solution. Fluorescence emission was measured every 5 minutes for 3
hours at 590 nM with 525 nM excitation on a Tecan Safire2. To produce percent
depolarization, the area under the resultant curve was calculated and normalized to the
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assay controls. Peptide titration curves were fit to sigmoidal dose-response curves
using Graphpad PRISM 7 to obtain EC5o values.
iBH3 assays
Cells were suspended in MEB buffer (150 mM mannitol, 50mM KCI, 10 mM
HEPES, 5 mM succinic acid, 20 pM EGTA, 20 pM EDTA, 0.1% BSA, final pH 7.4) at
0.5*1 06 cells/mL (adherent lines) or 2 *106 cells/mL (suspension lines). Cell suspension
was added to a 384 non-binding well plate (10 pL/well) containing peptides at 2X final
concentration in MEB with 20 pg/mL digitonin. Plates were incubated at 25 'C for 1 hr.
To terminate exposure, 10 pL of 4% formaldehyde in PBS was added to each well,
plates were incubated for 10 min before addition of 10 pL N2 buffer (1.7M Tris, 1.25M
glycine, pH 9.1) for 5 min. 10 pL of staining buffer (2% Tween20, 10% BSA, PBS)
containing 10 pg/mL Hoechst 33342 and 1.25 pg/mL anti-cytochrome c Alexa647
conjugate (BioLegend clone 6H2.B4) was added to each well before sealing the plate
and shaking overnight. The median fluorescence of the cytochrome c channel of
Hoechst positive singlets was recorded by an IntelliCyt iQue Screener Plus.
Cytochrome c release was determined by normalizing the median fluorescence intensity
(MFI) data to positive control wells (Alamethicin) and negative control wells (DMSO) as
follows:
Cytochrome c release = 1 -(MFISample-MFIAlamethicin)I(MFIDMSO-MFIAlamethicin)
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Chapter 3
Peptide design by optimization on a high-dimensional, data-
parameterized protein interaction landscape
V. Xue, J.M. Jenson, and A.E. Keating designed and wrote the study. L. Stretz performed the




Many applications in biotechnology require optimizing protein or peptide binding
affinity and specificity for one target among many similar, evolutionarily related family
members. For example, this is necessary to make specific detection reagents, or to
inhibit one paralog that is implicated in disease without affecting others that are
important for the maintenance of healthy cells. The underlying problem is that of
navigating a high-dimensional landscape in both sequence variables (L dimensions,
where L is the protein length) and target affinities (N dimensions, if there are N paralogs
of interest). Because the protein designer begins a problem with no understanding of
this complex landscape, the problem is typically treated by screening large, libraries of
candidate solutions that are often generated randomly and addressing each design
challenge with a new set of experiments. This is inefficient. Furthermore, because
functional protein sequences are rare, most screens only explore the local sequence
spaces around known binders, and therefore discover just a few function-enhancing
mutations at a time. A knowledge of the underlying protein landscape could open new
avenues for design and ways to access functional regions in sequence space that are
otherwise difficult to discover. We developed a protocol for using thousands of protein-
peptide binding affinities, measured with SORTCERY, to parameterize models in a
landscape where N = 3 members of the Bcl-2 family of apoptosis regulating proteins.
We showed that models trained on experimental data have predictive ability on
unobserved peptide sequences, and that optimization on a landscape defined by these
models generates new peptides that are distinct from any previously known binders and
have highly optimized interaction affinities and specificities. We generated 36 peptides
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that bind with high affinity and specificity to just one of BcI-xL, Mci-1 or Bfl-1, and
additional peptides that can bind selectively to two out of three of these proteins. The
successful designs demonstrate the power of this landscape-based design approach,
and the resulting peptides have potential for use as diagnostics or therapeutic leads.
Introduction
Protein-protein interactions (PPIs) play an essential role in all cellular functions,
including transcription, translation, signaling, homeostasis, and the regulation of
enzymatic activity. Protein interaction affinity and specificity are encoded in sequence
and structure in a complex mapping that we do not completely understand. A long-
standing goal in protein science is to describe the underlying relationships accurately
enough to inform studies of disease mechanisms, for example by predicting the effects
of mutations on function. Models that accurately link sequence to function can also
enable discovery of new binding partners and direct the engineering of proteins with
new functions.
Families of structurally similar protein domains that share an evolutionary history
provide intriguing, and often biomedically compelling, examples of how subtle details of
the protein sequence-structure relationship impact biological function. Diverged protein
paralogs often have distinct functions, e.g. distinct binding specificities, that can be
accommodated in a common structural scaffold. For example, the PDZ domain fold has
been evolved into proteins with at least 16 distinct specificity classes'. Many biomedical
applications require reagents that can bind or inhibit the function of just a single family
member within a larger family. Computational and experimental strategies for
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engineering selective inhibitors can be effective, but most methods treat each target
design as a new problem. A driving need for custom, selective, protein-binding
molecules has compelled our pursuit of new methods for modeling sequence-function
relationships that consider a wider swath of the protein sequence landscape for a given
type of domain.
Proteins of the B-cell lymphoma 2 (Bcl-2) family are critical regulators of
apoptosis that have emerged as promising therapeutic targets for the treatment of many
different cancers. Overexpression of human anti-apoptotic proteins Bcl-2, Mcl-1, Bfl-1,
Bcl-xL, and Bcl-w contribute to oncogenesis and resistance to chemotherapy 2 . These
five proteins are highly similar in structure and 18 - 53% identical in sequence3
Molecules that bind and block the functions of anti-apoptotic proteins have shown great
promise in pre-clinical and clinical studies4-7. It would be useful to design Bcl-2 family
member-selective inhibitors, rather than pan-family inhibitors, because off-target binding
can lead to cytotoxic effects 5'8 . The small molecule ABT-263, which binds and inhibits
the function of Bcl-2, BcI-xL and Bcl-w, was identified as a potential therapeutic for
treatment of acute lymphoblastic leukemia5 . However, ABT-263 inhibition of Bcl-xL leads
to dose-limiting thrombocytopenia, 9 . Venetoclax, an FDA approved therapeutic for
treating chronic lymphocytic leukemia, inhibits only Bcl-2 and not Bcl-xL or Bcl-w; fewer
side effects helped advance this molecule to the clinic4'6 . Selective inhibitors of BcI-2
family proteins also have utility for research and for cancer patient cell profiling0'". The
Bcl-2 family is just one example out of many protein families where understanding and
managing binding specificity is important for developing effective and safe therapeutics.
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Many native binding partners of Bcl-2, Mcl-1, Bfl-1, BCI-XL, and Bcl-w contain a -23-
residue Bcl-2 homology 3 (BH3) motif that forms an amphipathic helix upon complex
formation. Synthetic peptides with BH3 motif sequences can compete with native
interaction partners and function as inhibitors. Mapping how sequence determines the
binding profiles of BH3-like peptides could support the design of selective inhibitors with
applications as probes, diagnostics and therapeutics leads, but the >1028 possible
sequences for a 23-mer peptide pose a daunting challenge. Systematic mutational
analyses have provided information about the effects of single mutations in BH3
peptides, and library screening has uncovered functional sequences distinct from wild-
type examples3 ,1 -15 . However, as for most proteins, the biophysical study of BH3
structure-function relationships is hampered by the sparsity of available data in an
enormous sequence space. Ideally, computational methods would fill this gap, but
physical, structure-based modeling has limited accuracy for predicting folding or binding
energy differences among related protein complexes, especially in high-throughput16 .
Previous computational design of BcI-2 inhibitors installed known "hot-spot" residues at
the protein interface to stabilize binding, and used computation to generate a stabilized
scaffold to accommodate these residues1 7. Basing inhibitor design on known residue
interactions limits the novelty of solutions that can be obtained.
Experimental library screening is an effective method for discovering peptides
ligands that bind protein targets, including anti-apoptotic Bcl-2 proteins. Such
experiments typically consider only a single design objective (e.g. identify a tight and
selective binder of protein Bfl-1), and for every design objective, a new experiment must
be performed. The experiments usually focus on identifying a "winner," or a small set of
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the best binders out of an input library. Advances in technology have now made it
possible to use deep sequencing to obtain large amounts of phenotypic data from a
library screen, for example, readouts for all single-point and residue-pair mutations in a
modest-sized protein18 . This information is now available to guide protein design, and
the field can potentially advance faster by using it effectively.
A few exciting examples illustrate the potential of large amounts of experimental
data, treated in a systematic way, to improve design. An early example was the use of
peptide arrays to measure the effects of peptide point mutations on PDZ domain
binding19. This led to a simple model of what was important for binding that, in turn,
guided the design of PDZ "super-binder" peptides that would have been difficult to
identify without the underlying experimental dataset. More recently, the Baker Lab has
demonstrated how using high-throughput screening to assay the effects of all possible
point mutations in a designed protein can provide insights into limitations of
computational models and lead to their improvemento. Rocklin et al. showed that
computationally designing and testing thousands of novel mini-proteins, and applying
computational analyses to capture trends in folding stability, led to improvements in
computational design outcomes21 . Bedbrook et al. used activity data for hundreds of
variants of channel rhodopsins to train a model to captures the sequence features
important for expression and membrane localization, and used this model to predict the
22best members in a library and also improve the behavior of poorly localizing protein .
With increasing amounts of experimental data becoming more routinely
accessible, the synergistic application of high-throughput binding assays with data-
driven modeling holds great potential for advancing rational design. Here, we
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demonstrate the possibilities of this type of approach by applying the high-throughput
SORTCERY assay to generate quantitative protein-peptide interaction data for the Bcl-2
protein family members Bfl-1, Mcl-1, and BcI-xL. The data allowed us to develop family-
specific computational models that provide insight into the determinants of binding
affinity and specificity. We applied our models to peptide design, showing that this data-
driven approach rapidly and reliably provides peptides with custom desired binding
properties. Our success illustrates a new approach for integrating data collection and
modeling to map high-dimensional protein binding landscapes and guide exploration of
novel sequence spaces. This can enable discovery of novel peptides with high potential
utility.
Results
SORTCERY is a protocol for measuring the relative affinities of hundreds or
thousands of peptide binders in parallel2 3 24 . Yeast cells displaying different peptide
ligands are separated into pools based the binding signal using fluorescence activated
cell sorting (FACS). By deep sequencing the library DNA from cells in different pools, it
is possible to assign relative binding affinities on the cell surface. In previous work,
SORTCERY was used to rank-order ligands by affinity23 . We improved on the original
pipeline, as described below, by using the binding profiles of standards of known affinity
to convert quantitative SORTCERY outputs into binding affinities in standard units (e.g.
kcal/mol). This allowed us to directly compare the binding of ligands measured at
different target protein concentrations and also compare peptide binding affinities for
different target proteins. We call this elaboration of the original SORTCERY protocol
amped (affinity mapped) SOR TCERY (Figure 3. 1A).
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We applied amped SORTCERY to measure binding of the three Bcl-2 family
proteins Bcl-xL, Mcl-1, and Bfl-1 to members of a small yet diverse library of BH3-like
peptides (Figure 3.1A). Approximately 10,000 peptides to be measured were selected
from much larger combinatorial libraries that were previously designed to be enriched in
selective binders of BcI-xL, Mci-1 or Bfl-1 2 5 .The input libraries contained peptides with
up to 8 amino-acid mutations compared to human Bim or Puma BH3 motifs and had a
theoretical diversity of 27,696,384 possible members; we refer to this set of sequences
as the input library (Figure 3.1A). Clones to be assayed by amped SORTCERY were
selected from the input library by pre-sorting to include peptides with a range of binding
affinities for Bcl-xL, Mci-1, and Bfl-1 (see Methods). SORTCERY assays were then run
at 1 nM, 1 nM, or 100 nM of BcI-xL, Mcl-1, or Bfl-1, respectively, generating six datasets
(Table 3.1). Bfl-1 binding was assayed at a higher protein concentration than was used
for BcI-xL or Mcl-1 because few peptides in this library bound detectably at 1 nM. After
computational filtering, each experiment generated binding profiles for between 1292
and 3489 unique peptides.
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Figure 3.1. High-throughput measurement of thousands of BH3 mutant affinities for Bfl-1, Bcl-xL, and Mcl-
1 with amped SORTCERY. A) Schematic of data collection and modeling pipeline. Three computationally
designed libraries targeting Mcl-1 (red), Bfl-1 (green) and BcI-xL (blue) were synthesized in the context of
Bim and Puma BH3 scaffolds. In the left-most panel, "X" symbols indicate the positions that were varied
in each library. The six libraries were expressed on the yeast cell surface, cell populations were pooled,
and a subset of ~104 clones was evaluated for binding to the three receptors via a 12 gate FACS scheme.
Deep sequencing and computational analysis were applied to reconstruct the individual peptide binding
profiles across the 12 gates and determine mean affinity coordinates for each peptide. Standards were
measured to calibrate the mean affinity coordinate of each peptide to binding free energy in kcal/mol.
Experimentally determined receptor binding energies for 2679, 1292 or 3480 peptides binding to Bcl-xL,
Bfl-1, and Mcl-1 were identified, respectively. A histogram of the binding free energies show that the
peptides have cell-surface affinities between -14 and -9 kcal/mol. B) The binding energies for 420
sequences with experimentally measured affinities for Mcl-1, Bfl-1, and BcI-xL are plotted on a trisected
plane to visualize the specificity space. Each peptide is described by 3 vectors, each projecting the
negative binding free energy for Mcl-1, Bfl-1, or Bcl-xL, from the origin (0,0) toward one of three corners of
an equilateral triangle. The vectors are summed to produce a coordinate in 2D space that quantifies the
peptide binding preference for the three receptors. This projection removes the absolute quantification of












Table 3.1. Summary statistics of datasets collected.
RMSE
of energy
Receptor Pearson R mapped Replicate
concentration # unique of A to standards Replicate RMSE Replicate
Reference (nM) sequences # standards standards (kcal/mol) overlap (kcallmol) Pearson R
Bcl-xL_ri 1 2679 17 0.82 0.56
Bcl-xLr2 1 3457 18 0,85 0.50 1749 0.35 0.91
Bfl-1_r1 100 1292 16 0.88 0.33
Bfl-1_r2 100 3489 16 0.84 0.39 975 0.21 0.95
Mci-i_ri 1 3326 16 0.89 0.47
Mci-1_r2 1 3480 16 0.92 0.40 2315 0.21 0.98
SORTCERY measures affinity (A) in arbitrary units related to what FACS gates
each clone is distributed across. Theory predicts that A will be linearly correlated with
binding free energies over a certain resolution range, under certain conditions23 . To test
this relationship and to map affinity measurements to kcal/mol, peptide standards
spanning the SORTCERY dynamic range were individually titrated on the yeast cell
surface with each of the three receptors to determine dissociation constants (Figures
3.2-3.4). Measured A values correlated with individually measured binding free energies
with Pearson R = 0.81-0.92 (see Table 3.1). We used these measurements to map A to
binding free energies in kcal/mol (see Methods). Linear fits for 16-18 standards per
dataset gave RMSE of 0.34-0.56 kcal/mol over a range of dissociation constants from
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Figure 3.2. Mcl-1 titrations of peptide standards spanning the SORTCERY dynamic range. A) Individual
titrations are shown, one standard per plot. Experimental replicates are represented as different colors.
Fits to data are shown as solid lines. B-C) Correlation of the SORTCERY mean affinity coordinate (A) to
binding energy in kcal/mol is shown. Error bars for dissociation constants indicate standard deviations for
the individual titrations shown in A. Error bars for the SORTCERY mean affinity coordinates indicate the
standard deviation of the population across gates. The blue lines show the correlation for all of the data
points. The red lines show the correlation excluding points that did not have a numerical KD and points
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Figure 3.3. Bcl-xL titrations of peptide standards spanning the SORTCERY dynamic range. A) Individual
titrations are shown, one standard per plot. Experimental replicates are represented as different colors.
Fits to data are shown as solid lines. B-C) Correlation of the SORTCERY mean affinity coordinate (A) to
binding energy in kcal/mol is shown. Error bars for dissociation constants indicate standard deviations for
the individual titrations shown in A. Error bars for the SORTCERY mean affinity coordinates indicate the
standard deviation of the population across gates. The blue lines show the correlation for all of the data
points. The red lines show the correlation excluding points that did not have a numerical KD and points
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Figure 3.4. Bfl-1 titrations of peptide standards spanning the SORTCERY dynamic range. A) Individual
titrations are shown, one standard per plot. Experimental replicates are represented as different colors.
Fits to data are shown as solid lines. B-C) Correlation of the SORTCERY mean affinity coordinate (A) to
binding energy in kcal/mol is shown. Error bars for dissociation constants indicate standard deviations for
the individual titrations shown in A. Error bars for the SORTCERY mean affinity coordinates indicate the
standard deviation of the population across gates. The blue lines show the correlation for all of the data
points. The red lines show the correlation excluding points that did not have a numerical KD and points
whose titration curves saturated at lower binding signal than SORTCERY theory expected.
We quantified binding for 5769 unique peptide in this experiment. Binding
energies computed in two replicates were highly reproducible, with Pearson R values of

























BcI-xL. Other peptides were either not observed in all three data sets or had affinity
values outside the range we could quantify. To visualize the binding selectivity
landscape of the 420 sequences, we plotted the affinity of each peptide for each protein
in three dimensions (one dimension for each target protein) and projected this plot into
two dimensions, giving a trisected plane representation (Figure 3.1B). Peptides with
three measured binding energies included examples with 100-fold specificity for binding
Mcl-1 over Bfl-1 or Bcl-xL. In contrast, the most selective binders of Bfl-1 or Bcl-xL had
only a 10-fold preference for those proteins.
We reasoned that if we could use amped SORTCERY data to build a
computational model to capture how sequence determines binding, we could predict
binding free energies for peptides not measured in our experiments and generate a
more complete binding landscape. We tested two different models. Peptide binding free
energy was either expressed as a sum of independent contributions from individual
residues (linear model), or as a sum of contributions from residue pairs (polynomial
model of order two) (see Methods).
We used support vector regression against amped SORTCERY data to fit the
residue contributions for each model 26. We compared the performance of linear vs.
polynomial models trained on each data set using nested cross-validation. The second-
order polynomial models consistently outperformed linear models trained on the same
data, when evaluated using a validation set of sequences that was non-overlapping with
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We used the polynomial models to investigate whether high affinity for one










Figure 3.5. Computational models built on
SORTCERY datasets. A) Nested cross-
no validation performance for linear and
polynomial models trained on Mcl-1, Bcl-xL and
Bfl-1 datasets Bcl-xLr1, Bfl-1_r1 and Mcl-
1_r2. Light grey bars correspond to the
average R2 of models trained and evaluated on
the same data. Colored bars correspond the
average R2 of models evaluated on data held
out from training in nested-cross validation. B)
Specificity and affinity tradeoffs for BH3
peptides binding to Mcl-1 vs. Bfl-1. All
27,696,384 peptides in the designed library
were computationally scored for binding to McI-
1, Bfl-1, and BcI-xL. For a given target receptor
(x axis), peptides were binned by the predicted
target affinity. The median affinity of the off-
target (y axis) is plotted for each bin. The
00 101 102 shaded fill indicates the 25th and 75th
inity (nM) percentiles. Lines parallel to the 1:1 line
indicate increasing fold selectivity. C) Map of
the McI-1, Bcl-xL, Bfl-1 specificity landscape.
Receptor-specific affinity models were used to
explore specificity space. Black points plot the
specificity coordinates of the 420 sequences
with experimentally measured Mcl-1, Bfl-1, and
0 106 102 Bcl-xL binding energies. Orange points plot the
nity (nM) specificity coordinates of all peptides observed
to bind at least one receptor, using the model
foralilthree to predict the missing coordinate(s). Models
can also define extremes in the specificity
ad (5769)
tylimit (10) space for all theoretical library members,
.ciflcityimit(101 4 ) including those that were not observed
experimentally (pink), A further extrapolation
can map the predicted boundaries of specificity
for an integrated library space that includes all
substitutions that were sampled in any of the
six original input libraries (brown). See
methods for details.
other predictors25 . To investigate tradeoffs between selectivity and affinity, we compared
predicted peptide binding affinities for pairs of receptors. The tradeoffs observed
depended on which proteins were compared. For most pairs, there is a positive
correlation of the binding affinities. For sequences in the input library, the peptides
predicted to bind most tightly to Mcl-1 were predicted to bind >1000-fold weaker to Bcl-
XL and >100-fold weaker to Bfl-1, on average (Figure 3.5B). This suggests that
identifying tight Mcl-1 binders that are specific for that target may not be difficult, and
indeed several peptides with this property have been published14 . In contrast, the
peptides from these libraries that were predicted to bind tightest to Bfl-1 were predicted
to bind more than 10 times more weakly to Bcl-xL, but greater than 10 times more tightly
to McI-1, on average (Figure 3.5B). This analysis suggests that it might be difficult to
identify high-affinity binders of Bfl-1 that do not bind to Mci-1, which is consistent with
prior observations from library screening experiments 27.
Models that can be used to predict unmeasured affinity values made it possible
to plot all 5769 peptides from our experiment in three-dimensional specificity space;
these values are shown in orange in Figure 3.5C. We can extrapolate even further, to
compute the predicted distribution of all 27,696,384 input library sequences, the vast
majority of which of which were not tested experimentally for binding to any of the three
proteins. The extremes of this distribution are shown in light pink in Figure 3.5C; the
results predict that our input library was enriched in Mcl-1 specific sequences, relative to
Bfl-1 or Bcl-xL specific sequences. Finally, although our models were trained on
sequences from the input library space, we can make predictions about sequences that
lie outside this space. For example, we can consider the space of 1014 sequences that
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includes all combinations of residues that were considered at any position in any library.
This space, which we call the integrated library space (Table 3.2), includes many
residue combinations that were never sampled experimentally, including sequences that
mix and match residues from the BIM and PUMA backgrounds. Thus, the model is not
necessarily expected to make accurate predictions in these regions of the sequence
landscape. To visualize the integrated library space, we solved for the Pareto frontier of
selectivity (Figure 3.5A), i.e. for sequences that are predicted to be optimally specific.
Sequences at this boundary (dark pink in Figure 3.5A) demonstrate that predicted
selectivity can be as much as tenfold greater in the integrated space than in the input
library space. The models predicted a modest opportunity to increase Mcl-1 specificity
beyond what we observed in the SORTCERY screen, but predicted that the integrated
library contains members with much enhanced specificity for BfI-1 or BcI-xL, relative to
the input library.
115
Table 3.2. Summary of mutational spaces.
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To evaluate the predictive power of our models at the boundaries of the
integrated library space, and test the utility of the models for practical applications, we
used them to design selective peptide binders of Bcl-2 family members. We designed
three sets of peptides to bind selectively to just one of Mci-1, Bfl-1, or BcI-xL, and three
sets of bispecific peptides to bind selectively two out of three receptors: Mci-1 and Bcl-
XL, Mcl-1 and Bfl-1, or Bcl-xL and Bfl-1. In both cases we used constrained optimization
to balance the dual objectives of tight binding to the target(s) and weak binding to the
off-target(s) 28. For the single-receptor specific peptides, we maximized predicted target-
binding affinity, with a constraint on the affinity for off-target proteins that was
implemented as a lower limit on the predicted binding free energy (Figure 3.6B).
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Figure 3.6. Peptide design using computational models of the McI-1, Bcl-xL, and Bfl-1 specificity
landscape. A) Designed peptides plotted in the the specificity landscape. Selective peptides
were designed to bind to McI-1 (Red), Bfl-1 (Green), or Bcl-xL (Blue), without cross-reacting with
the other two receptors. Bispecific peptides were designed to interact with Mcl-1/Bfl-1 (orange),
BcI-xL/Bfl-1 (teal), and Mcl-I/BcI-xL (purple), without binding tightly to the off-target receptor. B-
C) Selective sequences were designed with constraint optimization. Monospecific peptides were
designed to maximize the binding affinity to the target receptor and constrained to bind weakly
to off-target receptors. Bispecific peptides were designed to maximize the specificity gap,
minimize off-target affinity, or maximize target affinity. D) Ratio of experimentally measured
design binding signal to Bim binding signal for Mci-1 (red), Bcl-xL (blue) or Bfl-1 (Green)
receptors. The designs are color-coded for the objective targets. (McI-1 - red, Bcl-xL - Blue, Bfl-1
Green, Mcl-1/Bfl-1 Orange, Bcl-xL/Bfl-1 Teal, Mcl-1/BcI-xL - Purple). E) Boxplot of the maximum
sequence similarity of the designed peptides to any previously observed sequence in the
training dataset. Designed peptides were all at least 4 mutations from any previously observed
peptide measured by SORTCERY, and some differed in 10 positions from the closest
characterized library member.
To evaluate whether the peptides that were designed to bind to just one protein
had the desired specificity traits, the peptides were expressed on the surface of







sorting (see Methods, Tables 3.3-5). For each sequence, the median binding
fluorescence signal at 100 nM was measured and normalized using the saturated
binding signal of BIM, a native BH3 sequence with KD < 1 nM on the surface of yeast
(Figure 3.6D). All 36 of 36 monospecific peptides designed and tested demonstrated the
desired selectivity for the target protein. The dissociation constants for the designs
binding to their targets were all estimated to be lower than 100 nM, with 28 lower than
10 nM, and 5 lower than 1 nM. All of the off-target binding affinities for the designs were
weak, with estimated KDs greater than 1000 nM. These values compare favorably with
the reported affinities and specificities of previously reported selective Bcl-2 binders that
were identified by screening targeted libraries of >106 sequences 13 ,14 ,25 ,27.
























































To design bi-specific peptides, we first identified sequences that maximized the
difference between the predicted affinities for targets Mcl-1 and Bfl-1 vs. off-target BcI-xL
(see Methods, Table 3.6). All seven peptides that were designed this way bound to Bfl-1
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and Mcl-1 with nanomolar affinity and bound to off-target BcI-xL with KD greater than
1000 nM. This may be the easiest bi-specific design problem, because our analysis in
Figure 3.5B predicted that affinities for Mcl-1 and Bfl-1 are more strongly correlated than
are affinities for Mcl-1 and Bcl-xL or Bfl-1 and Bcl-xL. Peptide designs 1, 2, 5 and 6 all
showed evidence of strong binding to Mcl-1 and Bfl-1 at 100 nM, with very low or
undetectable binding to Bcl-xL at the same concentration.









For the other combinations of targets, we suspected that tight and specific
binding might be harder to achieve, and we tested other approaches. The first was to
minimize the affinity of peptides for the off-target while constraining the predicted energy
of binding to the targets to be < -10 kcal/mol. From two attempts at bi-specific design
using this protocol, targeting either Mcl-1 and BcI-xL or Bfl-1 and Bcl-xL, neither gave
peptide with the desired profiles. The designs either bound to Bcl-xL but not BfI-1, or did
not bind to either target. This led us to try a third protocol that involved minimizing target
binding energy, subject to a constraint that off-target binding energy be greater than -10
kcal/mol (Figure 3.6C). Because there are two targets for a bi-specific design, we ran
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these target affinity-maximizing calculations twice. For the target that was not used for
binding score optimization, we imposed an upper-limit on the binding energy of -11
kcal/mol. We used these two strategies to design binders of Mcl-1 and BcI-xL, and
binders of BcI-xL and Bfl-1 (Tables 3.7,8). We obtained several dual-specific peptides
that bound tightly to Mcl-1 and Bcl-xL, with little or no binding to Bfl-1, as shown in
Figure 3.6D. However, peptides designed to bind to Bcl-xL and Bfl-1 often bound those
proteins with good signal at 100 nM protein concentration, but also bound to Mcl-1 as
well. Our best dual-specific Bcl-xL/Bfl-1 inhibitor was peptide XF13 which was -10 fold
selective over Mci-1.








































All of the peptides that were designed and tested were dissimilar from the
sequences used to train the models. Each design was at least 4, and as many as 10
mutations away from any previously observed sequence (see Figure 3.6E). This
establishes that the regression models were able to make accurate predictions about
regions of the sequence landscape well outside of the region they were trained on. The
sequences were on average -4 mutations away from others in each design set.
Encouraged by our initial results, we picked six designs for further analysis. Two
sequences from each set of monoselective designs were chosen based on the initial
cell display data. We performed binding titrations from 0.66 to 1000 nM, measuring
binding signal on the cell surface. The Mcl-1 designs (Ml and M9) bound Mci-1 with Kd
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< 0.66 nM and bound Bcl-xL and Bfl-1 with Kd > 1000 nM (Figure 3.7). These are upper
bounds on the dissociation constant because the binding signal for the Mcl-1 specific
designs was at or near saturation at 0.66 nM Mcl-1, and near baseline in 1 pM Bfl-1 and
BCI-XL. Concerns about ligand depletion limited the low end of our titrations, and non-
specific binding limited the high end. Likewise, we found that the Bcl-xL specific designs
X1 and X7 bound their target tightly (Kd values of 1.56 nM and 0.088 nM, respectively)
and had negligible binding to Bfl-1 and Mci-1 up to at least 1000 nM. Bfl-1 specific
designs F4 and F10 bound to Bfl-
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Figure 3.7. Yeast cell-surface binding curves for 6 receptor-specific peptide designs tested against Mci-1
(red), Bfl-1 (green), and Bcl-xL (blue). The Mcl-1 designs bind tightly with KD < 0.6 nM for Mcl-1 and >> 1
uM for Bcl-xL and Bfl-1. The Bcl-xL designs bind with KD - 1 nM for Bcl-xL and >> 1 uM for Bfl-1 and Mcl-





1 0-210- 1100 101 1-62 103j.
Given that the designed peptides have sequences very different from natural
BH3 sequences, we tested whether they bind in the same site as known BH3 peptides.
Protein binding to all 6 of the tested designs was abolished by the addition of BIM, in a
dose-dependent manner, consistent with competitive binding at the same site.
Moreover, we solved X-ray crystal structures of F4 and F10 bound to Bfl-1(Figures
3.8,9). Both complexes, Bfl-1:F4 and Bfl-1:F1O, were resolved at high resolution (1.48 A
In both cases) and the structures show that the designed peptides bind to Bfl-1 in a
geometry very similar to that of natural BH3s. Figure 3.9 shows a superposition of each
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Figure 3.8. Designed peptides directly target the binding grooves of Bfl-1, Bcl-xL, and Mcl-1. A) A high
resolution (1.48 A) X-ray crystal structure of Bfl-1 specific peptide F1 0 (cyan cartoon) with Bfl-1 (gray
surface). B) Visualization of the polynomial model weights for each residue in F1 0. C) Competition with
unlabeled Bim peptide for binding to 6 receptor-specific peptide designs. Binding was assayed using cell-
surface displayed peptide. D) Yeast cell-surface binding KDS for 6 receptor-specific peptide designs tested

























Figure 3.9. High resolution crystal structures of designed peptides show F4 and F10 bind similarly to
each other and to Bim BH3. A) Structural aligments of F4 (magenta ribbon) and F10 (cyan ribbon) bound
to Bfl-1 (gray surface). Structures were aligned on Bfl-1. B ) Structural aligments of F4 (magenta ribbon)
and Bim (green ribbon) bound to Bfl-1 (gray surface). Structures were aligned on Bfl-1.
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Table 3.9. Summary of X-ray data collection and refinement statistics.
Bfl-1:F4 BfI-1:F1O
Data Collection




a, P, y 90 114.733 90
Rmeas 0.069 (0.411)
Rpim 0.030 (0.218)
Mean l/a(l) 27.72 (2.22)
Completeness (%) 92.01 (61.95)
Redundancy 4.5 (2.7)
Refinement
Resolution (A) 37.76 - 1.481(1.534 - 1.481)
Unique Reflections 23970 (1596)
Rwork/Rfree 0.1343/0.1658(0.1776/0.2755)
Number of non- 1562hydrogen atoms
Wilson B-factors 19.88
Rmsd
Bond lengths (A) 0.007
Bond angles (0) 0.76
Values in parentheses are for the hiqhest-resolution shell.
A benefit of performing rational design using predictive models, such as the ones
we used here, is that the models provide detailed hypotheses about why certain
complexes are stable vs. unstable. Figure 3.8B shows the residue contribution weights
from our three different models mapped onto the structure of F10 bound to Bfl-1 using a
heatmap to indicate residues that are net stabilizing vs. destabilizing. The favorable
contributions of most residues to Bfl-1 binding are reflected in a mostly blue colored
peptide, at top. In contrast, our models for Bcl-xL and Mcl-1 binding highlight, in red,
residues that are predicted to destabilize binding and thereby contribute to specificity.
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The model weights indicate that the specificity of the designs comes from contributions
from many residues throughout the peptide, although some residues such as V3d are
predicted to be particularly important for disfavoring interactions with off-target proteins.
Discussion
Deep sequencing combined with library display technologies now makes it
possible to accurately describe and model larger parts of the protein interaction
universe than ever before. Amped SORTCERY provides a method to quantitatively
determine binding energies of thousands of diverse ligands in high throughput, and we
used it to measure peptide binding to a family of 3 structurally, functionally, and
evolutionarily related proteins: Bfl-1, Mcl-1, and Bcl-xL, mapping the specificity
landscape. We further expanded our description of the specificity landscape using
models trained on the experimental data. We demonstrated that statistical models
derived by regression could be used to design protein sequences up to ten mutations
away from the training set, and experimental testing confirmed that all of the designed
monospecific peptides and many of the dual-receptor specific had the desired binding
profiles.
One interesting observation is that our designed peptides were more specific for
their targets than was predicted by our models. The restricted dynamic range of the
SORTCERY affinity assay might help explain this, because it limited our ability to
accurately measured how destabilizing some mutations are. Models that underestimate
destabilizing effects could lead to overestimates of how well the designs bind off-target
proteins. Performing SORTCERY at higher concentrations could enable more accurate
measurement of weaker affinities.
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Many statistical models assume that the effects of multiple mutations are
additive, even though epistasis can be pervasive and its effects significant29-33. Prior
work suggests that epistasis can be important for determining the binding of BH3
peptides to Bcl-2 family proteins. For example, Jenson et al. demonstrated that there
can be a context dependence to the effect of substitutions made in Bim vs. Puma BH3
peptides 25. Specificity inducing mutations in the Puma BH3 context did not provide
specificity in the Bim BH3 context2 5. Jenson et al. additionally observed energetic
coupling between N-terminal and C-terminal residues in a designed Bfl-1 selective
binder. DeBartolo et al. reported only a modest correlation between the mutational
effects of point residue changes in Bim vs. Noxa BH3 peptides for Mcl-1 binding, and in
Bim vs. Bad for Bcl-xL binding34 . A residue may influence another by interacting with it
directly. Additionally, non-additivity can arise when mutations change the docking of the
peptide in the binding groove, thereby altering contributions from any residues that are
re-positioned by the structural change.
Coupling between residues poses a challenge for modeling because substantial
amounts of data are required to accurately capture epistatic effects with a statistical
model. Each mutation must be observed in sufficiently many sequence contexts to
determine the relevant dependencies. By analyzing AAG values from high-throughput
SORTCERY experiments, we found evidence of non-additivity, indicating that our
datasets do sample context-dependent events. Consistent with residue-residue coupling
contributing to binding, we found that second-order polynomial models evaluated on the
validation data consistently outperformed linear models trained on the same data. In
other words, the linear models can't describe the data as accurately because they fail to
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capture some replicable structure in the data that the polynomial models capture
through the pair terms.
Strikingly, we were able to use data collected in multiple local sequence spaces
to build models that had utility for navigating the binding landscape outside of those
spaces. In our initial input libraries, the peptides were sourced from six individual
libraries. Although each library covered a distinct set of sequences, we combined the
observations to build a single model and demonstrated success identifying sequences
within the larger, integrated library space, despite these sequences never having been
experimentally sampled. Notably, the tests that we challenged our models with were
design tasks. Design may be an easier task than prediction in regions of the landscape
that are remote from the training data. This is because regression modeling captures
the average contribution of a residue or residue pair in different contexts. If the training
data are dominated by a single canonical peptide binding mode, then average residue
contributions may be good estimates of the actual contributions of residues in this
binding mode. A model with these features would be good at describing the canonical
mode, and at designing sequences that bind well in that mode. Such a model would be
less good at scoring peptides that bind with a different geometry. Consistent with this,
X-ray crystallography revealed that designs F4 and F10 closely imitate the binding
poses of Bim BH3 (Figure 3.9). Also consistent with this, our models underestimate the
Bfl-1 specificity of previously described peptide FS2. FS2 binds to Bfl-1 in a shifted and
rotated geometry relative to other known BH3 peptides, and the residue weights that are
appropriate for those peptides do not provide accurate binding predictions for FS2
(although FS2 is still recognized as a tight and Bfl-1 selective binder).
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An advantage design guided by this type of model is that once the model is built,
searching sequence space is trivial, and it is simple to optimize for features that can be
hard to screen for experimentally. Here, we took data from libraries that were carefully
designed for mono-selectivity and used it to design bi-specific binders, which may not
be present in the input libraries, and even if they are, would require a long series of
affinity and specificity maturation cycles to identify. One could imagine adding additional
constraints to design for features that would be even more difficult or impossible to
screen for experimentally, such as charge, which can impact solubility and cell delivery,
or minimal predicted immunogenicity. The formalism of the design optimization can
readily accommodate diverse constraints on protein sequence.
The increasing ease with which it is possible to generate and screen peptide
libraries suggests that mapping landscapes through model building, as we have done
here, could become a useful and routine tool in the repertoire of protein design
methods. An interesting question for the future is what sequence space should be
sampled to support initial model building. Naive empirical models will be most accurate
within or close to the sequence space on which they were trained, and one way to
broaden this space would be to measure affinities for sequences that vary more sites
and residues. However, there is a tradeoff between increasing library diversity and
obtaining adequate coverage of combinations of residues. Sampling from broader
sequence space additionally decreases the chances of observing binders. In this work,
we biased the input sequences towards those deemed likely to bind by using prior
modeling and experimental analysis of the Bcl-2 family; this focused our sampling.
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Structure-based design, using experimental or predicted complex structures, may
represent a promising way to achieve this for other protein families.
Methods
Yeast growth and sorting
Yeast cultures were diluted from glycerol stocks to an OD600 of 0.05 in SD+CAA
(5 g/L casamino acids, 1.7 g/L yeast nitrogen base, 5.3 g/L ammonium sulfate, 10.2 g/L
Na2HPO4-7H 20 and 8.6 g/L NaH 2PO4-H 20, 2% glucose) and grown for 12 hr at 30 C.
Each culture was then diluted to an OD600 of 0.005-0.01 in SD+CAA and grown to an
OD600 of 0.1-0.6 at 30 *C. To induce expression, 40 mL of each culture was diluted into
1L SG+CAA (5 g/L casamino acids, 1.7 g/L yeast nitrogen base, 5.0 g/L ammonium
sulfate, 10.2 g/L Na2HPO4-7H20 and 8.6 g/L NaH 2PO4-H 20, 2% galactose) and grown
for 20-24 hr at 30 C. Cells were filtered with either a 0.45 pm bottle-top filter or a 96-
well plate filter, washed twice with BSS (50 mM Tris, 100 mM NaCl, pH 8, 1 mg/mI
BSA), and resuspended in BSS with least 10-fold molar excess target protein and
incubated for 2 h at room temperature with gentle shaking. Cells were filtered, washed
twice in chilled BSS, resuspended in a 1:100 dilution of mouse anti-HA (Roche,
RRID:AB_514505) and rabbit anti-c-myc antibodies (Sigma, RRID:AB_439680) primary
antibodies in a volume of 2 mL per 108 cells, and incubated for 15 min at 4 0C. Cells
were filtered, washed twice in chilled BSS, resuspended in a 1:40 dilution of APC rat
anti-mouse (BD, RRID:AB_398465) and 1:100 dilution of PE goat anti-rabbit (Sigma,
RRID:AB_261257) secondary antibodies in a volume of 2 mL per 108 cells, and
incubated in the dark for 15 min at 4 C. Cells were filtered and washed 2x in chilled
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BSS before resuspending the labeled cells in BSS and using BD FACSAria flow
cytometer or a BD FACSCanto using FACSDiva software for cell sorting or analysis.
High-throughput affinity sorting and sequencing
To select a diverse pool of -10,000 unique BH3 sequences for multi-receptor
Sortcery, we grew the six yeast display libraries described in Jenson et al. and pooled
the libraries prior to incubating with 100 nM Bfl-1, McI-1, or Bcl-xL . Cells were sorted
into 12 gates set to separate binders of different affinities as described in Reich et al. 24
Sorted cells were grown overnight in SD+CAA. An equal number of cells from the Bfl-1,
McI-1, and Bcl-xL sorts were pooled together to make a final pool of -10,000 cells. Of
the -3,333 cells from each sort, most were selected from the highest affinity gate (-540
cells) and the fewest were selected from the lowest affinity gate (-25 cells) with a linear
sampling gradient in between. The mixed library was grown overnight and stored in
glycerol stocks.
To experimentally determine affinities of yeast-displayed peptides for Bfl-1, Mcl-
1, and Bcl-xL, we sorted the mixed library into 12 affinity gates and subsequently deep-
sequenced DNA from cells collected in each gate following the Sortcery protocol
described in detail by Reich et al.2 4
Designed clones were verified for their specificity preferences with titrations.. The
median binding signal of the binding population was recorded for each clone and
applied to estimate an approximate KD. Clones were assigned to the bin at which the
estimated 1/2 max binding signal would occur. Sequences for which the signal was
below 1/2 max signal of Bim at 1000 nM were assigned as >1000nM.
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Crystallography
Crystals of Bfl-1 in complex with F4 and F10 were grown in hanging drops over a
reservoir containing 1.8 M ammonium sulfate, 0.1 M MES pH 7.0 at room temperature.
The protein was mixed with peptide at a 1:1 molar ratio and concentrated to 4 mg/ml in
20 mM Tris, 150 mM NaCl, 1% glycerol, 1 mM DTT, pH 8.0. The hanging drops
contained 1.5 pL of complex mixed with 1.5 pL of reservoir solution. Crystals were cryo-
protected (2.0 M lithium sulfate with 10% glycerol) and flash frozen. Diffraction data
were collected at the Advanced Photon Source at the Argonne National Laboratory, NE-
CAT beamline 24-ID-C. Both datasets were integrated and scaled to 1.48 A using
HKL2000 and phased using PHENIX ridged body refinement of chain A of structure
4ZEQ using PHENIX 35,36 . The peptide was built into the remaining difference density.
Several iterations of refinement using PHENIX and COOT to improve the structural
models 36' 37.
Computational Processing of SORTCERY Data
Filtering sequences for high-fidelity reads
Deep-sequencing data were filtered for high quality reads with at least 99% base
call accuracy and matching specified multiplex barcodes used to individually identify
each experiment. Paired-end reads that did not overlap were discarded, and
overlapping DNA segments were reassembled. Unique sequences that had at least 100
reads were processed for further analysis.
Generating clone profiles over gates and average affinity coordinates
Clonal cell counts per gate were estimated as a function of the deep sequencing
read counts. Because different numbers of cells are collected in different gates, read
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counts do not map directly to cell counts. To calculate the cell count for sequence x in a
given gate i, ni (x), we first calculated the clone's relative frequency in that gate as the
number of reads for sequence x in gate i, r(x), divided by the sum of all reads for all
sequences for gate i. The clone's relative frequency is then scaled by the observed
number of cells recorded to hit gate i in a fixed amount of time, ci.
ni(x) = (Z,~r,(x)
EALri U)
Calculated cell counts were normalized to determine the probability distribution over




To mitigate the effects of sequencing error on our analysis, DNA sequences were
clustered by sequence similarity using USEARCH with a 3 percent identity cutoff. Within
each DNA cluster, the sequence with the most reads was assigned as the parent of the
cluster and all other sequences were assigned as daughters. Daughter probability
distributions over gates were compared to parent profiles. A daughter sequence was
split into its own cluster if its probability distribution over gates differed significantly from
the parent probability distribution (chi-squared test with Bonferroni correction: alpha-
value < 0.005/# clones). Otherwise, daughter sequences were combined with parent
sequences and each cluster was assigned a new probability distribution profile over
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gates. Sequences that only occurred in one gate were removed, because profiles for
individual clones measured independently always span multiple gates. We also
removed sequences with non-unimodal profiles using a custom python script.
The probability distribution of cells over gates for each sequence approximates the
distribution of measured clones along an axis of affinity23 . Profiles were used to
compute an mean affinity coordinate, A, for each sequence using:
i=12
Mean coordinate value = i
i=1
DNA sequences were translated into protein sequences for all subsequent analyses,
yielding a list of protein sequences and their associated A, values. Redundant protein-
to-energy mappings originating from synonymous mutation were removed.
Sequences that may have originated from spurious mutation, PCR error, and
cross-library contamination were removed from the dataset by filtering for only
sequences that matched the designed library input using regular expression on the DNA
level.
Sequences were classified into three categories of affinity (unresolvable tight,
resolvable, and unresolvable weak). These sequences were separated based on the
calculated shape of the probability distribution function of the peptide across FACS
gates. If the maximum mode of the distribution occurred in gate 1 or 12, the binder was
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classified as resolvable tight or weak. The remaining sequences were classified as
resolvable.
Mapping mean affinity coordinate to AG
The average affinity coordinates for different clones reflect relative binding
affinities, but absolute values are specific to a given experiment. To compare affinity
values across experiments, we used standards to calibrate the affinity axis ito give
binding free energy in kcal/mol. Standards were selected to span the SORTCERY
affinity range of each experiment. For each standard, a binding curve was measured via
yeast titration and fit to give the standard free energy of binding. We applied linear
regression to map A, values to energies. Although a linear fit is an approximation of the
true relationship between A, and AGbinding, fitting the theoretical curve gave minimal
differences in values.
Regression modeling to relate peptide sequence to AGbinding
Support vector regression (SVR) models were trained to predict SORTCERY-
measured affinity from protein sequence. SVR solves for a function that has at most
epsiloni deviation from the observed value: Y? -- < 6 where Yi =T. I + As this
constraint problem is not always feasible, slack variables zetai are introduced for each
data point and minimized. This results in the primal form of the SVR regression
problem, which balances model complexity and performance as follows:
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min -w +C i +)
subject to yj - wT#(X,) 
- b _ e + (j,
WT $(X,) + b - yj < E + ,
(j(* ;> O, i = 1, ... , n
The epsilon parameter defines a range of insensitivity to noise and the C parameter
defines the cost of adding slack to the model. C can be interpreted as a scalar that
varies the complexity of the model. Smaller C allows the model to be simpler by
permitting more slack on the model optimization. The epsilon parameter and C
parameter for the final models are identified via nested cross-validation. SVR was used
as implemented in sklearn 8
Protein sequences were converted into numerical vectors via a binary amino acid
encoding. This procedure encodes a protein sequence of length n into a n*20 length
vector where each position/residue is represented as a one or zero, depending on
whether the position/residue is present in the sequence. For a peptide of length 22, as
for Bcl-2-peptide interactions, the resulting encoding is a binary vector of length 440,
with 22 non-zero values.
A generalizability score was determined for each dataset via 10-fold nested
cross-validation. An input dataset is split into 10, top-level subsets. Each top-level
subset (1/10 of data) is a validation dataset V which will be each report the performance
of models trained on the remaining 90% of data Tr.
The models trained on the dataset Tr retrieve their hyperparameter from a
nested ten-fold cross-validation within the dataset Tr. Dataset Tr is partitioned in 10
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parts , where now each part (Te) is used to test models trained on the remaining 90% of
data (S) A grid of hyperparameters, were evaluated (epsilon and C) on each Te and the
best performing hyperparameters inform the models trained on Tr. The grid of
parameters explored 2-14 - 26 for C and epsilon [0 - 1], in 0.05 intervals Performance of
models trained on Tr and evaluated on V reports an estimate of generalizability. The
best hyper-parameters for the final models were selected by args which performed the
best on the Te datasets. (The V dataset is only used to report genera lizability).
We tested a linear kernel rT z and a second order polynomial kernel (x' Zr in
our model building and comparisons. This primal optimization problem is solved in the
dual form by construction of the Lagrangian objective function, which is beyond the
scope of this paper2 .
Support vector regression models were used as implemented in Scikit-learn.
Scikit-learn solves the support vector regression objective function in dual form and
returns the dual weights as a solution to the fitting problem. To extract out the
component, pairwise weights from the dual coefficients, the following function was
applied.
xi is the expanded polynomial vector of a given training input point and ( ai -ai*) is the
dual coefficient. This equation tells us that the weight vector is a weighted sum of the
expanded polynomial vectors. The dual coefficient can be interpreted as the weighted
contribution of the data point to the weight vector26.
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Design with integer linear programming
Six design objectives were pursued with integer linear programming (ILP).
Monospecific peptides were designed to bind to Bcl-xL, Mcl-1, or Bfl-1. Bispecific
peptides were designed to bind Bcl-xL and Mci-1, Bcl-xL, and Bfl-1, or Mcl-1 and Bfl-1.
These peptides were designed to bind selectively to their intended receptor by
maximizing the target binding affinity, maximizing the specificity gap, or by minimizing
the off-target binding affinity. For each set of designs, 200 sequences were iteratively
solved with ILP, from which 7-12 sequences were selected to be evaluated. The models
weights used for design were derived from functions trained from an earlier curated
datasets which did not aggregate on DNA sequence similarity.
Designed sequences were restricted to select from residues in the input library
space and excluded Cys residues. However, sequences could choose residues from
either Bim or Puma scaffold sequences interchangeably which expanded the potential
sequence space to the order of 1014.
Constraints were included during optimization to prevent including residues with
low confidence. The sequence space was restricted to allow only position/residue terms
that were observed at least 25 times in all three training datasets. The models are prone
to overfit rare examples, thus, adding constraints such that a given residue must be
observed frequently helps to prevent designing in spaces with low confidence.
Designing sequences with ILP also required including formal constraints that
describe properties of a peptide. For example, a peptide must only have one residue at
each position. Also, if a residue is selected for design at a given position, the
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corresponding squared term must also be included. Finally, pair terms for which the
component terms have both been included must also be included.
The scoring function is the sum of the receptor-specific pairwise weights
multiplied by the one-dimensional binary indicator vector Phi(x). For a sequence of
length n, this is equivalent to the sum the product of pair weights and indicator variables
xi and xj. The variables xi and xj identify whether an amino acid is present at a specific
position. Receptor-specific energy functions were developed for Bcl-xL, Mcl-1, and Bfl-1.
These are referred to as X, M, and F below.
n-20 n20
y = WG(X)= S, iIXzIxj
To design receptor-specific peptides, sequences maximized binding affinity to the
target receptor were solved for (i.e. to minimize binding energy). Constraints were
imposed to require that the designs bind the target with AG 5 -10.9 kcal/mol (10 nM)
and bind the two off targets with AG > -9.5 kcal/mol (Kd greater than 107.9 nM). The off-
target affinity boundary was selected to be the affinity at which the population of non-
resolvable weak binders started to appear. An example of the Bcl-xL receptor-specific
designs is provided below.
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min X(x)
subject to F(x) > -9.5 Bfl-1 off-target constraint
M(x) > -9.5 Mci-1 off-target constraint
X(x) < -10.9085 Bcl-xL target constraint
N(xi) > 25 for i = 1, . . . , 22 Frequency constraint
The design routine generates 200 peptide sequences. To select the set of
sequences to be experimentally tested, applied a consensus-based approach by
rescoring all designs using six re-trained energy functions for each of the three
receptors. The six SVR models were trained with linear or polynomial kernels on three
different sets of experimental data, for each receptor and averaged. Models were
trained on replicate 1, replicate 2, or a union of replicate 1 and replicate 2 datasets.
Twelve sequences for each receptor were selected to be evaluated. These 12
sequences were selected for the largest mean specificity.
For the bispecific designs targeting Bcl-xL and Bfl-1 (with specificity against Mcl-
1) or the bispecific designs targeting Mcl-1 and BcI-xL (with specificity against Bfl-1), the
sequences that minimized the off-target affinity were solved for. Constraints were added
to require tight binding of the two targets, AG <= -10 kcal/mol, and weak binding to the
off-target, AG >= -8.5 kcal/mol. The following shows the constraints for designing Bcl-xL
and Mci-1 bispecific peptides:
max F(x)
subject to F(x) > -8.5 Bfl-1 off-target constraint
M(x) < -10 Mci-1 target constraint
X (x) < -10 Bcl-xL target constraint
N(x-) > 25 for i = 1, ... , 22 Frequency constraint
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To select the set of sequences to be experimentally tested, all of the designs
were rescored using 6 re-trained energy functions for each of the 3 receptors as
described above. Seven bispecific sequences with the largest mean specificity were
selected to be tested.
To design bispecific peptides that bind to Mcl-1 and Bfl-1, without binding tightly
to Bcl-xL, I solved for sequences that maximized the gap between Bfl-1 and Bcl-xL
binding energies. (This is equivalent to maximizing the set of weights derived from the
difference of Bcl-xL and Bfl-1 models). Constraints were added to require that the Mcl-1
and Bfl-1 binding energies that differ by at most 0.2 kcal/mol. No additional binding
energy constraints were applied to the target or off-target binding energies.
max Dx-f (x)
subject to Df-m(x) <= 0.2 Target similarity constraint
Df-n(x) >= -0.2 Target similarity constraint
N (xi) > 25 for i = 1,.. . 22 Frequency constraint
To select the set of sequences to be experimentally tested, I re-scored all
designs using 6 re-trained energy functions for each of the 3 receptors as described
above. Seven bispecific sequences with the largest mean specificity were selected to be
tested.
To redesign the bispecific peptides, we added additional residue constraints,
optimized target binding as an objective function (rather than maximizing the specificity
gap or minimizing the stability of the off-target), and added additional requirements, as
described below, to select a more diverse set of sequences.
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To prevent the potential inclusion of destabilizing residues in the designs, we
limited the sequence space to include only those residues observed in tight binding
peptides for the target (peptides with SORTCERY AG < -10.5 kcal/mol). We added
constraints to require that the predicted binding energy for each of the two targets be
less than -11.3 kcal/mol. This boundary was chosen because it was the minimal
predicted binding affinity among the successful mono-receptor specific sequences.
Furthermore, we chose to minimize the binding energy of the targets instead of
maximizing the off-target energy. Given that ILP can only optimize one objective at a
time, we solved two optimizations for each dual-specificity design problem, one
optimizing the binding energy to the first target, and the second optimizing the binding
energy to the second target. To enforce specificity we imposed a constraint on the off-
target binding energy: AG >= -10 kcal/mol. The optimization problem was therefore:
min X(X)
subject to F(x) > --9.5 Bfl-1 off-target constraint
AI(x) < -11.3 Mcl-i target constraint
X (x) < -11.3 Bcl-xL target constraint
N(xi) > 25 for i = 1... 22 Frequency constraint
xl E binders for i = 1 ... , 22 Residue constraint
To select the ten best Bcl-xL and Bfl-1 bispecific peptides and ten best Mcl-1 and
BcI-xL bispecific sequences, we applied the consensus-based method to compute
average scores for each design binding to each receptor. We selected the top 5
sequences, based on affinity for one of the targets, that had at least two mutations
relative to higher ranking designs.
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In the second round of design for BcI-XL and Bfl-1 bispecific peptides and Mci-1
and Bcl-xL bispecific sequences, we used FlexPepDock to score the population of
sequences designed to confirm whether the changes in our optimization problem were
consistent with structural models.
Solving for boundaries of peptide specificity
Input library
The boundary of specificity for the input library was identified by estimating a
solution to the concave hull problem for the full set of 27,696,384 library members.
After mapping each sequence to an x,y coordinate, we estimated the shape by plotting
the minimum and maximum y values for each group of rounded x values (2 decimal
places) and vice versa.
Integrated library
The boundary of specificity for the integrated library space was calculated via
ILP. The angular and radial coordinate on the 2D plot is determined by the ratio of
binding affinity of a given peptide for the three receptors. At any given coordinate, there
are two target receptors and an off-target receptor. The radial position is determined by
the energy gap between the tighter of the two target binders and the off-target binder.
The angular coordinate is determined by the affinity ratio between the two target
binders. For every pair of target receptors, McI-1/ BcI-xL, Mcl-1/BfI-1, Bcl-xL/Bfi-1, the
energy gap between the two pairs is fixed as a constant between -6.8 and 6.8 kcal/mol,
and the sequence with the lowest off-target affinity is identified via ILP. This
optimization problem identifies a sequence that lands on the boundary of specificity.
(This boundary is still constrained by the need to have 25 observations per receptor)
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Plotting specificity vs. affinity tradeoffs
All 27,696,384 peptides in the designed library were computationally scored
against Mcl-1, Bfl-1, and Bcl-xL. For a given target receptor, all peptides were binned by
the predicted target affinity. The median affinity of the off-target is plotted for each bin.
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Chapter 4
Tertiary structural motif sequence statistics enable rapid discovery of
novel ligands for anti-apoptotic Bfl-1 and Mcl-1
V. Frappier, J.M. Jenson, and A.E. Keating designed and wrote the study. V. Frappier, J. Zhou,
and G. Grigoryan designed peptides with dTERMen, V. Frappier performed the benchmarking,
and J.M. Jenson performed all of the experiments.
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Abstract
Understanding the relationship between sequence and structure well enough to
design novel sequences from a structural template has been a longstanding goal
in protein design. To this end, the Protein Data Bank (PDB) has been a key resource for
defining and developing the general design criteria for structural features like rotamer
positions and dihedral angles. Here, we show that by decomposing protein structures
from the PDB into sets of well-defined, non-contiguous structural motifs (TERMs) it is
possible to rapidly and accurately predict the binding energies of peptide-protein
interactions at least as well as existing state-of-the-art methods without computationally
expensive structural relaxation and minimization or experimental screening. We
demonstrate the potential of this approach by designing highly diversified peptides more
than 14 mutations away from their naturally occurring counterparts to target the anti-
apoptotic proteins Bfl-1 and Mcl-1. We found that 15 of 17 designs bound tightly to their
intended target. Further, high-resolution structures of the designed peptides revealed at
least one example where a mutation was accommodated by minor adjustments in
backbone geometry that would not have been predicted if modeling was performed on a




Protein-protein interactions (PPIs) are central to nearly all biological processes,
play a major role in cell homeostasis 2, and contribute to pathology in countless human
diseases 3. Reagents that can disrupt PPIs are highly sought after for basic research
and therapeutic development. The primary reason that there are so few PPI inhibitors,
relative to the 400,000 predicted biologically functional PPIs4 , is that the size and
complexity of many protein interfaces make them difficult to target5 . For example, large
binding sites that have multiple, widely spaced hotspots are notoriously difficult to
disrupt with small molecules, as are flat interfaces that lack pockets 6'7 . Antibodies and
nanobodies can be used to block PPls and have the advantage, relative to small
molecules, of binding to larger protein interfaces. But the difficulty of delivering such
large molecules into the cell, coupled with the low stability of some antibody-derived
agents in the reducing environment of the cytoplasm, has largely limited their
application to extracellular targets or chemically permeabilized cells ex vivo.
Furthermore, there are many PPI interfaces that are difficult to target with antibodies.
Peptides provide a complementary and highly promising approach to targeting
PPI interfaces8 10 . Peptide-protein interactions are ubiquitous in nature, where there are
many examples of short segments in a protein binding to large, structurally complex
protein surfaces. The latest delivery technologies make targeting intracellular proteins
with peptides increasingly possible. For example, peptides can be delivered into cells by
chemically modifying them to increase hydrophobicity and hide hydrogen bonds',
conjugating them to transduction domains (such as cell-penetrating peptides, CPPs)1 -
15, or delivering them using cationic lipid carriers1 6 . Nevertheless, there are well-known
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obstacles to developing useful peptide inhibitors. Peptides derived from naturally
occurring sequences have non-optimal pharmacological properties, because they
weren't selected for function as reagents or therapeutics. Furthermore, native ligands
often have a binding specificity profile different from what is desired for a given
application. Significant sequence optimization is typically required to minimize off-target
binding, increase protease sensitivity, reduce immunogenicity, and improve
pharmacokinetics. Not all of these potential pitfalls are unique to peptides, but there can
be many failure modes in the peptide development pipeline. Because we lack the ability
to predict pharmacological potential a priori, an ability to rapidly generate numerous
diverse peptide sequences that tightly bind/inhibit a target PPI would be transformative
for the development of peptide therapeutics.
Current approaches for discovering diverse peptide PPI inhibitors for inclusion in
drug development pipelines are sometimes effective but are inefficient. The state of the
art of discovering novel proteins or peptides that modulate function relies heavily on
experimental screening. However, experimental screening of peptide libraries requires
that one choose a sequence/structure scaffold in advance, which is often a naturally
occurring ligand, around which only a vanishingly small fraction of the sequence space
can be queried. This approach, which selects for the "best" binders in a population,
does not typically provide diverse leads. Rational design, e.g. using computational
models to search sequence-structure space on a much larger scale, can effectively
guide screens into spaces far beyond those represented in nature1 7. However, given the
essentially infinite space to explore, and the difficulty of accurately predicting the best
binders, the success rates of rational, structure-based methods have so far been low.
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Successful design studies have used prior information about known binding sequences,
or known binding hot-spot residues, to help define the design strategy and guide the
search. This limits the diversity of solutions that can be discovered. Furthermore, even
when such information about sequence/structure elements that promote binding is
available and can be exploited, computational design often must be followed by
extensive optimization using experimental screening to identify functional designs.
Recent methodological developments have shown that mining sequence-
structure relationships from the Protein Data Bank (PDB) has the potential to improve
the efficiency and efficacy of structure based modeling and design. It has long been
recognized that protein structures are composed of recurring structural elements, and
the large number of solved structures now makes it possible to compile a finite, yet
near-complete, list of the recurring tertiary structural motifs (here called TERMs) that are
needed to construct any protein structure18 . Recent analyses have also demonstrated
that TERMs have characteristic sequence preferences that can be detected by
statistical analysis of solved structures. These observations provide the foundation for a
formalism that can quantify the quality of fit of any sequence on any specified structural
scaffold19. This is exactly what is needed to predict the influence of a sequence
mutation, or to perform computational design as a sequence optimization problem for a
given structure.
TERM-based computational analyses have already demonstrated utility for
challenging modeling tasks. For example, a statistical analysis of TERM sequences is
remarkably effective at discriminating between good and poor structure prediction
models, on par with or exceeding leading model quality assessment metrics19. Zheng et
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aL. also showed that TERM sequence statistics capture aspects of protein
thermodynamics and can be used to predict stability changes upon mutation as well as,
or better than, state-of-the-art physics-based or statistical methods. Finally, TERM-
based sequence-structural relationships can be applied to protein design. We call
design using TERM sequence statistics dTERMen (design with TERM energies), and
Mackenzie et al. have shown that this approach to identifying the best sequence for a
given structure recapitulates native-like sequences given either NMR or X-ray native
backbones and can be used to rationalize observed evolutionary variation18 . As a
method for protein design, dTERMen is distinct from many other existing methods
because it does not at any stage perform explicit modeling of the designed structure.
This leads to substantial time savings, but could potentially lead to problems including
steric clashes or other structural frustration.
In this work, we applied dTERMen to a new application: analyzing and re-
designing peptide binders of biomedically important proteins. As targets, we chose the
anti-apoptotic proteins Bfl-1 and Mcl-1. These proteins are members of the Bcl-2 protein
family, along with paralogs Bcl-2, BcI-xL, and Bcl-w. Bfl-1 and Mcl-1 promote cellular
survival by binding to and sequestering pro-apoptotic BH3 domains and have well-
established roles supporting cancer cell survival and the development of
chemoresistance20,2. However, there are no clinically approved inhibitors targeting Bfl-1
or Mcl-1, despite considerable interest and investment. Small molecules, peptides, and
mini-proteins have been described as potential inhibitor leads1 0,22-25 , but given the high
attrition rates of inhibitor leads during development, success is not yet assured.
Therefore, we tested the ability of dTERMen to generate additional peptide sequences
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that can be included as scaffolds for ongoing drug-development pipelines. Our success
validates dTERMen as a promising and novel approach for rapid early stage discovery.
Results
Benchmarking dTERMen performance
To evaluate the potential of dTERMen for designing peptide ligands for Bfl-1 and
Mcl-1, we tested its performance on a variety of PPI prediction tasks using binding data
for Bcl-2 family proteins. dTERMen has not previously been used to predict binding
affinities, and in fact the method is parameterized using sequence preferences from
only single-chain structural motifs. Nevertheless, the binding of peptides to Bcl-2
proteins is a coupled binding-and-folding reaction that resembles single-chain protein
folding in some respects, and the resulting complexes share characteristics of folded
structures, including a globular arrangement of packed helices and a hydrophobic core
at the interface. Furthermore, there is precedent for extrapolating single-chain statistics
to model PPIs 26.
To evaluate binding prediction performance, we used a dataset consisting of
4386, 4491 and 3805 measurements of peptides binding to BcI-xL, Mci-1 and Bfl-1,
respectively. Affinity values were obtained using SORTCERY 27,28, a high-throughput
method for quantifying dissociation constants of peptides displayed on the surface of
Saccharomyces cerevisiae. The peptides that were tested contained between 1 and 8
mutations made in the background of the BH3 sequences of human BIM or PUMA, and
had SORTCERY-determined dissociation constants of 0.1 to 320 nM (binding energies
of -13.8 to -8.9 kcal/mol), with some peptides classified simply as binding tighter or
more weakly than the extremes of this range.
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We defined several prediction tasks using the BcI-2 family interaction data. The
easiest task was to discriminate the 20% tightest binders of a particular protein from
sequences that were observed in the 20% weakest binding affinity, at the concentration
tested (1 nM for Mcl-1 and BcI-xL, 100 nM for Bfl-1). We also defined an enrichment
task, which involved identifying the top 10% highest affinity binders and, finally, the
extremely difficult test of predicting quantitative affinities within a 5 kcal/mol range in
binding energies. In addition, we tested the ability of dTERMen and other methods to
predict the binding preferences of peptides for one Bcl-2 family protein vs. another.
Here, too, we defined easier and more challenging tasks, first asking if we could
correctly predict the binding behavior of peptides that interact tightly with one protein but
not detectably with another, and second testing the ability of different methods to predict
differences in measured binding energies. As input into the calculations, we used a
subset of solved structures of Bcl-2 protein-peptide complexes that were selected to
span observed binding geometries. We compared the performance of dTERMen with
that of commonly used methods Rosetta29 and FoldX30.
Table 4.1. Predicted performance of dTERMen compared to Rosetta and FoldX.
meanAUC mean cor mean spec mean Enrich
FoldX-moan 0.752035 0.311641 0.184434 21.377008
FoldX_ min 0.856194 0471359 0.385888 29.141456
Rosetta mean 0.752452 0.335921 0.268465 24.443816
Rosettamin 0.783532 0.373168 0.288744 26.037904
dTERMen- mean 0.772331 0.368573 0.292424 30.848460
dTERMen min 0.804637 0.408427 0.364274 35.606232
meanAUC= Predicted ability to discriminate between the tightest 20% and weakest 20% of binders, averaged across Bcl-xL, McI-
1, and Bfl-1 SORTCERY datasets.
meancorr= Observed correlation with measured affinities, averaged across Bcl-xL, Mcl-1, and Bfl-1 SORTCERY datasets.
meanspec= Ability to predict differences in measured binding energies between proteins, averaged across Bcl-xL, Mcl-1, and Bfl-1
SORTCERY datasets.
meanEnrich= enrichment of top 10% of binders, averaged across Bcl-xL, Mci-1, and Bfl-1 SORTCERY datasets.
FoldX, Rosetta, and dTERMenmean= average performance over all structural models
FoldX, Rosetta, and dTERMenmin= best performing structural model in tested set.
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We first tested whether different modeling approaches could discriminate high
affinity binders from peptides that were not observed to bind or bind weakly at the
concentrations tested. We ran a binary classification test and report the results in Table
4.1 as the area under the receiver operating characteristic (ROC) curve (AUC). An AUC
value of 1 corresponds to a perfect discrimination of peptides labeled as tight binders
vs. non-binders, and an AUC value of 0.5 represents the performance of random
guessing. We found that that predictive power varies significantly as a function of the
template using for modeling. One striking example comes from the FoldX predictions
made on the Bcl-xL dataset, where the AUC values range from 0.39 (worse than
random) to 0.82 based on the template used for modeling. In one case, multiple
complexes found in one crystal structure (5C6H) gave AUC values ranging from 0.65 to
0.82. Unfortunately, there is no reliable way to know, a priori, which template will give
the best results. We chose to report in Table 4.1 the average performance of each
method over all templates. Performance averaged for all protein targets shows that
dTERMen (AUCavg = 0.77) has similar predictive power to the other scoring methods,
Rosetta (AUCavg = 0.75) and FoldX (Ravg = 0.75). However, this small difference is
driven by better performance on the Bcl-xL dataset, for which dTERMen (AUCavg = 0.75)
is better than Rosetta (AUCavg = 0.69) or FoldX (AUCavg = 0.69). As expected, the
Pearson correlation values between the binding energies and prediction values for each
template follow an almost identical trend than the AUC values. Performance averaged
for all protein targets shows that dTERMen (Ravg = 0.37) is marginally better than the
other scoring methods, Rosetta (Ravg = 0.34) and FoldX (Ravg = 0.31). Moreover, some
methods perform significantly better on some templates than others, and no single
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method is consistently better than the others (table 4.1). This analysis shows that
dTERMen has predictive performance on par with some of the most commonly used
structure-based prediction tools, and thus has potential for application in protein design.
Many applications seek the tightest binding sequences, given that these may
have the greatest potential as reagents or therapeutics. But discriminating tight binders
from weaker binders is more difficult than recognizing the difference between tight
binders and non-binders. We used an enrichment test to evaluate method performance
on this task. Specifically, we used each method to rank all of the 4386, 4491 or 3805
sequences that had measured affinity values for Bcl-xL, Mci-1 or Bfl-1. We then
examined the top 10% of ranked sequences to determine what proportion of the top
10% of experimental binders were captured. For a perfect method, the answer would be
100%. Results for dTERMen, FoldX and Rosetta are reported in Table 4.1. Overall,
dTERMen (Binderavg = 31%) has better enrichment value than Rosetta (Binderavg =
24%) and FoldX (Bindervg = 21%). In contrast to the other benchmark metrics,
dTERMen tends to be consistently better than the other methods, for which it scores
better for 69% of the templates. In the other tasks, however, this value is around 38%,
which is close to random.
It is not surprising that binding affinity predictions depend on the input template
structures, particularly for dTERMen and FoldX, which do not perform template
structure backbone relaxation (dTERMen does not perform any structural modeling at
all). We were struck, however, by the strong dependence of the predicted binding
affinities on the choice of template structure and thought this might be an area where
dTERMen could provide an advantage. The robustness of prediction performance to
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very small differences in input structures was evaluated using 294 pairs of closely
related templates with binding site and peptide backbone atom RMSD < 1 A. For each
pair, we computed the correlation of predicted binding energies for all peptides with
measured dissociation constants. On average, dTERMen (Ravg = 0.77) is much less
sensitive to small differences in input template than FoldX (Ravg = 0.55). When run with
default options, the Rosetta (Ravg = 0.60) "relax" protocol is similar to FoldX, although
further structural sampling could, at least in theory, lead to a convergence of the
Rosetta predictions made on different templates, albeit at a higher cost in computing
time.
For all methods, prediction performance could potentially be increased by using a
more aggressive conformational search, such as peptide re-docking or MD simulation,
although this would be computationally expensive for benchmarks of this size (around
140,000 complexes). A more computationally tractable approach to structural sampling
is to evaluate each sequence on a finite number of input structures, and take the lowest
predicted binding energy (corresponding to the most stable complex) as the predicted
energy. This variation in scoring protocol was tested for all 3 benchmarks: tight
binder/non-binder discrimination, tight binder enrichment, and affinity correlation. A
summary of the performance is reported in Table 4.1. Without exception, performance
improved for all methods when more templates were used. Compared to Rosetta and
dTERMen, FoldX benefited the most from the additional sampling: where expected
performance increased from 0.31 to 0.47 for Pearson correlation to binding affinity
values, 0.75 to 0.85 for AUC values, and from 21% to 29% for enrichment of top binder.
dTERMen designs
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Because dTERMen performed at least as well as established scoring functions in
benchmarking, we reasoned that it might be useful for designing peptide binders. The
only input that must be specified for dTERMen is the design template structure. We
chose 5 structures as design templates: two structures of Bfl-1 complexes and three
structures of Mcl-1 complexes. Templates were chosen to sample structural diversity,
because distinct templates could potentially provide access to distinct sequence
spaces.
For Bfl-1 targeted designs, we selected the structure of Bfl-1 bound to the natural
ligand PUMA (PDB ID 5UUL) and of Bfl-1 bound to a Bfl-1 selective peptide (FS2) that
was identified in a previously reported screen (PDB ID 5UUK) 23. Because the
backbones of PUMA and FS2 are shifted 1.2 A and rotated 170 relative to one another
in the Bfl-1 binding pocket23, we expected to see differences in the optimal sequences
identified by dTERMen for these two templates. For the Mcl-1 targeted designs, we
used structures of Mcl-1 bound to the natural ligand BIM (PDB ID 2PQK31 ) and to a
stapled variant of the natural ligand BID (PDB ID 5C3F 3 2); these two structures have
similar binding modes (peptide RMSD < 1), but the Mcl-1 protein has differences in the
binding pocket. We also used a structure of peptide FS2 bound to Mcl-1. FS2 has low
affinity for Mcl-1 (Kd > 3 uM) but engages the protein in a unique binding pose (PDB ID
5UUM)23 .
Four sequences were designed on each template, using slightly different
versions of dTERMen and imposing constraints on the identities of some residues.
Specifically, the residue at position 4b of many native BH3 peptides serves as an N-
terminal helix cap for helix 5 of Mcl-1 or Bfl-1. This residue is often asparagine,
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aspartate or histidine. dTERMen chose threonine at this position, and a careful
investigation into why revealed that the database of single-chain structures used to
extract TERM statistics did not contain any examples of a corresponding TERM with
asparagine, which is apparently a motif found only in inter-chain arrangements. We
chose to fix position 4b as asparagine to mitigate the risk of using inappropriate
statistics for this inter-chain TERM. BH3 residue 3b also makes a helix-capping
interaction in some solved structures, so in half of the designs (FO1-F04, M01-M04) we
retained the wild-type residue from PUMA (arginine) or BIM (alanine) at this site.
Figure 4.1 shows sequence logos built from the top 100 sequences that were
designed on each template. As anticipated, the peptide sequences designed on
different templates were highly distinct. Particularly notable is the variability at the highly
conserved positions 3a and 3f. In the natural BH3 sequences position 3a is highly
conserved as a leucine. Although dTERMen overwhelmingly chose leucine at this
position for designs templated on 5UUL and 5C3F, there was unanticipated sequence
diversity predicted for the other design templates. Most notably, designs from the 5UUK
and 5UUM templates preferred isoleucine and methionine over leucine. Position 3f is
conserved an aspartate in the natural sequences, but dTERMen chose a variety of
residues across all the templates. Furthermore, the designed sequences were very
different from any previously known BH3 sequences. Figure 4.1B shows the minimum


























FS2 FOl F02 F05 F06 PUMAF03 F04 F07 F08 BIM M0 M05 M06 BID M03 M04 M07 FS2 M09 M10
S<1nM N <10nM *<1OOnM <1000 nM >1000 nM
Figure 4.1. dTERMen as a predictive tool. A) Sequence logos generated by the dTERMen scoring
function for each of the design templates (5UUL, 5UUK, 5C3F, 2VM6, and 5UUM). Heptad notation for
the peptide sequences is shown above the logos. A list of the natural BH3s is in Table 4.2. B-C) The top-
scoring sequences from A were selected for experimental testing. The sequences of the top Bfl-1 designs
(B) and the top Mcl-1 designs (C) were compared to known natural ligands. A list of the top sequences is
shown in supplementary table 2. D) The designed sequences were cloned into yeast for cell surface
display and the binding affinities of the designs were approximated using a sparse titration. This enabled
qualitative comparison of the design binding affinities to the templates. All measurements were performed
at least twice.
To evaluate the predictions made by dTERMen, 17 designed peptides were
selected for experimental testing. An additional sequence designed on template 5C3F
was not tested because it was very similar to design M07. Peptide sequences are listed
in Table 4.3. Protein binding was assayed by yeast-surface display. Binding data from
yeast-surface display assays have been shown to correlate well with solution affinity
measurements, and numerous BH3 peptides shown to be tight binders on the yeast cell
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surface have been validated as having high affinity in solution. When the dTERMen
designs were assayed for target binding, 7 out of 8 of the peptides designed to bind Bfl-
1 gave strong binding signal at 100 nM Bfl-1 and 8 of 9 sequences designed to bind
Mcl-1 gave similarly strong signal at 100 nM McI-1 (Figure 4.1D). Measurements at 4
concentrations allowed us to put bounds on the cell surface dissociation constants, as
reported in Figure 4.1 D. The results show that a constraint on the helix-capping residue
at position 3b was not necessary for these sequences to bind their targets tightly;
peptides with and without this residue fixed bound tightly to their targets. Peptides
designed based on the 5UUM template, a complex that includes Mcl-1 bound to low-
affinity ligand FS2, bound approximately 100 fold more tightly than did FS2 itself.
Table 4.2. List of Natural BH3 sequences composing the sequence logo in Figure 4.1A

















Alignment of BH3 sequences from template structures (bold) and dTERMen designed
Sequence

























The two designed peptides that did not bind their targets with high affinity were
F6 and M6. F6 is the only peptide we designed with a residue larger than alanine or
glycine at position 3e. Position 3e is uniformly conserved as small in all native BH3
motifs and in previous designed binders of Bfl-1 and Mcl-1. Modeling F6 on template
5UUK with Rosetta highlights clashes due to the close proximity of the Ca position of F6
position 3e and the backbone of Arg 88 in helix 5 of Bfl-1 (Figure 4.2G). It seems likely
that valine is too large to be accommodated at this site. For design M6, it seems likely
that the substitution of arginine and aspartate at positions 3b and 3f of BIM with leucine
and methionine, and concomitant disruption of a charged network between the peptide
and the protein may have been destabilizing. These features are consistent with F6 and
















Figure 4.2. Side chain clashes for dTERMen designs on 5UUK (FS2:Bfl-1) template. A representative
sample of residues from the dTERMen designs were predicted to clash for all rotamers in model
structures, even with side chain repacking in Rosetta. The backbone dependent rotamers with the least
predicted clashing are shown. (A) Valine at position 2g of F1 (gray) is predicted to clash (red disks) with
L52 of Bfl-1 (green). (B) Methionine at position 3a of F1 (gray) and F5 is predicted to have minor clashes
with M75, E78, and F95 of Bfl-1 (green). (C) Valine at position 3d of F1 (gray), F2, F5 and F6 is predicted
to clash with V44 and V48 of Bfl-1 (green). (D) Isoleucine at position 3e of F1 (gray), F2, F5 and F6 is
predicted to clash with V44 of Bfl-1 (green). (E) Leucine at position 2g of F2 (gray), F5, and F6 is
predicted to clash with L52 of Bfl-1 (blue). (E) Isoleucine at position 3a of F2 (gray) and F6 is predicted to
have minor clashes with E78 and T91 of Bfl-1 (blue).
There is substantial interest in developing Bcl-2 family paralog selective
inhibitors. To determine whether our designs cross-react with other anti-apoptotic family
members, we tested binding of each peptide to Bcl-xL, Bcl-2, Bcl-w, McI-1 and Bfl-1.
Interestingly, the Bfl-1 binders that were designed on the structure of PUMA bound to
Bfl-1 bound tightly to most if not all five proteins, like the parent PUMA peptide. In
contrast, peptides designed on 5UUK, the structure of FS2 bound to Bfl-1, were > 100-
fold selective for Bfl-1, like FS2 itself. The data were less clear for McI-1 binders, some
of which were selective (Ml, M5) and some of which were not (M2, M3, M4, M6, M7)
(Figure 4.1D).
To determine whether the designed peptides maintained the binding mode of
peptides in the templates they were designed on, we solved crystal structures for four of
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the peptides that bound tightest to their targets: F1 and F4 in complex with Bfl-1, and
M1 and M7 in complex with Mcl-1 (Figure 4.3). Statistics for data collection and
refinement are reported in Table 4.4.
FS2:Bfl-1(5UUK) F1 PUMA:Bfl-1(5UUL)
BIM:Mcl-1 (2PQK) Mi BID:Mcl-1 (5C3F)
Figure 4.3. Structural comparison of designs and their templates. X-ray crystal structures of F1 bound to
Bfl-1 (A), F4 bound to Bfl-1 (B), MI bound to Mci-1 (C), and M7 bound to Mcl-1 (D) are compared to their




Table 4.4. Summary of X-ray data collection and refinement statistics.
Bfi-I:FI Bfl-1:F4 McI-1:M1 Mci-1:M7
Data Collection
SpaceGroup P1211 P1211 P212121 P3221
Cell parameters
a, b, c 43.223 42.92 47.718 43.466 42.905 46.666 64.792 69.733 84.853 80.758 80.758 57.95
a, P, Y 90 115.957 90 90 114.206 90 909090 9090120
Rmeas 0.078 (0.399) 0.078 (0.43) 0.137 (0.981) 0.122 (.0698)
Rpim 0.029 (0.169) 0.036 (0.259) 0.047 (0.398) 0.045 (0.338)
Mean l/a(l) 30.92 (2.9) 22.4 (2.0) 15.6 (0.655) 18.32 (1.49)
Completeness (%) 91.49 (77.84) 94.60 (74.42) 95.81 (67.33) 97.31 (78.96)
Redundancy 6.5 (4.3) 4.1 (1.9) 7.7 (3.9) 6.7 (3.4)
Refinement
Resolution (A) 38.86 - 1.587 42.56 - 1.752 24.3 - 1.945 26.77 - 2.247(1.644 - 1.587) (1.815 - 1.752) (2.015 - 1.945) (2.327 - 2.247)
Unique Reflections 19602 (1654) 15074 (1193) 27713 (1926) 10410 (831)
Rwork/Rfree 0.1706/0.1952 0.1826/0.2074 0.1993/0.2340 0.1771/0.2122(0.237210.2628) (0.2626/0.3506) (0.3105/0.3380) (0.2314/0.2456)
Numberof non- 1623 1528 3055 1481hydrogen atoms
Average B-factors 21.08 26.3 29.58 39.34
Rmsd
Bond lengths (A) 0.006 0.003 0.005 0.011
Bond angles (*) 0.77 0.54 0.93 1.38
Values in parentheses are for the highest-resolution she.
The structure of F1 in complex with Bfl-1, resolved to 1.58 A, shows that this
peptide binds very similarly to FS2 in template 5UUK (Figure 4.3A). It is striking how
similar the pocket-facing positions of the designed peptide F1 and template peptide FS2
are, even though the sequence identity of these two peptides is low (27%) and no
information about the FS2 sequence was used in the design process. Modeling F1 onto
the FS2 backbone in structure 5UUK indicates a minor clashes are anticipated between
M3a with residues in the P2 pocket (M75, F95, and E78), 14a with V44 in helix 2 of Bfl-1,
and V3d with V48 and V44 of helix 2 of Bfl-1 (Figure 4.2). Substantial clashes are
anticipated between V2g and L52 of helix 2 of Bfl-1, but the solved structure shows how
backbone adjustments can accommodated this residue. The small clash appears to be
the reason the C-terminus departs from its path in 5UUK. There are also deviations
between the N-terminus of FS2 in 5UUK and F1 in our new structure, which appear to
arise from changing tryptophan at position 2 to tyrosine, as well as from a change in N-
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terminal capping. FS2 is capped at the N terminus by the acetyl group, whereas for F1
this is a networked interaction involving Sif and D2b.
We solved the structure of F4 bound to Bfl-1 to 1.75 A and found that the C-
terminal end of the peptide rearranges (Figure 4.3B). In the original template (5UUL),
the helix begins to unwind around position 4d, but in the redesigned structure it the last
three or four residues are in an extended conformation. This could be due to mutation of
position 22 from glutamate to valine, as it ends up being flipped down and in an
extended conformation. We also found that dTERMen had poor statistics for structural
elements at the C-terminus of 5UUL, which might have contributed to the helical
unwinding. At the N-terminus, the sequence of F4 is very different from that of PUMA;
there is only 1 conserved position in the last 10 residues. A very important change is
glycine to alanine at position 2e. In 5UUL this is a very tightly packed helix-helix
position, where only glycine can sterically fit, but TERM statistics indicated that alanine
is common in very similar geometries. The solved structure shows how the F4 helix
shifted slightly to accommodate alanine and other sequence changes.
We solved the structure of M1 bound to Mcl-1 to 1.95 A and found that that it
binds very similarly its template 2PQK (Figure 4.3C). However, the structure of M7
bound to Mcl-1 at 2.25 A resolution revealed a substantial change in the binding mode
of the peptide relative to the positioning of stapled BID in the design template (Figure
4.3D). The helix is shifted in the groove by 2.56 A, and canonical BH3 interactions
including aspartate at 3f and leucine at 3a are completely rearranged, as are the
hydrophobic contacts (Figure 4.4B, C). In Mcl-1 alpha helix 4 is rearranged (Figure
4.4A). Interestingly, when evaluated using dTERMen, the M7 sequence scored worse
170
on the solved structure than it did on the template model. One complication in
evaluating this structure is that there are close contacts between two copies of the Mcl-
1:M7 complex near the C-terminal end of the binding groove and with alpha helix 4 of
Mcl-1 (Figure 4.5). It is possible that these influenced the binding mode; we can't rule







Figure 4.4. Comparison between the crystal structure of M7 (orange) in complex with Mcl-1 (yellow) and
its design template 5C3F (Bid-MM in blue and Mcl-1 in green). A) Structural alignment reveals a
rearrangement of alpha-helix 4 of McI-1. B) In 5C3F, as in most Mcl-1:BH3 structures, an aspartate in
peptide position 3f forms a salt-bridge network with R263 and D256 of BfI-1 (hydrogen bonds show as
blue dashes). A similar salt-bridge network is observed in the M7:Mcl-1 complex, but with an aspartate
one helical turn away in peptide position 4b (hydrogen bonds show as orange dashes). C) The shifted




Bid-MM:McI-1 (5C3F) M7:Mci1 symmetry reLaeu
BC
Figure 4.5. Crystal packing in the M7:Mcl-1 crystal structure. A) Symmetry related molecules (gray) in
M7:McI-1 crystal would be expected to clash with the Mcl-1 conformation (B) and peptide conformation
(C) observed in 5C3F.
There are a few features of design M7 that may account for this shift. First,
alanine at position 10 is over packed when modeled on the 5C3F backbone.
Nevertheless, we tested this design because wanted to assess whether the backbone
would adjust to accommodate the mutation, as was observed in the structure of F4
bound to Bfl-1. Interestingly, 5C3F and 2PQK backbones are very similar around this
position and dTERMen design calculations on both templates predicted that alanine and
glycine were both favorable. Alanine was chosen as optimal in the 5C3F-based design,
173
whereas glycine was preferred for the 2PQK-based template. It may be that the Mcl-1-
peptide complex could not relax sufficiently to accommodate the addition of a methyl
group. Another element that may have contributed to the re-positioning of the peptide in
the groove may be the choice of residues at positions 3f and 4b, which form an interface
with the protein on one side of the helix. BID, and all other native BH3 peptides, have
aspartate at position 3f, but in design M7 this residue is leucine, and position 4b is
aspartate. In the crystal structure, peptide M7 is shifted such that Asp 4b can play a
similar role to that of Asp 3f in 5C3F, by interacting with Arg 263 in Mcl-1 (Figure 4.4B).
In summary, x-ray crystallography revealed that backbone positioning of two of
the crystalized designs were sub-angstrom matches of their design templates, one
bound in a geometry that shared high similarly with its template, and the remaining
design bound in an unexpected, dramatically shifted orientation.
DISCUSSION
Using dTERMen, we were able to rapidly design in entirely new regions of
sequence space without the need for explicit modeling of complex structures or
expensive experimental library screening. Previous work has shown that this is not a
trivial task. Even in carefully designed libraries only < 8 mutations away from natural
BH3 domains, most sequences fail to bind Bfl-1 and Mci-122 23 33. In contrast, with
dTERMen, 15/17 of the designs bound with native-like affinity, even though the
sequences were 14-22 mutations away from known BH3 binders (Figure 4.1B, C).
Our design protocol provided access to novel sequences. Some of the tight
binders we discovered using dTERMen lack the highly conserved leucine and aspartate
residues common to all known, native BH3 sequences (Figure 4.1A). This pair of
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residues has been used in the past to define the BH3 motif. Not only do our results
suggest that these residues are not necessary for binding, but they show that dTERMen
is a useful tool for discovering binders that can't be predicted or even recognized based
on conserved sequence features.
By using different design templates, we were able to find solutions in distinct
regions of sequence space, as illustrated in Figure 4.1A. This may seem to be at odds
with our finding that dTERMen is robust to small differences in input structure, but the
templates used for design were deliberately chosen to sample different backbone
geometries. We expected these templates to match with different TERMs from the PDB,
and thus to generate different sequence predictions. Templates 5UUL and 2PQK
included peptides with native sequences that have evolved for tight binding. Other
templates we tested, 5C3F and 5UUM, featured peptides that bound their targets more
than 3 orders of magnitude more weakly. It is interesting that both structures of high-
affinity and low-affinity peptide complexes led to novel, high-affinity peptide binders
when used as input to the design calculations. Design on other solved structures could
potentially provide access to even greater diversity. Going beyond solved structures, it
may be possible to perform dTERMen design on predicted structures with binding
modes that are not represented in the PDB.
Designs that are diverse in sequence are potentially valuable because they
provide opportunities to optimize pharmacological properties not related to binding.
These properties could influence whether these peptides are disruptive to membranes
and how readily they can be delivered to cells. Several studies have shown that the cell
permeability of stapled helical peptides depends on peptide properties including charge
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and hydrophobicity34 . The charge of a peptide can also affect how efficiently it is loaded
into nanoparticles. Different sequences will also have different cross-reactivity,
immunogenicity, and protease sensitivity, so having many option to choose from
increases the chances of developing useful reagents and lead therapeutics.
Interestingly, design using dTERMen is compatible with imposing constraints on peptide
properties such as net charge, so if the desired physical characteristics of a peptide
inhibitor are known, they can be used to direct the search into promising sequence
spaces.
The dTERMen scoring potential is based on sequence statistics for structural
elements observed repeatedly in nature. There is no formal relationship between these
statistics and protein stability or affinity, so the scoring may reflect any number of
evolutionary pressures including stability, specificity, folding kinetics, solubility, or other
factors. We interpret the success of dTERMen in design as evidence that whatever
evolutionary forces may be contributing to the statistics, there must be a substantial
contribution from the free energy of the sequence adopting the evaluated structure. The
fact that we designed helix-helix interactions in this project, which are common in the
PDB, may be part of the reason our dTERMen designs performed so well. This method
is not expected to perform as well on structural motifs that are sparsely sampled in the
PDB. However, more structures are deposited in the PDB every day, so the range of
accessible design targets is expected to improve over time 19.
One attractive feature of dTERMen is that it doesn't require structural modeling
or minimization; the design optimization is performed in sequence space. Although the
PDB structure-mining that is needed to build the scoring function can be somewhat time
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consuming, once such a function is derived, it is possible to perform design, or to
evaluate thousands of sequences, in seconds. Another advantage of dTERMen is that
there is a structural "fuzziness" built in, because the sequence statistics used for
modeling are derived from close, but not exact, matches of TERMs. This makes the
method more robust than FoldX to small variations in input structure, as shown in our
benchmark testing, and also accounts for some amount of backbone relaxation. In this
work, we saw one example where a mutation was accommodated (in peptide F4) that
would not have been predicted if modeling was performed on a rigid scaffold. On the
other hand, dTERMen design failures may result from over-packing the protein-peptide
interface beyond what can be accommodated by small structural rearrangements. This
may be what happened in designs F6 and M6, which did not bind tightly to their targets.
Future design studies will help calibrate the methods so that diverse sequences can be
obtained with high success rates. Combining dTERMen with a post-analysis procedure
that includes all-atom modeling, e.g. using Rosetta, could be one way to recognize
mutations that can vs. cannot be accommodated. Although this would increase the
computational costs, such a secondary evaluation could readily be performed for a
modest number (hundreds or thousands) of promising candidates designs.
One unexpected result from this work is that the specificity profiles of the designs
were observed to be template dependent (Figure 4.1D). This is particularly striking in
the case of the FS2 template. Although no off targets were considered during design,
the peptides designed from the FS2 structure were highly Bf-1 selective and in fact
provide outstanding leads for development as Bfl-1 targeting agents. This specificity of
peptides F1, F2 and F5 may be a result of the unique way FS2 engages Bfl-1. FS2
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adopts a non-canonical binding mode that has not been observed for natural BH3
ligands. It may be that the interactions that support the FS2 binding mode are under
less evolutionary pressure to mirror those required for BH3 binding in the other family
members and are thus more likely to be unique (Figure 4.6). This is consistent with the
idea that a peptide that makes contacts outside of the conserved binding cleft can use
these contacts to achieve intra-family specificity24 .
Residue conservation relative to Bfi-1




0 - residue is unique to Bfl-1
Figure 4.6. FS2 (white, cartoon) binding mode might have more potential than Puma (dark gray, cartoon)
binding mode to interact with residues that are unique to Bfl-1 (colored spheres). Similarity based on
Blosum62 matrix.
This proof-of-principle study makes us enormously enthusiastic about the
potential of dTERMen for designing peptide binders and inhibitors. The ease of use, fast
run times, and very high success rates on a difficult problem provide compelling
evidence of the promise of this approach. There are ample opportunities to improve
dTERMen further, for example by deriving TERM statistics from a database that
includes protein-protein and protein-peptide interfaces, and/or combining this sequence-
based design approach with all-atom modeling to better assess what mutations can be
accommodated by structural relaxation. We look forward to tackling increasingly difficult
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EBY1 00 yeast cells were transformed using the Frozen-EZ Yeast Transformation
II Kit (Zymo Research) according to the manufacturer's protocol. For a plasmid
backbone, we used the Puma PCT plasmid23 and digested it with xhol (NEB) and nhel-
HF (NEB) according to the manufacturer's protocol. The inserts were constructed with
PCR using primers that encoded the peptide sequence flanked with at least 40 bp of the
plasmid sequence on either side of the insertion site to facilitate homologous
recombination. The inserts and plasmid backbones were mixed at a 5 to 1 ratio for
transformation. The transformation mixture was spread onto SD + CAA plates (5 g/L
casamino acids, 1.7 g/L yeast nitrogen base, 5 g/L ammonium sulfate, 10.2 g/L
Na2HPO4-7H20 and 8.6 g/L NaH2PO4-H20, 2% glucose, 15-18 g/L agar, 182 g/L
sorbitol) and grown at 30 'C for 2 to 3 days. To confirm each strain, colony PCR
followed by sequencing was performed on single colonies. Sequence verified colonies
were grown overnight in SD+CAA (5 g/L casamino acids, 1.7 g/L yeast nitrogen base, 5
g/L ammonium sulfate, 10.2 g/L Na2HPO4-7H20 and 8.6 g/L NaH2PO4-H20, 2%
glucose). The saturated overnight cultures were diluted with to a final concentration of
15% glycerol and stored at -80 0C.
Yeast growth and FACS analysis
A small amount of frozen culture was scrapped from the top of frozen culture
stocks to inoculate SD+CAA. After passaging overnight at 30 C, cultures were diluted
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to an OD600 of 0.005-0.01 in SD+CAA and grown to an OD600 of 0.1-0.6. Cells cultures
were then diluted 25-fold with SG+CAA (5 g/L casamino acids, 1.7 g/L yeast nitrogen
base, 5.0 g/L ammonium sulfate, 10.2 g/L Na2HPO4-7H20 and 8.6 g/L NaH2PO4-H20,
2% galactose) to induce peptide expression and grown for 20-24 hr at 30 'C. To
measure binding to surface-displayed peptides, cells were filtered with a 96-well plate
filter (105-106 cells/well), washed twice with 150 pL BSS (50 mM Tris pH 8, 100 mM
NaCl, 1 mg/ml BSA), and resuspended in BSS with least 10-fold molar excess target
protein and incubated in the filter plate for 2 h at room temperature with gentle shaking
for equilibration. To detect cell surface expression and binding of target protein, cell
suspensions were filtered, washed twice in chilled BSS, resuspended in a 35 pL of
1:100 dilution of primary antibodies (mouse anti-HA, Roche, RRID:AB_514505 and
rabbit anti-c-myc antibodies, Sigma, RRID:AB_439680) in BSS and with gentle shaking
for 15 min at 4 *C. Cells were then filtered, washed twice in 150 pL chilled BSS,
resuspended in 35 pL of a solution of secondary antibodies in BSS (1:40 dilution of APC
rat anti-mouse, BD, RRID:AB_398465 and 1:100 dilution of PE goat anti-rabbit, Sigma,
RRID:AB_261257) and incubated with gentle shaking in the dark for 15 min at 4 C.
Cells were filtered and washed twice more in 150 pL chilled BSS to remove unbound
antibodies. Labeled cells were resuspended in BSS and analyzed using a BD
FACSCanto with FACSDiva software.
Protein and peptide purification
Sequences for the myc-tagged Mcl-1, Bfl-1, Bcl-2, Bcl-w, and Bcl-xL proteins
used for binding assays can be found in (ref). Sequences for the untagged Bfl-1 and
Mcl-1 proteins used for crystallography purified as previously described23 and frozen at -
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80 C. The peptides used for crystallography were synthesized at the MIT biopolymers
facility with N-terminal acetylation and C-terminal amidation and were purified by HPLC
on a C-18 column with a linear gradient of acetonitrile and water. Purified peptides were
lyophilized and resuspended in DMSO. Peptide masses were confirmed by mass
spectrometry.
Crystallography
Crystals of Bfl-1 in complex with the designed peptides were grown in hanging
drops. To set the drops, untagged Bfl-1 (8 mg/mL in 20 mM Tris, 150 mM NaCl, 1%
glycerol, 1 mM DTT, pH 8.0) was mixed in equal molar ratio with the designed peptides.
1.5 pL of the Bfl-1/peptide mixture was pipetted onto a glass coverslip and mixed with
with 1.5 pL of well solution (1.8 - 2.0 M NH4 SO4 , 50 mM MES pH 6.5). To cryoprotect
the crystals, they were transferred into a solution of 2.0 M LiSO4 with 10% glycerol.
Crystals were flash frozen in liquid nitrogen. Diffraction data were collected at the
Advanced Photon Source at the Argonne National Laboratory, NE-CAT beamline 24-ID-
C. The datasets were refined to 1.59 A and 1.75 A and scaled using HKL200035 . Phenix
was used to phase with the Bfl-1 chain from PDB id 5UUK. The peptides were modeled
into the difference densities using Coot. Iterative rounds of refinement and model
building were performed using Phenix and Coot36 ,3 7.
Crystals of Mci-1 in complex with the designed peptides were grown in hanging
drops. To set the drops, TCEP (100 mM) and ZnSO4 (50 mM) was added at 10%
volume to untagged Mcl-1 (8.5 mg/mL in 20 mM Tris, 150 mM NaCl, 1% glycerol, 1 mM
DTT, pH 8.0) before adding equal molar amounts of the designed peptides. To grow
crystals of Mcl-1 in complex with F1, 1.5 pL of the peptide protein mixture was mixed
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with 1.5 pL of well solution (peg 3350, 50 mM bis-tris pH 8.5, 50 mM NH4CH3CO2).
Crystals were cryoprotected by adding 3 pL of a solution of 37.5% glucose in peg 3350,
50 mM bis-tris pH 8.5, 50 mM NH4CH 3CO 2 directly to the drop 0.5 pL at a time. To grow
crystals of Mcl-1 in complex with F7, 2.5 pL of the peptide protein mixture was mixed
with 0.5 uL of well solution (1.4 M sodium citrate pH 6.5, 0.1 M HEPES pH 7.5). To
cryoprotect, crystals were transferred to 1.6 M sodium citrate pH 6.5, 0.1 M HEPES pH
7.5. Crystals were flash frozen in liquid nitrogen. Diffraction data were collected at the
MIT X-ray core facility. The datasets were refined to 1.95 A and 2.25 A and scaled using
HKL2000 35. Phenix was used to phase with the Mcl-1 chain from PDB id 3PK1. The
peptides were modeled into the difference densities using Coot36 . Iterative rounds of
refinement and model building were performed using Phenix and Coot 36 ,37.
Benchmarking
Automatic download and annotation of BcI-2 protein-peptide complex structures
Uniprot sequences for Bcl-xL, Bfl-1 and Mcl-1 were retrieved from Uniprot and blasted
against the PDB database (7 Nov 2017). Matched structures were downloaded and
standardized by removing hydrogens and heteroatoms and transforming
selenomethionine to methionine. Sequences were aligned and renumbered on their
corresponding Uniprot template sequence using Needle. Regions that weren't matched
or that were poorly aligned with the Uniprot sequence were removed from the structure.
Chains of length [20,39] with residues that have more than 30% of their Voronoi surface
in contact with the receptor were identified as interacting peptide. Unless specified,
peptides containing non-natural amino acids were removed from the dataset. Only the
first model of NMR ensembles was retained. If a structure included multiple complexes
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in the asymmetric unit, these were split into new files and analyzed separately. Finally,
chains were re-labelled so that the Bcl-2 protein is always chain A and the peptide is
always chain B.
Alignment on binding site and method for comparing peptide binding geometry.
For every complex, residues within 8 A of any peptide atom were considered part of the
binding site and all complexes were structurally aligned using only their protein binding-
site atoms, using 3DCOMB. To define a common reference point for all bound peptides,
each peptide carbon alpha was represented as a node and a edge was created if the
distance between 2 nodes was below a threshold. The distance threshold was initially
set at 2 A and gradually increased by 0.1 A until largest clique in the graph included all
complexes . This clique represented a set of carbon alpha that are all within the
distance threshold and represent the "anchor" used for setting the registry. This position
was arbitrarily set to residue number 100. RMSDs between peptides in different
complexes were calculated using this alignment using only overlapping nodes.
Structural scoring functions dTERMen19, FoldX4.0 30, and Rosetta29 were tested
for their ability to predict peptide-protein binding affinity and specificity using binding
data obtained using the SORTCERY protocol 27,2 8. Scoring was based on 20-residue
peptides. The scored segment was chosen by structural inspection to include those
positions that make extensive contacts with the protein and that are unlikely to be
influenced by crystal contacts in the templates used for modeling.
Each structure was used as a template for dTERMen, generating a scoring
function for that template, i.e. a function that can score any peptide binding to the
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template-structure protein. FoldX4.0 was used to predict binding affinity by first using
FoldX4.0's "repair" function. Then, for each peptide in SORTCERY dataset, the repaired
template was transformed using the "mutate" function to generate the sequence of
peptide query and scored using the "complex" function. For Rosetta scoring, complex
structures generated by FoldX were relaxed with Rosetta using Talaris2014 or BetaNov
force fields. Relaxed structures were run through the surface analyzer "mover". Values
from cross and separated AG were kept as predicted binding energy.
The predictive power of the different structural scoring functions and protocols
was assessed by calculating the correlation between the binding energy determined by
SORTCERY, in kcal/mol, and each method's predicted binding energy (in arbitrary
units). Method's ability to identified top 10% binder vs. the rest was evaluated using
AUC of ROC curve. Finally, some sequences are found in more than one dataset and
their difference in binding energy represent their specificity. Using sequence that bind
tightly at least of the 2 receptors, ability of methods to predict specificity was assessed
by obtaining the correlation between experimental AAG and predicted AAG. Multiple
templates were tested for each protein receptor, and the predictive power was
evaluated for each template individually for binding affinity or all possible combinations
for specificity. Average performance on all templates was reported and represents the
expected value if a random template is chosen. We also report prediction performance
using the template that gave the lowest energy for each sequence.
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Conclusions and future directions
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There are many possible ways design peptides with desirable interaction profiles.
My thesis work describes three distinct approaches to design tight and selective peptide
inhibitors of anti-apoptotic proteins, with an emphasis on Bfl-1. In one approach, I used
models built on small-scale mutational datasets and structure-based models to design
peptide libraries of BH3 variants. These libraries were screened to identify tight and
selective peptide inhibitors of Bfl-1. In another approach, I contributed to constructing a
computational model of the specificity landscape of Bfl-1, Bcl-xL, and Mci-1 that was
built on high-throughput affinity measurements of thousands of mutant BH3s. This data-
driven model provided valuable insight in to the binding preferences of these related
proteins and enabled us to design in a mutational space that is far larger than what is
experimentally tractable. In a complementary approach, I described the use of a
structure-based computational model built from sequence statistics extracted from the
PDB to design BH3 mimetics with sufficient accuracy to forgo experimental screening.
This thesis describes the design of and experimental validation of more than 22
novel Bfl-1 inhibitors, 20 novel Mcl-1 inhibitors, and 12 novel BcI-xL inhibitors. The
models used to design these peptides predict many hundreds of additional sequences
with similarly promising interaction profiles. Although the peptides described in this
thesis are far from orally available therapeutic drugs, these peptides do have immediate
value as research tools. For example, peptides from this thesis are already being used
by other research labs to study Bfl-1 function and to diagnose Bfl-1 dependence.
Further, lessons from my work can inform future efforts develop the next generation of
BH3 mimetics, as discussed below.
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The data-driven approach described in chapter 3 of this thesis to design
interaction specificity can be applied to other design tasks, including peptide delivery
into cells. Factors such as positive charge, a-helicity, charge distribution, peptide
sequence, and hydrophobicity have been proposed to contribute to cell uptake
propensity'. However, much of what is currently known is about cellular delivery is
inferred from (and biased by) the few sequences that have worked before. Given
sufficient data, it should be possible to build a computational model to design peptides
with improved cellular uptake. One of the major roadblocks to doing this is collecting a
sufficiently large and diverse dataset to build a useful model. Some cell delivery
platforms might be adaptable to high-throughput screening. One potential example is
bioreversible esterification 2,3. By esterifying carboxylate-containing side chains
(aspartate and glutamate), the negative charge of the peptide is masked and the
peptide is rendered more hydrophobic, facilitating translocation directly through the
plasma membrane. Once inside the cell, endogenous esterases unmask the peptide's
negatively charged side chains and it is thought that Coulombic repulsion with the
anionic head groups of the plasma membrane prevents peptide escape. Because
bioreversible esterification enables one-way trafficking directly across the membrane,
there may be an opportunity to screen membrane translocation in esterase-containing
liposomes, which can be readily adapted for high throughput screening. Alternatively, it
might be possible to measure cell delivery in plate-based screens using a variety of
reporters including functional readouts (like mitochondrial depolarization in the case of
Bfl-1 inhibiting peptides), dye labeled peptides, or radiolabeled peptides.
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The results in this thesis can potentially be applied to the development of small
molecules targeting Bfl-1. For example, previous screens for small molecule inhibitors of
Bfl-1 identified electrophilic small molecules as hits4. Presumably, this is because
electrophilic small molecules have the potential to form covalent adducts with C55 of
Bfl-1, which resides on the edge of the BH3 binding groove. The crystal structure of an
electrophilic variant of a Bfl-1 selective peptide presented in Figure 2.20 could provide a
valuable guide for rational design of small molecules to covalently react with C55 and
make additional contacts in the BH3 binding groove. My thesis work also demonstrated
that Bfl-1 is amenable to crystallization, opening the possibility that crystal soaking
experiments with small molecule fragments might be a fruitful approach to designing
small molecules to inhibit the Bfl-1 binding groove.
The results of my work also suggest peptide modifications that might improve the
margin of specificity for Bfl-1, which could broaden the therapeutic window for future
generations of potential therapeutic peptides. For example, one structural feature that is
unique to Bfl-1 and might be leveraged in future work to augment Bfl-1 selectivity is
glutamate at position 78 of BfI-1. All anti-apoptotic Bcl-2 proteins including Bfl-1 have a
deep, highly conserved hydrophobic pocket (P2 pocket) into which a highly conserved
leucine (L3a) docks upon BH3 binding. But the P2 pocket of Bfl-1 is unusual in that it is
formed with a gluatmate (at position 78) instead of all hydrophobic residues. Interactions
with this unusual structural feature could potentially be leveraged to enhance Bfl-1
selectivity beyond what is reported in this thesis. Unlike natural BH3 motifs, which all
have a leucine at position 3a, the designed peptide F1 described in chapter 4 of this
thesis has a methionine at position 3a that docks into the P2 pocket. The X-ray structure
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of F1 bound to Bfl-1 reveals that the terminal methyl of M3a is only 3.3 A from the
carboxyl group of E78. This structure could be used as a template to design peptides





Figure 5.1. Structural positioning of glutamate at position 78 of Bfl-1. A) E78 of Bfl-1 forms one face of
the otherwise hydrophobic P2 pocket of Bfl-1 (gray surface). B) The X-ray crystal structure of the
designed Bfl-1 selective peptide F1 described in chapter 4 of this thesis (purple) bound to Bfl-1 (green).
The close proximity between M3a of F1 and E78 of Bfl-1 is highlighted with a dotted yellow line.
The results in chapter 4 of this thesis show that dTERMen is an efficient
approach to design novel BH3 peptides. Because the dTERMen scoring function is built
upon common structural tertiary motifs found in many evolutionary distinct proteins, it
may be possible to use dTERMen to predict non-obvious binding sites or to identify
novel binding modes. An example of a relatively simple binding mode of interest might
be a helix that binds the BH3 binding groove of Bfl-1 (or other anti-apoptotic protein) in a
flipped conformation relative to canonical BH3 peptide binders. Binding in a reversed
orientation might have the advantage of providing new, unexplored sequence spaces
with new opportunities for selective binding.
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In recent years, there has been significant progress in targeting BcI-2 family
proteins with BH3-mimetics. One outstanding example was the development of a small
molecule (ABT-199) that selectively inhibits Bcl-2, which has been approved by the FDA
for clinical use5 . This required years of work, guided by intensive NMR studies of
fragment binding- 7. Since then, small molecules selectively targeting Mcl-1 have also
been developed 7. This thesis, I describe the design of BH3 mimetic peptides with a high
degree of specificity for Bfl-1. The design processes and peptide reagents developed in
this work represent progress toward the larger goal of creating therapeutic peptides or
small molecules selectively targeting Bfl-1 to treat human disease.
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